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Abstract 
 
Immune-mediated glomerulonephritis and vasculitis accounts for over 10% of end-
stage renal failure in the UK. The anti-neutrophil cytoplasm antibody(ANCA)-associated 
vasculitides (AAV) are a specific subset, characterised by the production of ANCA, and are 
idiopathic multi-system vasculitides affecting mainly small-calibre vessels and renal 
glomeruli. Extensive human and animal work by our group and others has attempted to 
dissect the mechanisms which underlie the pathogenesis of these conditions. Recently, an 
important development in our understanding of cellular immunity has been the identification 
of a subset of T-cells characterised by production of the pro-inflammatory cytokine 
interleukin-17 (IL-17). T-helper-17 (Th17) cells are implicated as critical mediators of 
autoimmune disease. 
 
  I have attempted to characterise whether there is a role for Th17 cells in the 
pathogenesis of experimental glomerulonephritis and AAV. I have shown that IL-17-
deficient mice are protected from nephrotoxic nephritis and have used cell transfer 
experiments to see whether disease susceptibility or protection can be conferred. Using bone 
marrow transplant experiments, I have also demonstrated (1) that haematopoietic cells are 
critical mediators of disease and (2) that local production of IL-17 has an unexpected 
protective role. In human work, using samples from patients with AAV, I have shown that 
IL-17 is over-expressed in serum from both acute and convalescent patients and is closely 
associated with levels of related cytokines such as IL-23. Patients with AAV have memory 
Th17 cells that respond to stimulation with ANCA autoantigens. IL-23 levels correlate with 
AAV disease activity. 
 
This work demonstrates a role for IL-17 and Th17 cells in experimental 
glomerulonephritis and AAV. IL-17 blockade is being trialled as a therapy for a number of 
autoimmune diseases. Improved understanding of the mechanisms of pathogenesis and 
protection by IL-17 in AAV and glomerulonephritis will enable better prediction of the 
effects of IL-17 blockade and bring benefits to patients.  
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Chapter 1 
Introduction 
 
 
1.1 Overview 
 
The work described in this thesis is a study of the role of the cytokine IL-17 in the 
pathogenesis of glomerulonephritis and anti-neutrophil cytoplasm antibody (ANCA)-
associated vasculitis (AAV).  In this work I have used both the murine model of nephrotoxic 
nephritis (NTN), and serum and cells from patients with AAV to perform my experiments. 
The introductory chapter begins with an overview of the pathogenesis of immune-mediated 
glomerulonephritis and AAV, with a discussion of the relevant cellular and humoral immune 
mediators and a description of three animal models that are widely used for investigation in 
this field. The second part of the introduction focusses on IL-17, with a discussion of the 
structure and functions of IL-17A and its cellular origins, particularly with regard to T-helper 
17 (Th17) cells. I then go on to review the evidence for its role in autoimmunity with an 
emphasis on glomerulonephritis and AAV. These two strands are then drawn together with a 
discussion of emerging evidence for a protective rather than pathogenic role for IL-17 and 
the clinical relevance of this work with regard to on-going clinical trials of IL-17 blockade. 
The chapter ends with the project hypotheses and aims.  
 
The second chapter describes the Methods, followed by three results chapters, each 
divided into introduction, aim, experimental design, results, discussion and a summary. 
Chapter 3 describes experiments comparing NTN in IL-17 deficient mice and wild-type 
(WT) controls, and a series of cell transfer experiments investigating the ability to transfer 
disease susceptibility or resistance between WT and IL-17 deficient mice. In Chapter 4, bone 
marrow chimeras were created to examine the role of IL-17 on circulating leukocytes and 
intrinsic renal cells in vivo together with an analysis of the immune response in the different 
experimental groups. Chapter 5 details published work in humans comparing the serum 
cytokine profile with regard to the Th17 axis in patients with AAV and controls and the 
identification of a memory Th17 subset responsive to ANCA autoantigens in patients with 
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AAV. The final chapter, Chapter 6, is a discussion of the limitations and future directions of 
all the work described.   
 
 
1.2 Pathogenesis of immune-mediated glomerulonephritis 
 
Most forms of glomerulonephritis are immunologically mediated. These may be the 
result of antibody-mediated or cell-mediated processes or both (Couser, 1993). The presence 
of immunoglobulin and complement deposits in renal biopsies from patients with 
glomerulonephritis supports a role for humoral immune processes, whilst T-cells are also 
found in the kidneys of humans with glomerulonephritis. Histologically, human proliferative 
glomerulonephritis is characterised by glomerular hypercellularity, due to infiltration of the 
glomerulus by circulating polymorphs, lymphocytes and monocytes, and proliferation of 
intrinsic renal cells, particularly mesangial cells. Glomerular hypercellularity may be 
accompanied by glomerular thrombosis, necrosis and crescent formation. Crescentic 
glomerulonephritis, the most severe form of immune-mediated glomerulonephritis, is caused 
by disruption in the integrity of the glomerular capillary wall leading to T-cell, macrophage 
and plasma protein infiltration into Bowman’s space. This correlates clinically with a rapidly 
progressive glomerulonephritis, with clinical features including haematuria, proteinuria, 
hypoalbuminaemia, hypertension and renal failure. If the lesions are extensive this may 
result in severe renal impairment and, untreated, this can progress to end-stage renal failure.  
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Figure 1. Histopathological image of human crescentic glomerulonephritis.  
Periodic acid Schiff stain of a renal biopsy showing crescent formation (*). Taken from 
(Araki and Ogane, 2008). 
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1.2.1 Classification of immune-mediated glomerulonephritis 
 
The presence and distribution of glomerular immune deposits on 
immunofluorescence staining of the renal biopsy can be used to classify the form of 
crescentic glomerulonephritis based on the Gell-Coombs classification for hypersensitivity 
reactions, and also has pathogenetic significance. Firstly, antibody may combine directly 
with an intrinsic glomerular antigen due to anti–glomerular basement membrane (GBM) 
disease or Goodpasture’s syndrome, resulting in linear deposition of IgG on the capillary 
wall and a linear staining pattern on immunofluorescence. The main target for the antibodies 
is the non-collagenous domain of the α3 chain of type IV collagen. Disease is of an acute 
onset, and rapidly-progressive glomerulonephritis in this condition frequently results in end-
stage renal failure, even with treatment. Secondly, immune complexes comprising non-renal 
antigens may localise to the kidney with a granular staining pattern on immunofluorescence. 
These antigens may be exogenous or endogenous, and the precise nature of staining depends 
on the predominant location of glomerular immune complexes. In systemic lupus 
erythematosus (SLE), there is a loss of tolerance to nuclear components including DNA and 
histones, and deposits may be mesangial, sub-epithelial or sub-endothelial. Whilst SLE is the 
archetypal example of this type of granular glomerular staining pattern, it may also occur in 
mesangio-proliferative glomerulonephritis, post-infectious glomerulonephritis and IgA 
nephropathy.  
 
In the third form of the classification, glomerulonephritis may be pauci-immune, with 
minimal antibody deposition in glomeruli and an absence of immune deposits on electron 
microscopy. This is most commonly found in association with ANCA, but in 5-10% of 
patients pauci-immune glomerulonephritis is ANCA-negative.  In the kidney, pauci-immune 
glomerulonephritis results in segmental necrosis of glomerular tufts, capillary rupture, 
accumulation and proliferation of monocytes and epithelial cells and the formation of 
crescents. The pathogenesis of glomerulonephritis and AAV will be discussed fully in 
sections 1.2.3 and 1.2.4 below but firstly, in the following section, I will describe the 
common experimental animal models that have been used to gain insights into pathogenesis.  
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1.2.2 Animal models of immune-mediated glomerulonephritis  
 
There are a number of commonly used rodent models for the study of experimental 
glomerulonephritis. With the advent of gene targeting and transgenic technology, these have 
allowed the study of the role of individual molecules in disease. Firstly I will describe the 
accelerated nephrotoxic nephritis (NTN) model, which resembles an immune-complex 
mediated glomerulonephritis, and is one of those most frequently employed in the study of 
glomerulonephritis. This is the model that I have used throughout this thesis. Subsequently, I 
will describe the model of experimental autoimmune glomerulonephritis (EAG) and a 
number of models dependent on MPO or PR3, which are directed at the study of AAV 
specifically. 
 
1.2.2.1 Nephrotoxic nephritis 
 
Classical NTN is induced in mice, rats or rabbits by injection of heterologous 
nephrotoxic serum (NTS), usually generated by injection of sheep or rabbits with murine or 
rat cortex tissue antigens. First developed by Lindemann at the beginning of the 20
th
 century 
(Lindemann, 1900), who demonstrated the nephrotoxicity of heterologous anti-kidney sera in 
experimental animals, it is the most widely used animal model of crescentic 
glomerulonephritis. It consists of two phases. The heterologous phase relates to glomerular 
injury and inflammation caused by the binding of injected foreign antibody in NTS to the 
GBM, prior to the evolution of an adaptive immune response. This is a passive model and is 
characterised by proteinuria, peaking within the first 24 hours, and a neutrophil influx 
peaking within the first few hours after injection of NTS. At low doses of NTS, injury may 
be self-limiting, otherwise the autologous phase of disease develops.  
 
The autologous phase occurs 5-7 days later. It is characterised by the appearance of 
circulating autologous antibodies directed against the deposited glomerular heterologous 
antibodies that are also deposited on the GBM, and an associated T cell response. The 
pattern of disease is usually mixed proliferative and thrombotic. The accelerated model of 
NTN in mice is induced by pre-immunising mice with sheep IgG prior to the injection of 
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sheep NTS, which leads to the superimposition of the heterologous and autologous phases, 
as the host immune response is primed. In addition, adjuvants such as those containing killed 
mycobacteria are often included in the pre-immunisation, which further enhances the 
immune response. Injury in the model without pre-immunisation is less acute than the 
accelerated (pre-immunised) model (Kay, 1940), and is therefore perhaps closer to the 
pattern of injury in most forms of human disease. However the accelerated model, which 
relies on the secondary immune response, tends to produce more rapid and severe injury 
with more consistent outcomes.  
 
Although this is an immune-complex mediated glomerulonephritis, histologically the 
staining pattern on immunofluorescence is linear. Sheep or rabbit antisera are raised in 
outbred animals and each batch of NTS is unique. This may influence the ensuing immune 
response and leads to variation in renal immunopathology between batches. Therefore all 
experiments in this thesis were performed using the same batch of NTS. In rats, the Wistar-
Kyoto (WKY) strain is particularly susceptible and the genetic basis of this has been 
partially elucidated (Aitman et al., 2006), and is discussed further in section 1.2.3.4. In mice, 
disease is usually more variable and often more thrombotic than that in the rat model. 
However, murine models obviously offer the advantage of disease induction in a wide 
variety of genetically-modified strains which has contributed to our mechanistic 
understanding of disease. Studies using NTN have shed light on the involvement of many 
immune effectors in glomerulonephritis. The following section 1.2.3 on the pathogenesis of 
immune-mediated glomerulonephritis will review in detail evidence gleaned using murine 
and rat models of NTN. 
 
1.2.2.2 Experimental autoimmune glomerulonephritis 
 
EAG is a model of Goodpasture's disease. This model was first developed in sheep 
injected with human collagenase-solubilized GBM (Steblay, 1962).  However now, most 
commonly, WKY rats are immunized with collagenase-solubilized GBM or the recombinant 
NC1 domain of the α3 chain of type IV collagen [α3(IV)NC1], and develop circulating and 
deposited anti-GBM antibodies with focal necrotizing glomerulonephritis and crescent 
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formation. Although the WKY rat is most widely used, Brown Norway rats are also 
susceptible to disease, and this model has also been reproduced in mice. Collagenase–
solubilised fraction of bovine, rat or human GBM, and now recombinant α3(IV)NC1 from 
humans, rats or mice has been used. A number of mouse strains such as DBA/1, DBA/2, 
BALB/c and SJL mice are susceptible to EAG. However, in mice disease develops more 
slowly, is less severe, and less reproducible (Hopfer et al., 2003), and therefore this model is 
most widely used in the rat.   
 
Much of the work leading to mechanistic understanding of EAG has been carried out 
in our own laboratory by John Reynolds and Charles Pusey. Both cellular and humoral 
factors are important in disease. The antibody staining pattern on immunofluorescence is 
linear. Passive antibody transfer can induce disease in susceptible rat strains (Reynolds et al., 
2006), or by transfer of serum from C57BL/6 mice with EAG to recombinase-activating 
gene (RAG)
-/-
 mice (Dean et al., 2005). T cells also have a role in mediating disease since 
transfer of memory Th cells from splenocytes in rats results in an enhanced antibody 
response following injection of homologous GBM (Reynolds et al., 1993). T-cells can also 
mediate a directly injurious response since CD4+ T cells which have been primed in vitro 
can cause crescentic GN in the absence of IgG deposition (Wu et al., 2002), and disease can 
develop in B-cell (µ-chain) deficient mice (Dean et al., 2005). However, a functioning T cell 
receptor is required for pathogenesis of EAG since T cell receptor (TCR)
-/-
 mice do not 
develop disease either following immunisation with α3(IV)NC1 or following passive 
antibody transfer (Kalluri et al., 1997). 
 
As I have hypothesised for NTN, the Th17 pathway also appears to play a role in the 
pathogenesis of EAG. Mice deficient in IL-23, a key Th17 pathway cytokine, have been 
shown to be resistant to EAG (Ooi et al., 2009). Additionally, Hopfer and colleagues used 
DBA/1 susceptible mice with EAG to demonstrate a significant accumulation of CD4+ T 
cells, both Th1 and Th17, in the later crescentic phase of the disease, and autoreactive Th1 
cells which produced IFNγ in response to stimulation with α3(IV)NC1 (Hopfer et al., 2012). 
Separately, mice deficient in the inhibitory FcγRIIb receptor developed enhanced disease 
with massive pulmonary haemorrhage and crescentic glomerulonephritis, and therefore 
FcγRIIb may have a regulatory role in EAG (Nakamura et al., 2000). The importance of 
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CRGN1 in mediating susceptibility of WKY rats to EAG as compared with Lewis rats, 
similar to the susceptibility described in NTN, has also recently been demonstrated 
(Reynolds et al., 2012). 
 
1.2.2.3 Experimental vasculitis  
 
There are a number of animal models of MPO-mediated vasculitis and these are 
described in the following section. The proof that autoimmunity to neutrophil cytoplasmic 
antigens can cause crescentic glomerulonephritis has come from studies in mice, and 
induction of disease in these models has enabled further analysis of effector mechanisms and 
revealed considerable information about the pathogenesis of AAV in vivo (Heeringa and 
Little, 2011). 
 
In the rodent, MPO-ANCA are sufficient to generate glomerulonephritis and renal 
vasculitis, in the absence of antigen-specific T-cells. In a passive murine model, MPO-
deficient mice were immunised with mouse MPO. Subsequently, transfer of anti-MPO 
splenocytes, or anti-MPO IgG, from these mice into RAG-deficient mice (which lack T and 
B cells), induced vasculitis and glomerulonephritis (Xiao et al., 2002). However, since the 
MPO is a neo-antigen, this model does not involve breaking tolerance and is therefore not a 
model of the immunogenesis of the ANCA autoimmune response, although it does provide a 
model of the pathogenesis of glomerular injury. In subsequent work, the renal injury in this 
model was found to be dependent on complement activation (Xiao et al., 2007) and on the 
presence of neutrophils (Xiao et al., 2005). 
 
 
 In another model devised by the same group, MPO-deficient mice are immunized 
with MPO and then irradiated prior to receiving MPO-positive bone marrow, which in the 
presence of MPO-ANCA is sufficient to generate glomerulonephritis (Schreiber et al., 2006). 
Exposure to MPO-ANCA over a longer time-frame in this model may represent human 
disease more closely. In this model too, mice deficient in the complement C5 receptor 
(Schreiber et al., 2009) are protected from disease, and administration of a C5 inhibitor is 
protective in WT mice injected with anti-MPO IgG and lipopolysaccharide (LPS) (Huugen 
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et al., 2007). Paradoxically, in humans, AAV is a pauci-immune condition and serum levels 
of complement are unaltered, but these results suggest an unexpected role for complement in 
pathogenesis, although the exact mechanism by which this is mediated is unknown.   
 
 
In a third model which is rather different to those previously described, ANCA are 
generated following immunisation of C57BL/6 mice with human MPO. Mice develop both a 
cellular and a humoral response to human MPO, which cross reacts with murine MPO. 
Injection of a sub-nephritogenic dose of anti-GBM serum localises neutrophil influx and 
degranulation to the kidney with deposition of MPO and local microvascular injury (Ruth et 
al., 2006). Subsequently CD4+ MPO-specific T cells recognise their target antigen and 
recruit macrophages to the kidney resulting in focal and necrotising GN.  The authors have 
called this model autoimmune myeloperoxidase-induced glomerulonephritis (AIMPOGN). 
One plausible explanation linking the cellular and humoral pathologies in this model of 
AAV is a planted antigen hypothesis. The antigen (MPO or PR3) is targeted to the kidney 
and focuses the ensuing cellular immune response. This could occur following low level 
neutrophil accumulation in the glomerulus followed by ANCA binding to neutrophils and 
leading to degranulation. MPO/PR3 released from the neutrophils could then become 
trapped within the glomerulus. A subsequent cellular response to the deposited autoantigen 
could direct the delayed type hypersensitivity (DTH) response within the kidney. In this 
model, in which NTS is used to localise injury to the kidney, T cell depletion but not 
immunoglobulin deficiency abrogated disease.  
 
Since this model relies upon injection of nephrotoxic serum to localise the immune 
response, it is not truly pauci-immune. The same group have reproduced this model in WT 
and IL-17 deficient mice, in the same way as my project has planned to for NTN, and found 
that the IL-17 deficient mice were protected from this MPO-mediated disease (Gan et al., 
2010). This effect was partially mediated through decreased neutrophil recruitment, although 
it is unclear in WT mice whether the neutrophils are activated by ANCA and then recruit 
Th17 cells, or whether Th17 cells recruit neutrophils which are subsequently activated by 
ANCA. Neutrophils can produce CCL20 which is chemotactic for Th17 cells, but Th17 cells 
can also produce CXCL8 which is chemotactic for neutrophils. In an unmanipulated model 
of AAV, spontaneous crescentic glomerulonephritis forming/Kinjoh (SCG/Kj) mice 
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spontaneously develop crescentic glomerulonephritis, systemic vasculitis and perinuclear 
(P)-ANCA, however this is in association with heavy glomerular immune deposits and 
therefore again is not pauci-immune (Neumann et al., 2003). 
 
Experimental Autoimmune Vasculitis (EAV) is a robust rat model of systemic anti-
MPO associated vasculitis developed in our laboratory. WKY rats injected with human MPO 
in complete Freund’s adjuvant (CFA) produce MPO-ANCA that cross-reacts with rat MPO 
and is associated with pauci-immune focal necrotising glomerulonephritis and pulmonary 
haemorrhage 4-8 weeks later (Little et al., 2005). Leucocyte-endothelial interactions were 
visualised by intra-vital microscopy in this model, and were enhanced in association with 
MPO-ANCA, with a resultant increase in micro-vascular injury. Blockade of tumour 
necrosis factor (TNF)α in EAV after the establishment of glomerulonephritis resulted in 
reduced pulmonary haemorrhage and crescent formation, and reduced leucocyte 
transmigration across venules when visualised by intra-vital microscopy (Little et al., 2006). 
Therefore, TNFα has a role in the pathogenesis of this model, and blockade of TNFα has 
been a useful therapeutic target in the treatment of AAV in some studies (Booth et al., 2004; 
Booth et al., 2002), although not in others (Wegener's Granulomatosis Etanercept Trial 
Research, 2005). 
 
These MPO models are all limited by one or more of the following factors: the need 
to use adjuvant; the ‘one-hit’ nature of the injury; MPO as a neo-antigen and the ensuing 
mildness of disease. Hence, none really mirrors human disease exactly. However, they have 
nonetheless contributed greatly to pathological insights as described above. In addition, a 
number of signalling pathways involved in neutrophil activation such as phosphoinositol 3 
kinase-γ (PI3Kγ) (Schreiber et al., 2010) and the P38 mitogen-activated protein kinase 
(MAPK) pathway (van der Veen et al., 2011) have also been implicated in disease by virtue 
of experiments in animal models.  
 
 
In contrast to MPO-AAV, there is less evidence for the pathogenicity of PR3-ANCA 
in vivo. No case of human disease transferred by anti-PR3 has ever been reported. In WT 
mice, transfer of murine PR3-ANCA, made by immunizing PR3/neutrophil elastase double-
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deficient mice with murine recombinant PR3, has been shown to amplify local inflammation 
(Pfister et al., 2004), but these mice did not develop glomerulonephritis. Immunisation of 
autoimmunity-prone non-obese diabetic (NOD) mice with recombinant murine PR3 and 
CFA resulted in the development of cytoplasmic (C)-ANCA without disease. However, 
subsequent transfer of splenocytes from these mice into NOD/severe combined 
immunodeficiency (SCID) mice did result in systemic vasculitis and crescentic 
glomerulonephritis. Interestingly, transfer of splenocytes from similarly immunized 
C57BL/6 mice into RAG-deficient mice did not result in disease and so these C-ANCA-
mediated effects appear to be closely dependent on genetic background (Primo et al., 2010). 
In a step forward, most recently, Little and colleagues who developed the EAV model have 
demonstrated pathogenicity of human PR3-ANCA in vivo. By irradiating 
NOD/SCID/IL2Rγ-/- mice and transplanting human haematopoietic stem cells they created 
chimeric mice. Transfer of human IgG from patients with PR3-ANCA into the chimeric 
mice resulted in haematuria, punctate lung haemorrhage and proliferative glomerulonephritis 
in a proportion of animals compared to none of the controls (chimeric mice given IgG from 
patients with non-ANCA renal disease or healthy controls) (Little et al., 2012). Therefore 
this model should provide a useful mechanism for further study of the effects of human PR3-
ANCA in vivo. 
 
 
1.2.3 Immune mediators of glomerulonephritis 
 
I will now go on to discuss the basis of the immune-mediated pathogenesis of 
glomerulonephritis, and evidence for the cellular and non-cellular mediators of disease in 
detail. Much of this evidence has come from work carried out in the animal models 
described above. 
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1.2.3.1 Cells of the adaptive immune system 
 
T cells 
 
In the effector phase, T cells are most prominent in proliferative and crescentic 
glomerulonephritis, where they are usually associated with other mediators of delayed-type 
hypersensitivity including macrophages and fibrin. In ANCA-associated crescentic 
glomerulonephritis, T cells are invariably present, frequently in the absence of glomerular 
antibody deposition. CD4+ T cells can mediate glomerular immunopathology by cytokine 
secretion, by activating effector cells such as macrophages or by inducing autoantibodies or 
immune-complexes. CD8+ T cells mediate cellular cytotoxicity and regulatory T cells 
suppress the immune responses of other cells and maintain tolerance to self-antigens.  
 
CD4+ T cells 
 
The observation that nephritic kidneys demonstrate macrophage and T cell 
infiltration together with fibrin deposition, led to the hypothesis that crescentic 
glomerulonephritis develops as a consequence of delayed type hypersensitivity. CD4+ T 
cells may provide help to B cells in producing an autologous antibody response or they may 
cause injury directly by activating macrophages locally in the kidney. Mice deficient in CD4 
are protected from autologous NTN while mice deficient in CD8 are not protected (Tipping 
et al., 1998). CD4 deficient mice also have impaired immunoglobulin production which is 
consistent with a role for CD4+ T cells providing B cell help, and expression of major 
histocompatibility complex (MHC) class II on intrinsic renal cells is necessary for renal 
injury which further implicates CD4+ T cells in pathogenesis (Li et al., 1998). More 
specifically, mice deficient in µ-chain lack mature B cells and circulating antibody but have 
intact cell mediated immunity. These mice develop proliferative glomerulonephritis and 
crescents despite the absence of immunoglobulin which again supports a role for T cells in 
this model (Li et al., 1997).  
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There are also strain specific differences in T cell phenotype that appear to influence 
disease outcomes. NTN in C57BL/6 mice is predominantly Th1 mediated with pronounced 
DTH responses and production of IFNγ (Huang et al., 1997b). Depletion of CD4+ cells with 
a monoclonal antibody showed that disease was T cell dependent. BALB/c mice on the other 
hand classically show a Th2 response and in this strain disease is attenuated and is not 
dependent on T cells (Huang et al., 1997b). Consistent with this, modulation of the immune 
response in mice with NTN towards a Th2 phenotype by administration of exogenous IL-4 
or IL-10 attenuates disease (Kitching et al., 1997) and mice deficient in IL-4 develop more 
severe nephritis (Kitching et al., 1998). Administration of IL-4 to WKY rats also attenuates 
disease in NTN (Cook et al., 1999). Conversely, manipulation of the Th1 axis either by 
neutralising IL-12 (Kitching et al., 1999b) or using IFNγ-deficient mice (Kitching et al., 
1999a) results in less severe disease. Overall, Th1 polarised immune responses appear to 
dominate in crescentic glomerulonephritis and subsequently direct cell-mediated immune 
glomerular injury (Tipping and Holdsworth, 2006). The differentiation of CD4+ T helper 
cells, including Th17 cells, is discussed in more detail in section 1.3.3. 
 
CD8+ T cells 
 
 CD8+ T cells are cytotoxic T cells that recognise antigen presented in association 
with class I MHC, which is expressed on all nucleated cells. On encountering a cell 
expressing the appropriate antigen and self MHC, they are able to release pre-formed 
effector molecules such as perforins and granzymes which eventually result in apoptosis 
(programmed cell death). Alternatively, expression of Fas-ligand by CD8+ T cells can bind 
to Fas on activated lymphocytes, ligation of which results in activation of caspases and also 
leads to apoptosis. This mechanism is thought to be important in regulating peripheral 
immune responses. 
 
 Although there is much greater evidence supporting a role for CD4+ T cells in the 
pathogenesis of glomerulonephritis, there is conflicting evidence with regard to CD8+ T 
cells. CD8+ T cells have been shown to accumulate in glomeruli in glomerulonephritis. 
Moreover, depletion of CD8+ T cells in rats with autologous NTN reduced macrophage 
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infiltration and proteinuria without affecting CD4+ T cell numbers (Huang et al., 1997a). 
However, CD8-deficient mice with NTN developed more severe disease (Tipping et al., 
1998).  
 
Regulatory T cells 
 
 Regulatory T cells (Tregs) suppress activation of the adaptive immune system and 
maintain tolerance to self-antigens. Tregs may be naturally occurring or induced (adaptive). 
Naturally occurring Tregs originate in the thymus and express high levels of CD4, CD25 and 
the transcription factor FoxP3, and low levels of CD127. Induced Tregs are non-regulatory 
CD4+ T-cells that acquire CD25 expression outside the thymus, and are typically induced by 
inflammation and disease processes such as autoimmunity and cancer. Under the influence 
of TGFβ, induced Treg cells mature in peripheral sites from CD4+ Treg precursors, where 
they acquire the expression of markers typical of Tregs, including CD25 and CTLA-4. Upon 
up-regulation of the transcription factor Foxp3, Treg cells begin their suppressive effect. 
Tregs have a broad T cell receptor diversity that is biased towards self-antigens. They exert 
their effects by production of immunosuppressive cytokines such as IL-10 and TGFβ, cell 
contact-mediated regulation via the T cell receptor and via co-stimulatory molecules such as 
CTLA-4. Unlike other T cells, Tregs do not produce IL-2, although IL-2 is a potent inducer 
of Treg activity.  
 
Humans with mutations in FoxP3, and therefore defective Treg function, are unable 
to suppress or eliminate the activity of auto-reactive immune cells and therefore suffer from 
a rapidly fatal autoimmune disorder known as IPEX syndrome – Immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked syndrome. Tregs have also been shown to have a 
protective role in the pathogenesis of NTN. In mice with NTN, depletion of Tregs led to an 
aggravated Th1 response and worse disease (Paust et al., 2011). Conversely, adoptive 
transfer of Tregs into mice with accelerated NTN 1 day prior to injection of rabbit 
nephrotoxic serum ameliorated disease. Interestingly this did not affect humoral responses or 
antibody deposition but reduced infiltration of CD4+ and CD8+ T-cells and macrophages 
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(Wolf et al., 2005). The reciprocal relationship between the development of pro-
inflammatory Th17 cells and Tregs is discussed further in section 1.3.3.2.  
 
B cells 
 
Both B cells and T cells are lymphocytes that derive from a common primitive 
lymphoid progenitor and together form the adaptive immune system. B cells are central to 
the humoral response and principally function to produce antibodies against antigens, to act 
as antigen-presenting cells (APCs), and after activation by antigen to eventually develop into 
memory B cells or plasma cells. Once each B cell receptor binds its cognate antigen and 
receives a second signal from a Th cell, the B cell undergoes clonal differentiation to form 
plasma cells that produce antibody or memory B cells.  B cells that are too strongly reactive 
to self-antigen are eliminated by the mechanisms of clonal deletion, receptor editing and 
anergy. A subset of regulatory B cells, which have an immunosuppressive function 
analogous to Tregs and are characterised by the production of IL-10, has recently been 
described (Mauri and Bosma, 2012). 
 
The development of the autologous phase of NTN is characterised by the presence of 
circulating host antibodies against the rabbit or sheep antigen deposited on the GBM, 
indicating a clear role for B cells in disease. However, mice with deletion of the µ 
immunoglobulin heavy chain (µ-chain deficient mice), that have no B cell response but 
intact cell-mediated immunity, can develop proliferative GN in NTN indistinguishable from 
that in heterozygous mice, despite the absence of circulating and deposited mouse antibody. 
Therefore glomerulonephritis can develop independently of an antibody response as a result 
of DTH (Li et al., 1997). Similarly in an MPO-model of AAV, B cell-deficient mice with no 
ANCA were still able to develop severe crescentic glomerulonephritis (Ruth et al., 2006). 
However, antibody alone can also cause glomerulonephritis since transfer of anti-MPO IgG 
into RAG
-/-
 mice which lack circulating B and T cells did result in pauci-immune glomerular 
necrosis and crescents (Xiao et al., 2002). 
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1.2.3.2 Cells of the innate immune system 
 
Macrophages 
 
Macrophages have key roles in phagocytosis, antigen presentation and the production 
of soluble mediators of inflammation. They are critical cells in the pathogenesis of 
glomerulonephritis and express functional heterogeneity with roles in both tissue 
inflammation and repair. In normal tissues, there are low numbers of macrophages. However 
macrophage influx to the glomerulus and interstitium occurs in most forms of human 
glomerulonephritis, and also in experimental models of glomerulonephritis, in response to 
planted or endogenous glomerular antigens. Chemokines derived from cell-mediated 
immune reactions or activation by antibody via their Fc receptors drives macrophage 
localisation and immune damage (Couser, 1998). Binding of immunoglobulin to Fc 
receptors on macrophages provides important signals for their recruitment and activation. 
Both stimulatory and inhibitory Fc receptors have been identified, and the subclasses that 
best bind IgG have been characterized (See section 1.2.3.4). Activated glomerular 
macrophages produce a variety of proinflammatory mediators that amplify macrophage 
recruitment, activate or injure intrinsic renal cells and promote the deposition of fibrin and 
extracellular matrix accumulation. For example, the release of proteolytic enzymes, reactive 
oxygen species and nitric oxide can cause mesangial cell apoptosis and direct GBM damage 
(Duffield et al., 2000). 
 
It is now widely appreciated that macrophages are heterogeneous and macrophage 
subsets, designated M1 and M2, have been proposed to distinguish “classical” and 
“alternative” activation states, analogous to Th1 and Th2 helper T-cells (Gordon, 2003; 
Gordon and Taylor, 2005). Stimulation by TLR ligands and IFNγ drives macrophages 
towards classical M1 activation while stimulation by IL-4 and IL-13 from Th2 type 
responses drives alternative M2 activation. The M1 phenotype is characterized by the 
expression of proinflammatory cytokines, production of reactive oxygen species and 
enhancement of the Th1 response with strong anti-microbial activity. These macrophages are 
able to kill and degrade intracellular organisms. M2 macrophages on the other hand promote 
tissue remodelling and repair and have regulatory functions. They are highly phagocytic, 
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express scavenging molecules and mannose receptor and upregulate arginase. These two 
phenotypes have been extensively reviewed (Sica and Mantovani, 2012). Three further 
subsets of alternatively activated M2 macrophages have been proposed: those exposed to IL-
4 and IL-13, called M2a or wound-healing macrophages; those exposed to immune 
complexes and IL-1β or LPS, termed M2b; and those exposed to IL-10 and TGFβ or 
glucocorticoids, termed M2c or regulatory macrophages (Wang and Harris, 2011). 
  
More recently, a further pathway, ‘type II’ macrophage activation, has been proposed 
(Anderson and Mosser, 2002). Ligation of Fcγ receptors (FcγRs) on activated macrophages 
in conjunction with an inflammatory stimulus such as LPS results in a macrophage with 
similar activity to the alternatively activated macrophage; however they do not induce 
arginase production and preserve their ability to produce pro-inflammatory cytokines, e.g. 
TNFα, IL-1 and IL-6 (Gerber and Mosser, 2001). Alternatively-activated macrophages 
produce IL-10 which suggests they may have an anti-inflammatory role and this is supported 
by experimental evidence showing a protective effect of type II macrophages in mice given 
LPS compared with controls (Gerber and Mosser, 2001). 
 
Lastly, macrophages can also be activated by apoptotic cells which express cell 
surface markers that allow recognition and phagocytosis by macrophages. This is important 
for the resolution of inflammation and macrophages that ingest apoptotic cells in vitro 
develop an anti-inflammatory phenotype with increased expression of TGFβ and 
prostaglandin E2 and decreased production of IL-8, TNFα and IL-1β (Voll et al., 1997).  
 
There is good experimental evidence for the role of macrophages in renal injury. 
Early work by Holdsworth and colleagues showed that depleting macrophages using anti-
macrophage serum in rabbits with experimental glomerulonephritis results in amelioration of 
disease (Holdsworth et al., 1981). Conversely, reconstitution of bone marrow-derived 
macrophages in rats treated with cyclophosphamide restores disease susceptibility and the 
degree of renal injury was related to the number of macrophages transferred (Ikezumi et al., 
2003). Depletion of macrophages using clodronate in rats with NTN reduced macrophage 
infiltration and proteinuria with no effect on CD4+ T cell numbers (Huang et al., 1997a). 
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Meanwhile work targeting a variety of pro-inflammatory mediators such as TNFα (Hruby 
and Lowry, 1991) and MCP-1 (Lloyd et al., 1997), among others, has shown that reduced 
macrophage infiltration is associated with reduced disease, although this work does not 
define a specific causative link. In rats with NTN, treatment with IL-4 reduced macrophage 
infiltration and proteinuria and glomerular injury (Cook et al., 1999). In ischaemia-
reperfusion injury, M1 macrophages have been shown to dominate in the kidney in the first 
48 hours, and macrophages of an M2 phenotype thereafter. Depletion of macrophages before 
induction of injury ameliorated disease but depletion of macrophages in the M2 phase 
slowed tissue repair. Therefore macrophages can promote both injury and repair in the same 
model, dependent on their phenotype and the phase of disease (Lee et al., 2011). Overall, 
depletion of macrophages or disruption of macrophage recruitment reduces macrophage 
accumulation and damage in diseased kidney. Macrophages as a target in renal disease or 
modulation of macrophage phenotype to treat renal inflammation may be a potential future 
therapeutic approach in glomerulonephritis (Wang and Harris, 2011).  
 
Dendritic cells 
 
Dendritic cells are primarily APCs and thus act as a bridge between innate and 
adaptive immunity. Dendritic cells are present in virtually all tissues, particularly those in 
contact with the external environment, such as in the skin as Langerhans cells. They can also 
be found in an immature state in the blood. They perform sentinel functions and, once 
activated, migrate to lymph nodes where they present antigen to T cells and B cells to initiate 
and shape the adaptive immune response.  
 
Work by Christian Kurts’ group and others has explored the role of dendritic cells in 
glomerulonephritis and identified an extensive network of CD11c+ dendritic cells in the 
tubulointerstitium of healthy murine kidneys (Kruger et al., 2004). There is considerable 
overlap between these cells and F4/80
+
 tissue resident macrophages.  Numbers of these 
CD11c+ cells in the kidney increased in NTN and they were preferentially attracted to 
inflammatory sites (Kruger et al., 2004). Their exact function in glomerulonephritis remains 
unclear since it seems that they attenuate disease in some models but exacerbate it in others. 
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In NTN, in acute disease, they appear to be anti-inflammatory since depletion of dendritic 
cells aggravated disease and in vitro they were found to stimulate the production of anti-
inflammatory IL-10 from CD4+ T cells (Scholz et al., 2008). However, later on in disease it 
appears that they acquire a more pro-inflammatory phenotype and depletion of kidney 
dendritic cells during these later stages was found to be protective rather than harmful 
(Hochheiser et al., 2011). 
 
Neutrophils 
 
Neutrophils are critical components of the innate immune system and form the first 
line of defence against micro-organisms.  Neutrophils are also participants in many different 
forms of glomerulonephritis, particularly in proliferative crescentic forms. Mechanisms of 
defence include phagocytosis of micro-organisms; the creation of neutrophil extra-cellular 
traps or the release of soluble anti-microbials including granular proteins such as 
myeloperoxidase. Myeloperoxidase is an essential molecule in the initiation and execution of 
the acute inflammatory response by neutrophils and, significantly, is also one of the antigens 
against which ANCA is produced in AAV. Neutrophils localised in glomeruli induce injury 
by undergoing a respiratory burst that results in the release of toxic oxygen metabolites, 
particularly hydrogen peroxide which is nephritogenic by virtue of its ability to interact with 
neutrophil-derived myeloperoxidase. Activated neutrophils can also secrete serine proteases 
such as elastase, proteinase-3 (another AAV target antigen), and cathepsin G that have been 
shown in vitro to damage the GBM (Johnson et al., 1988). Platelet-neutrophil interaction can 
augment this injury.  
 
In heterologous NTN, binding of heterologous antibody to the GBM induces an acute 
neutrophil mediated injury. Neutrophils accumulate rapidly, within 4 hours of injection 
(Cochrane et al., 1965), but they localise only briefly, and have largely dissipated by 24 
hours. Neutrophils have long been recognised as required for the early phase of disease and 
rabbits depleted of neutrophils have attenuated disease in NTN (Cochrane et al., 1965). The 
role of neutrophils has been examined further using a number of genetically modified mouse 
strains. Neutrophils in Beige mice are deficient in the neutral serine proteinases cathepsin G 
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and elastase. On injection of a heterologous anti-GBM antibody, Beige mice are protected 
from albuminuria and glomerular damage compared to WT mice, indicating a role for 
neutrophil serine proteases in the induction of glomerular damage (Schrijver et al., 1989). 
Subsequent bone marrow transplantation experiments by the same group confirmed that it 
was an intrinsic neutrophil defect rather than any local factors in the Beige kidney that was 
responsible for the attenuated disease (Feith et al., 1993). More latterly, work has shown that 
mice deficient in granulocyte colony-stimulating factor (G-CSF) or granulocyte–macrophage 
colony-stimulating factor (GM-CSF), which have low numbers of neutrophils, are both 
protected from the heterologous phase of NTN (Kitching et al., 2002). 
 
Mast cells 
 
Mast cells are innate immune cells most recognised for their role in allergy and 
anaphylaxis. They are predominantly resident in tissues and are granulated cells which 
contain histamine and heparin and can be stimulated to degranulate by direct injury, cross-
linking of IgE receptors or activation of the complement cascade. Degranulation releases 
preformed inflammatory mediators from the granules such as serine proteases, histamine and 
proteoglycans such as heparin, and also newly formed lipid mediators such as thromboxane, 
prostaglandin and leukotriene. Mast cells also have a role in host defence and have been 
implicated in the pathogenesis of autoimmunity. With regard to glomerulonephritis, the 
evidence has been somewhat contradictory. Mice deficient in mast cells (Kit
W
/Kit
W-v
) have 
been shown to develop more severe disease in NTN (Hochegger et al., 2005) or also to be 
protected from NTN (Timoshanko et al., 2006). Further supportive evidence for a protective 
role for mast cells in glomerulonephritis comes from work showing that adoptive transfer of 
Tregs which attenuates disease also leads to an accumulation of mast cells in local lymph 
nodes. The protective effect of Treg transfer was abrogated in mice deficient in mast cells. 
Finally, blockade of the cytokine IL-9 which is required for mast cell recruitment and 
proliferation also abrogated protection in mice receiving Tregs (Eller et al., 2011).  
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1.2.3.3 Intrinsic cells 
 
Intrinsic glomerular cells, especially mesangial cells, are considered to be actively 
involved in the pathogenesis of glomerulonephritis, but many of the mechanisms by which 
this occurs remain elusive. From in vitro studies, intrinsic cells are known to secrete 
cytokines and express cytokine receptors, MHC class II and co-stimulatory molecules. More 
recently the use of chimeric mice has enabled the role of intrinsic cells in in vivo 
pathogenesis to be examined (Tipping and Timoshanko, 2005).  
 
Work done by our group performing renal transplantation of kidneys from WKY and 
Lewis rats into F1 animals before inducing NTN has shown that WKY kidneys develop 
more severe disease and therefore that intrinsic cells in the kidney serve to influence disease 
outcome. Further evidence that strain affects disease susceptibility has come from 
differences in in vitro production of MCP-1 from stimulated mesangial cells which is greater 
in WKY than Lewis rats (Smith et al., 2007). However, mesangial cells are not the only 
intrinsic cells that have been shown to be involved in pathogenesis. Expression of TLR2 and 
TLR4 on intrinsic cells is required for full expression of disease in mice with NTN (Brown 
et al., 2006; Brown et al., 2007). In anti-MPO experimental glomerulonephritis enhanced 
with LPS, intrinsic TLR4 expression was found to be predominantly on glomerular 
endothelial cells, and glomerular endothelial cells stimulated with LPS are a prominent 
source of CXCL8 in humans (Summers et al., 2010). Tubular epithelial cells can also secrete 
cytokines (Jevnikar et al., 1991) and express MHC class II, and proliferation of glomerular 
epithelial cells may contribute to the cellular composition of crescents (Moeller et al., 2004). 
However, since the role of mesangial cells in modulating immune responses and contributing 
to the pathogenesis of glomerulonephritis is more widely appreciated than that of other 
intrinsic cells, I will go on to discuss mesangial cells specifically in more detail.  
 
Mesangial cells 
 
Mesangial cells are specialised pericytes of mesenchymal origin. Together with the 
extracellular matrix, they make up the mesangium that lies between the capillary loops and 
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the GBM. The precise mechanisms of mesangial cell function are not well understood but 
they maintain the structure of the glomerulus; modulate glomerular filtration rate by 
contracting and constricting capillaries in response to vasoactive stimuli; phagocytose 
macromolecules and immune complexes together with tissue resident macrophages; and 
respond to and secrete different cytokines.  
 
Mesangial cell proliferation and extracellular mesangial matrix deposition are 
frequently observed in many forms of glomerulonephritis and mesangial cells can respond to 
stimulation by cytokines of an autocrine or a paracrine origin. Activation or proliferation of 
mesangial cells in vitro can lead to the release of a number of pro-inflammatory mediators 
such as oxidants, proteases, prostaglandins, growth factors and extra-cellular matrix 
components (Couser, 1998). After glomerular injury, cytokines such as IL-1 stimulate 
mesangial cell proliferation to direct re-population of the injured areas whereas in glomerular 
disease, they maintain inflammation by promoting mesangial cell proliferation and 
extracellular matrix production leading to progressive glomerular damage (Cove-Smith and 
Hendry, 2008). TNFα and IL-6 (Gomez-Guerrero et al., 1994) and IL-12 (Bussolati et al., 
1999) are pro-inflammatory cytokines produced by mesangial cells which are important 
mediators in the development of GN. Although these results may also reflect cytokine 
expression by other intrinsic cells, bone marrow transplantation experiments have shown that 
intrinsic renal cell production of TNFα, IFNγ and IL-12 are required for full expression of 
murine crescentic GN (Timoshanko et al., 2002; Timoshanko et al., 2001; Timoshanko et al., 
2003). Mesangial cells can also produce anti-inflammatory cytokines, such as TGF-β 
(Kitamura et al., 1996) and IL-4 (Furusu et al., 1997) which act to alter the activation state of 
leukocytes, such as macrophages, and protect against glomerular damage. 
 
Mesangial cells can also play a role in antigen presentation to CD4+ cells in 
association with MHC class II presentation. Whilst resting mesangial cells do not express 
MHC Class II, they can do so after stimulation with IFNγ, and this is augmented in 
association with IL-1β or TNFα (Martin et al., 1989). MHC class II expression is required 
for crescentic glomerulonephritis since deficient mice are protected from glomerular injury 
and in chimeric mice it has been demonstrated that mice deficient in MHC class II only on 
intrinsic cells were still protected from disease, suggesting a central role for MHC class II 
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expression on intrinsic cells (mesangial cells, epithelial cells endothelial cells or intrinsic 
dendritic cells) interacting with CD4+ T cells in the development of cell mediated immune 
renal injury (Li et al., 1998).  
 
1.2.3.4 Other immune mediators of glomerulonephritis 
 
There is still much to learn about the molecular basis of glomerulonephritis, and in 
recent times a wealth of non-cellular mechanisms have been highlighted as relevant to 
disease. In our institution alone, a number of these interesting observations have been made. 
Gene copy number polymorphisms have been identified as predisposing to autoimmunity, 
and copy number variations in the FcγRIII gene in rats and humans determines susceptibility 
to glomerulonephritis (Aitman et al., 2006). In WKY rats, which are highly susceptible to 
glomerulonephritis, a genome wide screen for NTN susceptibility in the F2 offspring derived 
from susceptible WKY and resistant Lewis rats revealed 7 genetic susceptibility loci named 
Crgn1-7. One major quantitative trait locus designated Crgn1 was on chromosome 13 and 
contained the gene encoding activatory FcγRIII. In related work, the gene for the 
transcription factor JunD, a major determinant of macrophage activity, was found to be 
located within the Crgn2 locus on chromosome 16. JunD is overexpressed in macrophages in 
the susceptible WKY rat strain and is associated with increased macrophage recruitment and 
crescentic renal injury. Knock down of JunD in human and rat macrophages decreased 
macrophage activation and cytokine secretion, and transfer of this locus from protected 
Lewis rats to WKY rats resulted in attenuated disease (Behmoaras et al., 2008). In humans a 
low copy number of FcγRIIIb (the orthologue of rat FcγRIII) was associated with 
glomerulonephritis in patients with SLE (Aitman et al., 2006). 
 
Separately, mannose receptor, a pattern recognition receptor expressed on 
macrophages and mesangial cells, was shown to promote glomerulonephritis in mice with 
NTN by augmenting Fc-mediated functions and inhibiting apoptosis of mesangial cells - 
mechanisms that are independent of adaptive immunity (Chavele et al., 2010a). Finally, 
inhibition of spleen tyrosine kinase, a non-receptor protein tyrosine kinase expressed in cells 
of haematopoietic or epithelial origin, and a component of intra-cellular signal transduction, 
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can be inhibited by the use of fostamatinib disodium and dramatically attenuated NTN in 
WKY rats (Smith et al., 2010). In the following section, I have highlighted the role of Fc 
receptors, complement and coagulation as other non-cellular mediators of disease for which 
there is evidence in glomerulonephritis.  
 
Fcγ receptors 
 
Fc receptors bind the Fc region of immunoglobulin and are largely expressed on cells 
of haematopoietic lineages such as macrophages, neutrophils, mast cells, NK cells and B 
cells (FcγRIIb only). The most important group of Fc receptors are the Fcγ receptors which 
bind IgG. FcγRI (CD64) is a high affinity IgG receptor, whilst FcγRII (CD32) and FcγRIII 
(CD16) are low affinity receptors. FcγRI and FcγRIII share a common FcRγ chain and are 
stimulatory, whereas FcγRII (in mice) and FcγRIIb (in humans) are inhibitory receptors. Fcγ 
receptors may play a role in effector immune responses, antigen presentation, peripheral 
tolerance (FcγRIIb) and immune complex clearance. They can initiate a wide variety of 
cellular responses such as phagocytosis, endocytosis, antibody-mediated cellular 
cytotoxicity, mast cell degranulation, immunomodulation of antibody responses and 
lymphocyte proliferation (Tarzi and Cook, 2003).  
 
Many forms of human glomerulonephritis are characterised by some degree of 
deposition of immune complexes in the kidney. These immune complexes contain IgG that 
bind to FcγRs leading to immune-mediated inflammation via FcγR activation. With this in 
mind, the NTN model has been widely used to assess the contribution of Fcγ receptors to 
disease.  Mice deficient in FcRγ, which lack the activator receptors FcγRI and FcγRIII, and 
the high affinity IgE receptor FcεRI, are completely protected from disease (Park et al., 
1998). Non-haematopoietic cells such as mesangial cells have been shown to express FcγRs 
in vitro, however work carried out in NTN in our laboratory by Ruth Tarzi has shown that 
Fcγ receptors on circulating cells but not on intrinsic cells are required for disease. Using 
bone marrow transplant experiments in WT and FcRγ-/- mice, she found that mice deficient 
in FcRγ were protected from NTN regardless of the status of the intrinsic renal cells (Tarzi et 
al., 2002). Further work defined a role for both (high-affinity) FcγRI and FcγRIII for full 
Sally Hamour  PhD thesis 2012 
51 
 
expression of disease (Tarzi et al., 2003). The significance of Fcγ receptors in 
glomerulonephritis has also been demonstrated in both rats and humans as has already been 
discussed earlier in this section (Aitman et al., 2006; Behmoaras et al., 2008).  
 
Complement 
 
The complement system is made up of a large number of distinct plasma proteins 
synthesised in the liver that react with one another to opsonise pathogens and ‘complement’ 
the anti-microbial activity of antibody. A sequential enzyme cascade with amplification 
triggers the system by three pathways of activation: the classical pathway, which is triggered 
by antibody or by direct binding of complement component C1q to the pathogen surface; the 
mannan-binding-lectin pathway, which is triggered by mannan-binding lectin, a normal 
serum constituent that binds some encapsulated bacteria; and the alternative pathway, which 
is triggered directly on pathogen surfaces. All of these pathways converge to generate 
enzymatic activity that, in turn, generates the effector molecules of complement. The three 
main consequences of complement activation are opsonization of pathogens, chemotaxis for 
macrophages and neutrophils and direct cell lysis by the membrane attack complex, formed 
by the terminal components of the complement pathway.  
 
The classical pathway plays a role in both innate and adaptive immunity. The first 
component of this pathway, C1q, links the adaptive humoral immune response to the 
complement system by binding to antibodies complexed with antigens. C1q can, however, 
also bind directly to the surface of certain pathogens and thus trigger complement activation 
in the absence of antibody. The mannan-binding-lectin pathway uses mannan-binding lectin, 
a protein very similar to C1q, to trigger the complement cascade. This binds specifically to 
mannose residues, and to certain other sugars, which are accessible and arranged in a pattern 
that allows binding on many pathogens. In contrast to these two pathways, the alternative 
pathway does not depend on a pathogen-binding protein for its initiation, but instead is 
initiated by the spontaneous hydrolysis of C3 resulting in the formation of C3 convertase. 
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 Activation of complement mediates tissue damage via a number of mechanisms, 
including the generation of chemotactic anaphylatoxins, C3a and C5a, and by insertion of 
the membrane attack complex (complement components C5b-9) into cell membranes, which 
disrupts intracellular homeostasis leading to cell lysis and death. There is evidence for the 
inappropriate activation of complement leading to cell damage in glomerulonephritis. Mice 
deficient in both C3 and C4 are protected from the heterologous phase of NTN, although the 
protection is greater with C3 than C4 deficiency suggesting a role for both classical and 
alternative pathway involvement (Sheerin et al., 1997). Deficiency of inhibitory complement 
regulatory proteins such as decay-accelerating factor (DAF, CD55) and CD59 in mice 
exacerbates accelerated NTN with increased proteinuria and histological lesions (Sogabe et 
al., 2001; Turnberg et al., 2003), while mice deficient in Factor H have uncontrolled 
activation of C3 and develop spontaneous membrano-proliferative glomerulonephritis 
(Pickering et al., 2002). However, complement may also play a protective role in 
glomerulonephritis. Deficiency of C1q predisposes both mice and humans to the 
development of SLE. Accelerated NTN is more severe in mice deficient in C1q compared to 
WT mice with more severe thrombosis, increased neutrophils, increased IgG deposits and 
more apoptotic cells compared to controls. These findings suggest that a defect in the 
clearance of immune complexes and apoptotic cells within the kidney in C1q deficiency may 
contribute to aggravation of disease (Robson et al., 2001) .  
 
Coagulation 
 
 Deposition of fibrin in glomeruli and increased pro-coagulant activity are consistent 
features of proliferative and crescentic glomerulonephritis (Kincaid-Smith, 1972). The 
association of glomerular fibrin deposition with an influx of T cells and macrophages 
together with up-regulation of pro-coagulant tissue factor expression in crescentic 
glomerulonephritis suggests fibrin deposition may occur as part of an immune delayed-type 
hypersensitivity response (Neale et al., 1988). Fibrin is critical to disease progression, and 
rabbits defibrinated with ancrod show attenuated crescent formation and renal impairment on 
induction of NTN (Thomson et al., 1976). Mice deficient in fibrinogen are also partially 
protected from NTN (Drew et al., 2001). Tissue factor may also have fibrin-independent 
inflammatory effects in glomerulonephritis since in defibrinated rabbits, inhibition of tissue 
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factor resulted in additional attenuation of disease and decreased recruitment of T cells and 
macrophages and decreased expression of MHC class II (Cunningham et al., 2004).  
Similarly thrombin has effects in disease independent of its procoagulant activity. 
Antagonising thrombin with hirudin attenuates NTN, but mice deficient in the Protease 
Activated Receptor 1 (PAR-1, thrombin receptor) which have normal coagulation are also 
protected from renal injury (Cunningham et al., 2000).  
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Figure 2. Schematic overview of both the innate and adaptive immune mechanisms that 
mediate tissue injury in GN.  
Etiologic events expose immunostimulatory pathogen-associated molecular patterns 
(PAMPs) or danger-associated molecular patterns (DAMPs) that activate both the innate 
(red) and the adaptive (antigen specific, blue) immune systems, which also interact with each 
other. Activation of the innate immune system occurs immediately and involves toll-like 
receptors (TLRs) or NOD-like receptors (NLRs) on both circulating inflammatory cells and 
resident glomerular cells. TLR activation results in release of inflammatory mediators that 
cause glomerular injury. Some PAMPs and DAMPs can activate complement directly 
through the innate immune system. TLRs are also required to activate the adaptive immune 
system through APCs that promote differentiation of CD4 helper cells, B cell activation, and 
antibody production. Antibodies lead to circulating complex trapping or in situ formation of 
immune complexes that can activate both the TLR and complement components of the 
innate immune system. Complement activation generates the chemotactic factor C5a that 
attracts circulating inflammatory cells (including neutrophils, macrophages, basophils, and 
natural killer cells), which release mediators and damage glomeruli and C5b-9 that activates 
resident glomerular cells to do the same. CD4 Th1 and Th2 cells cause tissue injury 
primarily thorough macrophages and basophils, respectively, whereas Th17 cells can 
mediate glomerular damage directly. CD4 regulatory cells (Tregs) downregulate the adaptive 
immune response. Taken from (Couser, 2012). 
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1.2.4 Pathogenesis of ANCA vasculitis 
 
AAV represents a heterogeneous group of autoimmune disorders characterized by the 
production of ANCA, reactive to either PR-3 (PR3-ANCA) or MPO (MPO-ANCA) and 
inflammatory necrosis of arterioles, capillaries and venules.  The spectrum of AAV includes 
a number of clinically and pathologically defined entities: Granulomatosis with polyangiitis 
(Wegener’s) (GPA), microscopic polyangiitis (MPA), Churg-Strauss syndrome (CSS), and 
renal limited vasculitis. These multi-system conditions can affect any organ causing 
considerable morbidity, but the most life-threatening complications are associated with renal 
failure and pulmonary haemorrhage. AAV is the most significant cause of crescentic 
glomerulonephritis, especially in older populations (Moutzouris et al., 2009), and end-stage 
renal failure develops in over 20% of AAV patients with renal involvement at five years 
(Booth et al., 2003). 
 
The small-vessel vasculitides under the umbrella of AAV have differing clinical 
phenotypes. Inflammation of the upper and lower respiratory tract with granuloma formation 
characterises GPA, together with high rates of relapse and PR3-ANCA association. 
Involvement of the upper respiratory tract includes classical necrosis and collapse of the 
nasal bridge, epistaxis, conductive deafness, or subglottic stenosis. Orbital disease in GPA 
may present with proptosis. Patients with MPA do not have granulomata or ENT 
involvement, and are usually associated with MPO-ANCA, as are patients with CSS who 
also have late-onset asthma and eosinophilia. Renal-limited vasculitis is an isolated pauci-
immune crescentic glomerulonephritis in which MPO- or PR3-ANCA may be found. The 
binding of PR3-ANCA to normal ethanol-fixed neutrophils on immunofluorescence 
generally produces a typical granular cytoplasmic stain (C-ANCA) whereas MPO-ANCA 
generally produces a peri-nuclear staining pattern (P-ANCA), and this distinction is 
sometimes also used to categorise patients or to assist in diagnosis. 
 
In the following sections, I describe mechanisms and evidence for our understanding 
of the pathogenicity of AAV. However, much of the evidence which stems from animal 
models of MPO-mediated disease has already been discussed in section 1.2.2.3. 
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1.2.4.1 Mechanisms of pathogenicity of ANCA 
 
There is evidence for the involvement of both cellular and humoral arms of the 
immune system in disease pathogenesis, including direct pathogenicity of ANCA. ANCA 
are specific for MPO or for the serine protease PR3, which are found in the lysosomes of 
monocytes or as constituents of azurophilic neutrophil granules. The most compelling in vivo 
evidence for the pathogenicity of ANCA, comes from a single case report of pulmonary 
haemorrhage and glomerulonephritis in a neonate with trans-placental transfer of ANCA IgG 
from a mother with active MPO-ANCA vasculitis (Bansal and Tobin, 2004). However, in 
vitro experiments have also shed light on the pathogenicity of ANCA. Neutrophils and 
monocytes that have been primed by cytokines such as TNFα express PR3 and MPO on their 
surface.  ANCA activate the cell by binding to MPO or PR3 by the Fab’2 region (Williams 
et al., 2003) and also by Fc receptor engagement with the same cell (Mulder et al., 1994). 
Activation of neutrophils by ANCA results in the release of inflammatory cytokines such as 
IL-8, lytic enzymes and oxygen radicals (Harper et al., 2001; Hattar et al., 2002). This results 
in impedance of neutrophil migration (Radford et al., 2000) and therefore neutrophils 
accumulate in the vasculature. As a result, degranulation of neutrophils leads to further 
endothelial damage and inflammation of blood vessels (Cockwell et al., 1999).  
 
Of relevance to my hypotheses regarding the pathogenesis of AAV, ANCA-activated 
neutrophils have also been shown to produce IL-6, IL-17 and IL-23 and set up the conditions 
to amplify the Th17 response (Hoshino et al., 2008). Professional phagocytes usually 
scavenge apoptotic neutrophils in a non-inflammatory manner, however this mechanism is 
disrupted by ANCA (Harper et al., 2001; Harper et al., 2000) and therefore in AAV 
neutrophils are likely to undergo secondary necrosis which compounds inflammation. 
Primed neutrophils in the presence of ANCA are more adherent to TNF-stimulated 
endothelium (Radford et al., 2000) and in rats have increased capacity to trans-migrate 
across it (Little et al., 2005), with the result that these enhanced leucocyte-endothelial 
interactions promote microvascular injury. With regard to monocyte activation in AAV, this 
has been demonstrated with elevated levels of IL-6 and neopterin in acute disease but not in 
convalescence (Muller Kobold et al., 1999). Further in vivo experiments in mouse and rat 
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models of MPO-vasculitis have contributed greatly to understanding of pathogenesis and 
these have previously been discussed in section 1.2.2.3. 
 
1.2.4.2 T cells and pathogenesis of AAV 
 
Despite the pathogenicity of ANCA described above, paradoxically in patients 
glomerular pathology is pauci-immune, with cellular infiltration of T cells and macrophages 
but little or no immunoglobulin deposition (Cunningham et al., 1999). Cellular mediators are 
therefore now recognized to have a significant role in pathogenesis. Granuloma formation in 
GPA is typical of a DTH reaction and results from a cellular immune response (Lamprecht 
and Gross, 2007). In vitro, lymphocytes from patients are reactive to PR3 or MPO 
autoantigens and proliferate in active disease (Griffith et al., 1996). In AAV there is 
persistent T cell activation even when disease is quiescent (Marinaki et al., 2006) and 
treatment directed at T cells can be effective in disease (Schmitt et al., 2004). In some 
patients, ANCA titres rise prior to, or coincident with, disease relapses (Boomsma et al., 
2000), but this is not always the case (Girard et al., 2001), and therefore it is likely that 
cellular mediators also play an important role in the initiation of disease.  
 
Patients with GPA have an increased proportion of CD4+CD25+ cells but a reduced 
proportion of FOXP3+ Tregs. The proportion of FOXP3+ cells is inversely proportional to 
the rate of relapse. Furthermore, Tregs from patients with GPA are functionally impaired 
with decreased ability to suppress proliferation in response to PR3, and to suppress resultant 
production of IFNγ and TNFα compared to ANCA-negative patients and healthy controls 
(Morgan et al., 2010). Abnormal function of Tregs in GPA, along with decreased numbers 
and altered phenotype of dendritic cells, has also been reported by other groups (Rimbert et 
al., 2011). Work in our laboratory has shown that IFNγ-producing Th1 cells are increased in 
acute disease and decreased in remission, in association with a numerical rather than a 
functional deficiency of Tregs, and diminished levels of tryptophan (Chavele et al., 2010b). 
Taken together, these data suggest that this imbalance between activated and regulatory cells 
is likely to contribute to disease pathogenesis.  
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1.2.4.3 Genetic determinants of AAV 
 
Several factors that appear to contribute to the genetic risk of developing AAV have 
been identified. The expression of PR3 on the surface of neutrophils is genetically 
determined and is found at higher levels in patients with AAV and PR3-ANCA. 
Furthermore, this elevated expression is related to relapse (Rarok et al., 2002). α1-antitrypsin 
is a naturally occurring inhibitor of PR3 and patients with GPA have higher than expected 
carriage of the Z allele (Mahr et al., 2006). In both AAV and SLE, associated single 
nucleotide polymorphisms in the IL-2 receptor have been described (Carr et al., 2009a) and 
PTPN22 and CTLA-4 have been highlighted as susceptibility loci in AAV (Carr et al., 
2009b). AAV is thought to occur less frequently in black patients, however HLA-DRB1*15 
is associated with PR3-ANCA disease in African-Americans (Cao et al., 2011). Through the 
use of leucocyte gene expression profiles, ANCA signature genes on neutrophils have been 
determined and in patients with AAV these can be differentiated from healthy donors and 
patients with SLE (Alcorta et al., 2007). Most recently, a genome-wide association study has 
revealed both MHC and non-MHC genetic associations with AAV, which are distinct for 
GPA and MPA. Anti-PR3 ANCA was associated with HLA-DP and the genes encoding α1-
antitrypsin and PR3, while anti-MPO ANCA was associated with HLA-DQ (Lyons et al., 
2012).  
 
1.2.4.4 Sepsis and immune cross-reactivity in AAV 
 
The factors that precipitate the formation of ANCA are incompletely understood, 
however it has long been suggested that there may be a role for infectious episodes 
preceding episodes of AAV (Pinching et al., 1980). More recently, this hypothesis has been 
reinvigorated with a proposed model of molecular mimicry between ANCA targets and 
bacterial fimbrial adhesion proteins (Kain et al., 2008; Kain et al., 2012). Circulating 
autoantibodies to lysosomal-associated membrane protein-2 (LAMP-2), a heavily 
glycosylated type 1 membrane protein that is involved in homeostasis and cell-cell adhesion, 
are found at high prevalence in patients with pauci-immune crescentic glomerulonephritis. 
The epitope to which the antibody is directed shows 100% homology to the bacterial 
adhesion protein FimH, part of the fimbriae of gram-negative pathogens. Almost all of these 
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anti-LAMP-2-positive patients are also ANCA-positive and WKY rats injected with 
antibodies to LAMP-2 developed pauci-immune crescentic glomerulonephritis. This 
demonstrates that an early immune response to pathogen-derived peptides that show 
significant homology to peptide sequences in ANCA target antigens could result in immune 
cross-reactivity. However, these findings have yet to be replicated by other groups (Roth et 
al., 2012). 
 
 The proposition that infections may play a central role in triggering disease has been 
further explored by the characterisation of anti-complimentary PR3 antibodies in some 
patients with PR3-ANCA vasculitis (Pendergraft et al., 2004). Complimentary PR3 is a 
protein translated from the anti-sense DNA strand of PR3 and resembles a mirror-image of 
PR3. The complimentary PR3-sequence has considerable homology to S.aureus, which has 
previously been implicated in disease relapse (Stegeman et al., 1994), and homology to a 
number of other infectious pathogens. It has been suggested that antibodies which have been 
induced by infection, may be cross-reactive to the complimentary PR3 peptide, and can 
therefore subsequently act as immunological templates for anti-PR3 antibodies. Overall, 
despite a lack of definitive mechanistic evidence, it seems likely that infections are a 
significant stimulus for inducing immune responsiveness and therefore that preventing 
infection could allow patients longer periods between disease relapse (Stegeman et al., 
1996). 
 
1.3 Interleukin-17 
 
 This work in this thesis is a study of the role of the cytokine IL-17A in the 
pathogenesis of AAV and glomerulonephritis. The next section begins with an overview of 
the IL-17 cytokine family, followed by a detailed discussion of the structure and function of 
IL-17A, a review of its cellular origins and, finally, an analysis of the current evidence 
regarding its role in autoimmune disease. 
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1.3.1 The IL-17 cytokine family 
 
IL-17A was first cloned in 1993 from a murine cytotoxic T-lymphocyte hybridoma 
cDNA library when it was originally termed CTLA-8 (Rouvier et al., 1993; Yao et al., 1995; 
Yao et al., 1996). It is a 21kDa protein that has since been found to have wide-ranging 
biological functions that have been extensively reviewed (Onishi and Gaffen, 2010; Xu and 
Cao, 2010). Murine and human IL-17A share 63% homology and both are secreted as 
disulphide-linked homodimers. The gene for murine IL-17A codes for a 158 amino acid 
sequence and is located on chromosome 1, whilst human IL-17A consists of a 155 amino 
acid sequence encoded on chromosome 6. IL-17A and its receptor IL-17RA are central 
members of a family of 6 cytokines: IL-17A, B, C, D, IL-17E (also known as IL-25) and IL-
17F. Of these, IL-17A and IL-17F are so far the best characterised, and share the highest 
amino acid sequence homology. They signal through the same receptor and the existence of 
IL-17A-IL-17F heterodimers has also been demonstrated (Chang and Dong, 2007). IL-17A 
and IL-17F may be co-expressed and probably act both synergistically and independently.  
 
Studies in IL-17A
-/-
 and IL-17F
-/-
 mice have shown that whilst both have a role in 
mucosal immunity, IL-17A has a more important role in driving autoimmunity than IL-17F 
(Ishigame et al., 2009), although both contribute to host defence. IL-17E is a Th2 promoting 
cytokine playing a role in allergic responses and the functions of the remaining family 
members remain poorly defined (Iwakura et al., 2011). The IL-17R family consists of 5 
receptor subunits (IL-17RA-IL-17RE) which are all single trans-membrane domain 
containing proteins (Gaffen, 2009). Although it is still unclear how these subunits interact to 
form productive receptor complexes, the largest member of the family IL-17RA is a 
common signalling subunit used by at least 4 ligands. The heterodimer of IL-17RA and IL-
17RC acts as a receptor for IL-17A and IL-17F. IL-17RA is expressed ubiquitously and 
hence most cell types can potentially respond to IL-17, however the most significant target 
cells seem to be of mesenchymal or epidermal origin.  
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1.3.2 IL-17A 
 
IL-17A (henceforth referred to as IL-17) is a pro-inflammatory cytokine with 
pleiotropic immune functions. It has important roles in protection of the host from 
predominantly extracellular pathogens particularly bacteria and fungi, and mediates 
protection at mucosal and epithelial sites such as the skin, the gut and the intestine. It 
mediates chemotaxis of neutrophils and monocytes to sites of inflammation, and their 
expansion, and induces macrophages to produce IL-1β and TNFα (Jovanovic et al., 1998). 
IL-17 enhances production of haematopoietic growth factors and, locally, stimulates 
production of a variety of inflammatory mediators including IL-6, nitric oxide, G-CSF, GM-
CSF, transforming growth factor (TGF)-β, monocyte chemo-attractant protein (MCP), 
macrophage inflammatory protein (MIP)-2 and prostaglandin E2. Synergy with other 
inflammatory cytokines such as IL-1β, TNFα, IFNγ and CD40 ligand leads to up-regulation 
of gene expression and amplification of local inflammation. 
 
The primary function of the IL-17 pathway is in defence against infection by extra-
cellular bacterial and fungal pathogens. Deficiency in IL-17 or IL-17RA leads to 
susceptibility to lung infection with Klebsiella pneumoniae (Ye et al., 2001) and to oro-
pharyngeal candidiasis in association with decreased neutrophil recruitment (Conti et al., 
2009). IL-17 is required for clearance of Citrobacter rodentium, a gut pathogen (Mangan et 
al., 2006).  In humans, hyper IgE syndrome patients, in whom Th17 cell differentiation is 
suppressed by a STAT3 mutation, are highly susceptible to Staphylococcus aureus, Candida 
albicans, and Streptococcus pneumoniae infection, resulting in skin and lung inflammation 
(Milner et al., 2008). IL-17 has also been shown to be important in allergic responses (Nakae 
et al., 2002), ischaemia-reperfusion injury (Edgerton et al., 2009), transplant rejection (Chen 
and Wood, 2007) and tumour development (Zou and Restifo, 2010) – however a detailed 
discussion of these conditions is beyond the scope of this introduction. 
 
IL-17 targets various (mostly non-lymphoid) cell types, including fibroblasts, 
endothelial cells, epithelial cells, keratinocytes, and macrophages. Specific to renal disease, 
IL-17 stimulates tubular cells (Van Kooten et al., 1998) and mesangial cells (Paust et al., 
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2009) to produce neutrophil, macrophage and T cell chemoattractants. Although originally 
IL-17 was thought to be produced predominantly by CD4+ T-cells (Fossiez et al., 1996) it is 
important to note that IL-17 is in fact produced by a range of both innate and adaptive 
immune cells including CD8+ cells (Ciric et al., 2009), natural killer cells (Coquet et al., 
2008), γδT-cells (Lockhart et al., 2006; Roark et al., 2008), neutrophils (Hoshino et al., 
2008), monocytes and macrophages (Song et al., 2008). Lymphoid tissue inducer-like cells 
can also produce IL-17 (Cua and Tato, 2010). These are related to lymphoid tissue inducer 
cells, which express CD4, CD127 and RORγt and are required for the generation of 
functional secondary lymphoid tissue, and play a role in the induction and maintenance of 
self-tolerance. I will now go on to describe the differentiation and function of Th17 cells as a 
source of IL-17, before considering the role of innate immune cells in IL-17 production and 
IL-17-related pathogenesis. 
 
 
1.3.3 Th17 cells as a source of IL-17 
 
1.3.3.1 Development of Th cells 
 
CD4+ T cells play an important role in the initiation of immune responses. When 
stimulated by antigen, naïve CD4+ T cells activate, expand and differentiate into different 
effector subsets. This differentiation is initiated by signals from the TCR, co-stimulatory 
molecules and cytokine receptors. A ground-breaking and original observation historically 
suggested the existence of two subsets of Th cells characterised by the production of distinct 
cytokine profiles (Mosmann et al., 1986). Th1 cells produce IFNγ and TNF, promoting cell-
mediated immunity mainly directed towards intracellular pathogens. They direct DTH 
responses, activate macrophages and cytotoxic T lymphocytes and induce IgG subclass 
switching to favour complement fixation and opsonisation. Th2 cells on the other hand 
produce IL-4, IL-5 and IL-13, supporting humoral immunity. These cells have an important 
role in allergy and IgE-mediated hypersensitivity responses, and production of IgG and IgE 
with lower complement fixing capacity. The different cytokines produced by Th2 cells act as 
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regulators of Th1 responses, and suppress DTH responses and macrophage activation 
associated with Th1 cytokines such as IFNγ. 
 
Th1 and Th2 differentiation is initiated by activation of T cells in the presence of 
IFNγ or IL-4, respectively. These integrated signals then induce the expression of lineage-
specific transcription factors that drive Th cell differentiation. Transcription factors T-bet, 
STAT1 and STAT4 lead to Th1 cell production, whereas GATA-3 and STAT6 are specific 
for Th2 cells. A further subset of regulatory T cells (Tregs) which differentiate in the 
presence of TGFβ but in the absence of IL-6, have a specific transcription factor FoxP3, and 
are critical for maintaining self-tolerance and immune homeostasis and modulating response 
to infections. 
 
1.3.3.2 Th17 cell development 
 
The long-standing paradigm of Th1 and Th2 cells described in 1986 by Mossman 
and Coffman (Mosmann et al., 1986) was finally overturned in 2005 when Th17 cells were 
first characterised as a distinct lineage of Th cells (Harrington et al., 2005; Park et al., 2005). 
Three groups contemporaneously identified that TGF-β and IL-6 were required for their de 
novo differentiation in mice (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 
2006).  IL-23 is not an absolute requirement for Th17 differentiation but plays a role in 
terminal differentiation, population expansion and effector function (McGeachy et al., 2009). 
IL-21 can substitute for IL-6 as an alternative pathway to generate Th17 cells (Korn et al., 
2007) and Th17 cells can themselves secrete IL-21 resulting in an autocrine feedback loop 
(Nurieva et al., 2007).  
 
One fascinating aspect of this complex regulation of Th17 cell differentiation is that 
there is a reciprocal developmental pathway shared by Treg and pro-inflammatory Th17 
cells. When naïve T cells are activated in the presence of TGF-β alone, this leads to a 
suppressive Treg phenotype. However, the presence of IL-6 inhibits the upregulation of 
Foxp3 and the combination of TGFβ and IL-6 instead drives differentiation towards a pro-
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inflammatory Th17 phenotype (Korn et al., 2008; Mangan et al., 2006). Therefore the 
presence or absence of IL-6 dictates whether an immune response is dominated by FoxP3+ 
Tregs or Th17 cells. Thus, induction of Th17 cells not only results in a pro-inflammatory 
effector population but also deters Treg generation, potentially promoting autoimmunity 
through two pathways. In addition, regulatory T cells may themselves promote the 
development of Th17 cells in vivo during early Th17 cell priming, although not in the later 
activation stages (Chen et al., 2011). More recently, in mice, a pathway independent of 
TGFβ but reliant on the combination of either IL-1β and IL-6 or IL-1β and IL-23 has also 
been shown to induce production of IL-17 in naïve precursors (Ghoreschi et al., 2010). 
However, these ‘alternative’ Th17 cells, differentiated in the presence of IL-6, IL-1β and IL-
23, possess a different expression profile in terms of cytokines, transcription factors and 
surface molecules and appear to be more pathogenic than ‘classical’ Th17 cells (Ghoreschi 
et al., 2010). 
 
Development of human Th17 cells now appears to be similar to that in mice 
(McGeachy and Cua, 2008). Early studies suggested that there was no requirement for TGFβ 
signalling (Acosta-Rodriguez et al., 2007a) but this was subsequently disproved and, as in 
mice, TGFβ was considered to be an absolute requirement (Manel et al., 2008; Volpe et al., 
2008; Yang et al., 2008a). In the presence of TGFβ, either IL-1β and IL-6 (Acosta-
Rodriguez et al., 2007a) or IL-1β and IL-23 (Wilson et al., 2007) are necessary to drive Th17 
differentiation from naïve human Th cells. In keeping with the pro-inflammatory nature of 
Th17 cells and IL-17, their generation is tightly regulated and both Th1 and Th2 cytokines 
negatively regulate Th17 development (Harrington et al., 2005; Park et al., 2005). However, 
now that TGFβ independent pathways for development have emerged in the mouse 
(Ghoreschi et al., 2010), the role of TGFβ in human differentiation of Th17 cells continues 
to be debated and it may be that Th17 cells in fact represent a spectrum of phenotypes with 
differences in cytokine production and effector function (Peters et al., 2011). 
 
Th17 cells are characterised by the production of IL-17A, IL-17F, IL-21, IL-22 and 
(in humans) IL-26 (Wilson et al., 2007). They may also produce IFNγ (Wilson et al., 2007) 
and chemokines such as CCL20 and its chemokine receptor CCR6 (Turner et al., 2010). 
Human Th17 cells have also been shown to express CCR6 and CCR4 (Acosta-Rodriguez et 
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al., 2007b). Retinoic acid-related orphan receptor-γt (ROR-γt) is the lineage specific 
transcription factor for Th17 cells (Ivanov et al., 2006). ROR-γt is controlled by STAT-3. 
RORα is another ROR family member which has a similar and redundant effect in 
promoting Th17 differentiation (Yang et al., 2008b). Other transcription factors such as the 
aryl hydrocarbon receptor have also been implicated in control of differentiation (Quintana 
et al., 2008). Th17 cells function prominently at mucosal surfaces and help to promote 
neutrophil mobilisation and the expression of anti-microbial factors. Expression of CCR6 
helps to direct them to those mucosal areas (Acosta-Rodriguez et al., 2007b). The wide-
ranging pro-inflammatory functions of Th17 cells are related to those already described for 
IL-17. Importantly IL-17 and Th17 cells also drive inflammatory pathology in a number of 
autoimmune disorders.  
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Figure 3. (A) Simplified diagram of the Th1, Th2, Th17, and Treg subsets, showing key 
cytokines produced by these cells, and the cytokines and transcription factors critical to the 
development and expansion of these subsets.  
The biologic functions of Th cell subsets are briefly summarized. There is evidence that 
Th17 cells can acquire the capacity to produce IFNγ, and adaptive Tregs can, at sites of 
inflammation, lose their Foxp3 expression and acquire effector function. (B) Summary of 
potential mechanisms by which Th17 cytokines could mediate immune renal injury. Taken 
from (Kitching and Holdsworth, 2011). 
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1.3.3.3 Phenotypic instability of Th17 cells 
 
Defining pathogenicity resulting from Th17 cells is not straightforward. Although in 
vitro studies suggest that T cells follow a strict developmental program when activated with 
discrete cytokines, in vivo T cells are actually exposed to a complex cytokine milieu and 
display considerable plasticity. However, there may be more plasticity of the Th17 
phenotype compared to other Th lineages. Murine Th17 cells in vitro can polarise to a Th1 
or a double-positive phenotype in the presence of IL-12, whilst Th1 cells are unaffected by a 
pro-Th17 cytokine cocktail (Shi et al., 2008). In addition, a long-term Th17 cell population 
maintained in vitro with IL-23 and IL-1β could revert to a Th1 or Th2 cytokine-secreting 
profile by exposing it to the relevant polarising cytokines. In vivo, Th17 cells transferred into 
NOD/SCID mice were able to induce disease but rapidly converted to secrete IFNγ and 
upregulated Tbet (Bending et al., 2009). Additionally, populations of double-producer cells 
which can secrete both IL-17 and IFNγ have been described, notably in the eye (Luger et al., 
2008; Shi et al., 2008). In humans, double producers of IL-17 and IFNγ have been found in 
the gut of patients with Crohn’s disease (Annunziato et al., 2007) and in in vitro polarised 
Th17 cells from healthy volunteers (Boniface et al., 2010). Even more intriguingly, human 
memory FOXp3+ Tregs have been found secrete to IL-17 ex vivo and express the 
transcription factor RORγt (Ayyoub et al., 2009).  
 
Th17 cells themselves can produce IL-10 which can prevent Th17-mediated immune 
pathogenesis, and Th17 cells differentiated in the absence of IL-23 adopt a more suppressive 
phenotype in EAE, underlining the importance of IL-23 for full effector function (McGeachy 
et al., 2007). However, this effect may be model-specific since, in a model of colitis, these 
cells retained their pathogenicity even in the absence of IL-23 (Lee et al., 2009). 
Furthermore, IL-23 has been shown to be necessary for maintaining an IL-17 secreting 
phenotype but does not mediate commitment to the lineage (Stritesky et al., 2008). 
Considering the potent pro-inflammatory properties of Th17 cells, there may be an 
evolutionary advantage to retaining some plasticity between the Thelper cell lineages.  
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1.3.4 Innate immune cells as a source of IL-17 
 
 Published experimental work has predominantly focussed on defining the role of IL-
17 in relation to Th17 cells and as a mediator of adaptive immunity. However, the 
importance of IL-17 in innate immunity, whilst long recognised (Fossiez et al., 1996), is 
latterly being regarded with renewed interest (Cua and Tato, 2010). Innate immune 
responses recognise generic targets on pathogens using germline encoded receptors, whereas 
adaptive immune responses recognise specific targets using randomly generated receptors 
which have an essentially unlimited recognition repertoire. Interactions between innate and 
adaptive forms of immune recognition are essential for the effective functioning of the 
immune response. The interactions between innate and adaptive immunity are multiple, 
complex and bi-directional, with innate mechanisms being instrumental in the initiation of 
adaptive responses, and controlling the type of adaptive response induced; innate effector 
mechanisms are also recruited in the effector phase of adaptive responses.  
 
IL-17 plays a role in the interaction of innate and adaptive immune responses. In the 
early response to infection, IL-17 has a critical role in induction and migration of 
neutrophils. However, IL-23 can promote innate IL-17 producing cells as well as IL-17 from 
memory CD4+ cells (Cua et al., 2003). Cooperation between IL-17-producing γδ T cells and 
antigen-specific CD4+ T cells has been shown to enhance the pathogenesis of experimental 
autoimmune uveitis (Cui et al., 2009). Furthermore, there is increasing evidence that early 
IL-17 production may also influence the subsequent effector CD4+ T cell response, 
particularly Th1 cells (Khader et al., 2007), by inducing chemokines that attract Th1 cells 
and induce optimal production of IFNγ in the lung (Umemura et al., 2007). In this way, 
innate IL-17-producing cells promote a more potent adaptive immune response for a more 
efficient resolution of infection. Innate IL-17-producing cells can also interact with memory 
T cells during chronic inflammation (Sutton et al., 2009). 
 
Since IL-17 secreted by innate cells of the immune system is critical in mediating an 
early response to infection or injury, many of these cells are located in the skin or at mucosal 
surfaces such as the gut and the lung. IL-17 can be produced by γδ T cells (Lockhart et al., 
2006), macrophages (Song et al., 2008), NK cells (Passos et al., 2010), invariant NKT 
(iNKT) cells (Coquet et al., 2008), neutrophils (Hoshino et al., 2008), lymphoid tissue 
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inducer-like cells (Takatori et al., 2009), mast cells (Lin et al., 2011) and Paneth cells in the 
gut (Takahashi et al., 2008). Little is known about the regulation of differentiation and 
effector function of these cells (Hirota et al., 2012). However, their requirements appear to 
be different to those of Th17 cells, for example, IL-6 does not appear to be a requirement 
(Doisne et al., 2009). Many of these innate IL-17 producing cells express the IL-23 and IL-
1β receptors, engagement of which enhances IL-17 production (Cua and Tato, 2010). 
 
IL-17 is critical in the innate immune response to infection. For example, IL-17 is 
required for the innate immune response to urinary tract infection with E.coli in experimental 
pyelonephritis, and IL-17 deficient mice in this model have reduced infiltration of 
neutrophils and macrophages (Sivick et al., 2010). As well as their roles as sentinels in host 
defence, where they help to orchestrate a rapid response to infection, these innate cells may 
also contribute to pathogenesis in autoimmunity. Whilst they cannot initiate an immune 
response to self-antigen, innate immune cells may be able to influence the local cytokine 
milieu to favour chronic inflammation, possibly either by local IL-17 acting as a paracrine 
factor to promote activation of Th17 cells or by IL-17 acting on APCs which then produce 
cytokines that drive the development of Th17 cells (Cua and Tato, 2010). For example, IL-
17 from CD3+ γδ T cells has been linked to response to mycobacterial infection (Lockhart et 
al., 2006), but also to autoimmunity in collagen-induced arthritis (Roark et al., 2008), uveitis 
(Cui et al., 2009) and glomerulonephritis (Turner et al., 2012). Neutrophils in mice with 
AAV can up-regulate IL-17 in response to ANCA (Hoshino et al., 2008) and neutrophils 
have been identified as an important early source of IL-17 in renal biopsies of patients with 
AAV (Velden et al., 2012). 
 
The complexity of the interaction between IL-17 from innate and adaptive immune 
cells, their temporal relationship, and how this may combine to mediate host defence, or 
autoimmunity, are poorly understood. Along with the phenotypic instability of Th17 cells, 
and an emerging protective role for IL-7, this is yet another reflection of how our 
understanding of pathogenesis is still in its infancy in this rapidly moving field. However, at 
the simplest level, IL-17-producing innate cells appear to be important for early mucosal 
immunity before evolution of the adaptive immune response (Khader et al., 2009).  
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Figure 4. Activation of innate IL-17-producing cells.  
(A) Development of adaptive immunity and a polarized effector Th17 population takes up to 
5 days in vivo. This process requires antigen presentation by APCs, using classical MHC 
molecules, in the presence of TGFβ, IL-6, IL-21, IL-23 and IL-1β. This initial activation 
results in the upregulation of STAT3 and RORγt expression to enhance IL-23 responsiveness 
and induce IL-17 production. After rounds of proliferation and differentiation in the lymph 
node, polarized Th17 cells, with stable expression of RORγt and aryl hydrocarbon receptor, 
are ready to migrate into target tissues. (B) By contrast, innate cells that reside in peripheral 
tissues can be activated in the presence of cytokines, such as IL-23 and IL-1β, alone or in 
combination with direct PAMP recognition by pattern recognition receptors or through their 
TCR, when expressed. Because these cells constitutively express transcriptional regulators 
for IL-17 production, they can produce IL-17 protein within hours of stimulation. Taken 
from (Cua and Tato, 2010). 
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1.3.5 IL-17A in human autoimmune disease 
 
Central to this thesis is the fact that IL-17A promotes inflammatory pathology in 
autoimmune disease and I will go on to discuss evidence for IL-17 in both renal and non-
renal animal models of autoimmunity. In humans, although proving causation is difficult, 
patients with GPA in remission have been found to have an increased proportion of Th17 
cells within the activated CD69+ subset (Abdulahad et al., 2008), and work presented in this 
thesis has shown that in patients with ANCA-associated vasculitis, levels of both IL-17 and 
IL-23 are elevated and some memory cells respond to stimulation with ANCA antigens by 
producing IL-17 (Nogueira et al., 2010). In renal biopsies from patients with AAV, 
neutrophils, and to a lesser degree mast cells, are an abundant source of IL-17 (Velden et al., 
2012).  IL-17 has been detected in the synovium of patients with rheumatoid arthritis and 
induces proinflammatory cytokine production from synoviocytes (Chabaud et al., 1999). 
Serum levels of IL-17 and the number of Th17 cells is increased in patients with SLE (Wong 
et al., 2008) and is increased with disease activity (Yang et al., 2009). Similarly, serum 
levels of IL-17 are elevated in multiple sclerosis (Matusevicius et al., 1999) and myelin 
antigen-reactive Th17 cells are enriched in patients (Venken et al., 2010). IL-17 has also 
been found to be over-expressed in inflammatory airways disease (Hoshino et al., 2000), 
transplant rejection (Van Kooten et al., 1998), psoriasis (Teunissen et al., 1998), 
inflammatory bowel disease (Nielsen et al., 2003) and systemic sclerosis (Kurasawa et al., 
2000). 
 
1.3.6 IL-17 deficient mice 
 
IL-17 deficient mice for this study were a generous gift from Professor Yoichiro 
Iwakura at the Centre for Experimental Medicine, University of Tokyo. These were 
generated by replacing exons 1 and 2 of the IL-17 gene with a neomycin resistance gene. 
Chimera mice were generated using C57BL/6J blastocysts as the recipients and these were 
mated with C57BL/6J mice for germline transmission (Nakae et al., 2002).  
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IL-17 deficient mice are fertile and grossly phenotypically normal. Early assessment 
by Professor Iwakura’s group showed that IL-17 has a role in allergen-specific cellular and 
humoral immune responses. Delayed-type hypersensitivity responses, which characterise 
granulomatous lesions in GPA and are important in NTN, are reduced in IL-17 deficient 
mice. Contact and airway hypersensitivity responses are also reduced.  T cell proliferation in 
response to mitogenic stimuli is unaffected but T-cell dependent humoral responses are 
reduced with significantly lower IgG production in IL-17 deficient compared to WT mice. 
Neutrophil infiltration is reduced (Nakae et al., 2002). Since these early findings, as the 
result of a body of experimental work using IL-17 deficient mice, our understanding of the 
implications of IL-17 deficiency has broadened and become more detailed. The 
consequences of infection in IL-17 deficiency have already been outlined previously in 
sections 1.3.2 and 1.3.4, and I will now go on to discuss the role of IL-17 in organ-specific 
models of autoimmunity.  
 
1.3.7 Evidence for IL-17 in non-renal models of autoimmunity 
 
A number of studies have proposed a role for Th17/ IL-17 in the pathogenesis of 
certain experimental animal models and human immune-mediated diseases. The discovery 
that IL-23 (which stabilises the Th17 population and promotes terminal differentiation) is a 
heterodimer, sharing a structural p40 subunit with IL-12 (a Th1 cytokine) and expressing a 
unique p19 subunit (Oppmann et al., 2000) prompted a re-examination of experimental 
work, using IL-12p40 gene targeted mice and neutralizing antibodies to p40, that had 
originally suggested a primary role for IL-12–producing Th1 cells in the pathogenesis of 
autoimmune disease. Experimental autoimmune encephalomyelitis (EAE), a well-
established model for human multiple sclerosis, and collagen-induced arthritis (CIA) which 
models human rheumatoid arthritis were thought to be Th1 cell-mediated diseases, as IL-
12p40 deficiency attenuated disease severity. However, mice treated with anti-IFNγ or mice 
deficient in IFNγ also developed aggravated EAE and CIA (Ferber et al., 1996; Vermeire et 
al., 1997). Two groups independently provided an explanation for these findings. Cua (Cua 
et al., 2003) and Murphy (Murphy et al., 2003) both used p35 (IL-12
-/-
)-, p19 (IL-23
-/-
)- and 
p40 (IL-12
-/-
/IL-23
-/-
)-deficient mice to induce EAE or CIA. IL-23-deficient (p19
-/-
) mice 
showed dramatically attenuated disease development, indicating that IL-23 rather than IL-12 
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is required for the pathogenesis of EAE and CIA. Further studies revealed that neutralization 
of IL-17 or IL-17 deficiency rendered the mice resistant to EAE induction (Komiyama et al., 
2006) and impaired joint inflammation (Lubberts et al., 2004; Nakae et al., 2003). Adoptive 
transfer of pathological Th17 cells, but not Th1 cells, from established EAE mice also re-
established EAE in recipient mice (Langrish et al., 2005) and blockade of IL-23 ameliorated 
EAE (Chen et al., 2006). Taken together, these data suggest a central role of IL-17 or Th17 
cells in autoimmune disease development.  
 
However, although many autoimmune models are dependent on IL-17, this is not 
absolute and it remains true that in some models Th1 cells play a role. Diabetes in the NOD 
mouse is dependent on IFNγ, not IL-17 (Bending et al., 2009). In EAE and experimental 
autoimmune uveitis (EAU), both Th1 and Th17 cells can transfer disease (Kroenke et al., 
2008; Luger et al., 2008), although the pattern of disease is different in each, with Th17 cell 
transfer leading to a predominantly neutrophilic rather than mononuclear cellular infiltrate. 
Tbet and STAT4-deficient mice are resistant to EAE (Bettelli et al., 2004; Chitnis et al., 
2001) suggesting either that these transcription factors have important roles in both Th17 and 
Th1 inflammation or that co-operation between these two lineages is necessary for disease in 
this context. This complicates the picture with regard to causation of disease. The role of 
Th1 cells in autoimmunity cannot be discounted and the interplay between the Th1 and Th17 
lineages is far from completely understood (Damsker et al., 2010). It may be that these two 
cell lineages are able to co-operate to achieve certain effector functions rather than simply 
being antagonistic. 
 
1.3.8 Evidence for IL-17 in renal models of autoimmunity 
 
All of the following work relating to the role of IL-17 in renal disease has been 
published since I began work on this thesis, which reflects the recent and rapid evolution of 
understanding in this field. Like many of the experimental models discussed above, 
autoimmune glomerulonephritis had historically been considered to be a Th1-mediated 
condition, largely due to work carried out in genetically modified rodents (Kitching et al., 
1999a; Kitching et al., 1999b). Infiltration of T cells into the kidney is one of the central 
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features of autoimmune glomerulonephritis and is closely related to changes in renal 
function. Infiltrating T cells can cause damage either directly by cytotoxicity or secretion of 
cytokines, or indirectly by activating macrophages or inducing autoantibodies. Mice 
deficient in Th1 cytokines such as IL-12p40 and IFNγ are protected from renal injury and 
have reduced monocyte and T cell recruitment (Kitching et al., 1999a; Kitching et al., 2005), 
while antagonising the Th1 response with either anti-IL-12 or anti-IFNγ ameliorates disease 
(Huang et al., 1997b; Kitching et al., 1999b), and deficiency of the Th1 transcription factor T 
bet abrogates disease (Phoon et al., 2008).  Conversely, the Th2 cytokines IL-4 (Kitching et 
al., 1998) and IL-10 (Kitching et al., 2000) have been shown to be protective. 
 
However, in 2009, work in experimental glomerulonephritis was published by two 
groups which explored the attribution of pathogenesis entirely to Th1 cells in much the same 
way as had been done for EAE and CIA. This is work that answers some of my original 
hypotheses, and is similar to that which I have also described in my own experiments in 
Chapter 3, which were carried out contemporaneously to these with similar outcomes. Using 
the NTN model, Paust and colleagues demonstrated that mice deficient in IL-17 or IL-23 are 
protected from nephritis as measured by albuminuria, renal function and the presence of 
crescents, but less T cell and monocyte recruitment compared to WT mice (Paust et al., 
2009). Interestingly there were similar humoral responses in all groups. IL-23p19
-/- 
mice had 
fewer Th17 cells, in keeping with the role of IL-23 in maintaining the Th17 population, 
although even in nephritic WT animals only 3-7% of renal CD3+ T-cells in fact produced 
IL-17. They concluded that Th17 cells were important in pathogenesis and also showed that, 
in mouse mesangial cells, IL-17 was pro-inflammatory and promoted production of CCL2, 
CCL3 and CCL20 which contribute to recruitment of T cells and monocytes.  
 
Ooi and colleagues, in complementary work which was also published 
contemporaneously, used a model of experimental autoimmune glomerulonephritis induced 
by immunisation with α3(IV)NCI, the Goodpasture disease antigen, in a series of genetically 
modified mice to dissect the relative contributions of IL-12 and IL-23 in disease (Ooi et al., 
2009). Building upon previous work showing that IL-12p40
-/-
 animals were protected, but 
that IFNγ-/- animals developed more severe disease, they examined the contributions of the 
p35 and p19 subunits to pathogenesis. Using IL-12p35
-/-
 (IL-12 deficient, IL-23 intact), IL-
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12p40
-/-
 (IL-12 and IL-23 deficient) and IL23p19
-/-
 (IL-23 deficient, IL-12 intact) animals it 
was demonstrated that deficiency of IL-23 is necessary and sufficient to protect from disease 
regardless of IL-12 status, suggesting that the Th17 lineage might have primacy over the Th1 
lineage in the generation of disease. Interestingly, considering the reciprocal developmental 
pathways of Treg and Th17 cells, protection in the absence of IL-23 was not mediated by a 
reciprocal increase in FOXP3+ regulatory T-cells. Unusually in the IL-23
-/-
 mice in these 
experiments, along with less IL-17 there was also decreased IFNγ, IL-4, TNF and MCP-1 
suggesting a broader deficit in T-cell cytokine production than has been observed using these 
mice in other models of autoimmunity.  
 
A role for IL-17 has also been demonstrated in a renal model of AAV. Using an 
autoimmune anti-myeloperoxidase glomerulonephritis (AIMPOGN) model (Ruth et al., 
2006), Gan and colleagues demonstrated that IL-17
-/-
 mice are protected from disease, in part 
due to less neutrophil recruitment (Gan et al., 2010). In addition, direct intra-renal injection 
of MPO-sensitised mice resulted in reduced renal macrophage accumulation in IL-17
-/-
 
animals also demonstrating a role for IL-17 in orchestrating the delayed-type 
hypersensitivity reaction in the kidney. In all three of these models, NTN, EAG and 
AIMPOGN, although the experiments show that IL-17 contributes to disease, they do not 
demonstrate whether this critical production of IL-17 comes from innate or adaptive immune 
cells, or both.  
 
In NTN, further work has gone on to investigate specifically the ability of Th17 cells 
to transfer disease. Two groups, using a similar experimental system, used a planted antigen 
model with ovalbumin bound to the GBM of RAG
-/-
 mice and examined the ability of in 
vitro polarised antigen-specific T cells to transfer disease (Summers et al., 2009; Tulone et 
al., 2011). Both groups found that antigen specific Th17 cells transferred in this model could 
induce proliferative glomerulonephritis. However, whilst Tulone and colleagues observed no 
disease when comparable Th1 cells were transferred, Summers and colleagues found that 
Th1 cells could induce disease albeit over a longer time course (21 days compared with 3 
days using Th17 cells) and a slightly different pattern of disease (with increased macrophage 
activity and more crescents). 
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Work in murine lupus nephritis has also shown a role for Th17 cells in disease. In 
MRL/lpr lupus-prone mice, a significant number of double-negative (CD4- and CD8-) T-
cells in the tubulo-interstitium express IL-17 and this proportion increases with worsening 
disease (Zhang et al., 2009). MRL/lpr mice deficient in the chemokine receptor CXCR3 are 
protected from nephritis with decreased intra-renal numbers of both Th1 and Th17 cells 
(Steinmetz et al., 2009), demonstrating a role for both Th17 cells and CXCR3 in trafficking 
effector T cells. 
 
The relationship between Th1 and Th17 cells in glomerulonephritis is incompletely 
understood but some aspects of it might be temporal in nature. One group has identified a 
role for Th17 cells early in the course of nephritis. Early infiltration of Th17 cells triggers 
expression of CXCL9 in the kidney, which subsequently drives the infiltration of Th1 cells 
into the kidney by virtue of their expression of CXCR3, the CXCL9 receptor. Th1 cells are 
the critical mediators later on in disease and subsequently inhibit the Th17 response by the 
inhibition of CCL20 acting on its receptor CCR6 on Th17 cells. Thus there is a time-
dependent feedback loop which cross-regulates the Th1 and Th17 lineages (Paust et al., 
2012). Some of these findings have been corroborated by work which has also proposed a 
protective role for IL-17 later on in disease (Odobasic et al., 2011) and this is discussed 
subsequently in section 1.3.9. Overall, in conjunction with the findings that mice deficient in 
IFNγ (Kitching et al., 1999a) and Tbet (Phoon et al., 2008) are protected from 
glomerulonephritis, there is likely to be a role for both Th1 and Th17 lineages in the 
pathogenesis of experimental glomerulonephritis, as in other models of autoimmunity. 
 
1.3.9 An immuno-regulatory role for IL-17? 
 
There is a wealth of evidence, as has been described, for a pathogenic role of IL-17 
or Th17 cells in mediating disease. However, recently, a more nuanced perspective of the 
role of IL-17 in autoimmunity has emerged and there is now also limited evidence for an 
immune-regulatory role for IL-17. Activated autoreactive Th17 cells, when expanded in the 
presence of IL-6 and TGFβ produce large amounts of IL-10 and suppress pathogenic 
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autoimmunity. In contrast, IL-23 suppresses IL-10 production (McGeachy et al., 2007). The 
combination of IL-27 and IL-6 has also been shown to induce Th17 cells to produce IL-10 
(Stumhofer et al., 2007). In graft versus host disease, IL-17 deficient cells induce more 
severe disease than WT cells (Yi et al., 2008). In asthma, although IL-17 is required for 
disease initiation, IL-17 is suppressive in the effector phase (Schnyder-Candrian et al., 
2006), reducing pulmonary eosinophil recruitment and bronchial hyper-reactivity.  
 
In experimental models of colitis the evidence for a protective role for IL-17 varies 
depending on the model used. The potential contribution of IL-17 to a dextran sodium 
sulphate-induced acute colitis model is controversial; one study reported that IL-17
-/-
 mice 
displayed a reduced clinical score (Ito et al., 2008), whereas another study demonstrated that 
mice given anti-IL-17 showed severe weight loss and colonic epithelial damage (Ogawa et 
al., 2004). IL-17R deficient mice are protected in another model of chemical-induced colitis 
(Zhang et al., 2006). However, using the CD45RBhi model of colitis, transfer of IL-17
-/-
 or 
IL-17RA
-/-
 CD45RBhi cells into RAG
-/-
 mice resulted in worse disease, with accelerated 
wasting and an increased production of Th1 cytokines, than transfer of WT cells, 
demonstrating that IL-17 can be protective, signalling through CD45RBhi cells to dampen 
disease (O'Connor et al., 2009). Finally, in experimental autoimmune uveitis, treatment with 
anti-IL-17 antibodies blocked disease development, however, injection of uveitis-susceptible 
rats and mice with recombinant human IL-17 unexpectedly ameliorated disease (Ke et al., 
2009). There have also been recent suggestions of a biphasic effect of IL-17 in renal disease. 
In autologous (non-accelerated) NTN which follows a more indolent course, IL-17 promotes 
early kidney injury at day 6 but by day 21, IL-17 attenuates established disease (Odobasic et 
al., 2011). 
 
How IL-17 mediates protection and pathogenicity, potentially in the same 
experimental model, remains to be determined. However, it may be related to the temporal 
course of disease (Odobasic et al., 2011), or it may relate to the cell-type that is producing 
IL-17 and its relationship with the local micro-environment. The importance of non-Th17 
cells in IL-17 production is increasingly being recognised. For example, neutrophils are a 
significant source of IL-17 in human renal biopsies (Velden et al., 2012). Γδ Tcells have 
been proposed as the most significant source of IL-17 in joints in CIA (Tao et al., 2011) and 
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IL-17 production from γδ T cells also plays a role in EAE induction (Sutton et al., 2009).  
Most recently, and of relevance to my hypothesis, γδ T cells are important producers of IL-
17 in early NTN (Turner et al., 2012).  
 
 
 
 
 
Figure 5. The protective and pathogenic functions of Th17 cells.  
Depending on the local cytokine environment, different subsets of Th17 cells arise and 
mediate distinct effector function. In the presence of IL-23, Th17 cells seem to be pro-
inflammatory and can either make IFNγ themselves or work in concert with Th1 cells to 
drive a positive feedback pathway of tissue damage such as that seen in psoriasis or RA. In 
Crohn’s disease, Th17 cells can differentiate in the gut into protective or pathogenic Th17 
cells. In the presence of TGF-β and IL-21, Th17 are re-programmed into “regulatory” Th17 
cells which seem to protect from intestinal inflammation. Taken from (Marwaha et al., 
2012). 
. 
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1.4 Clinical significance of the project 
 
 AAV are complex, multi-system disorders that cause considerable morbidity and 
mortality. Rapidly progressive glomerulonephritis remains one of the most feared 
complications, with end stage renal failure developing in 20% of patients (Booth et al., 
2003). Without treatment, the prognosis for AAV is very poor – for example the median 
survival for patients with generalised GPA is only 5 months (Walton, 1958). However, since 
the 1970’s when treatment with steroids and cyclophosphamide was introduced, the outlook 
has improved considerably.  Induction of remission is now achieved in over 90% of patients 
by 6 months (Jayne et al., 2003), and five year survival rates are around 75% (Matteson et 
al., 1996). Despite these improvements, it remains the case that relapse rates are still high at 
up to 50% over 5 years (Westman et al., 1998). Even with best available therapy, it is also 
the case that side-effects of treatment contribute significantly to morbidity and mortality.  
 
At present, the long-term management of AAV requires balancing the burden of 
immunosuppression with control of disease activity. It is clear that more targeted, and less 
toxic, therapeutic protocols are required. In order to bring this about, the factors initiating 
disease and causing relapse must be more clearly defined. As understanding of the 
pathogenesis of AAV and immune-mediated glomerulonephritis advances, a number of new 
approaches to immunomodulation as a means of treatment have been explored. B cell 
depletion with rituximab appears to be effective (Jones et al., 2010; Stone et al., 2010), 
Alternatively, B cell modulation by LymphoStat B (Belimumab), a human anti-B 
lymphocyte stimulator (BLyS) monoclonal antibody, has shown promise in phase III trials in 
SLE (Furie et al., 2011) and could be considered in AAV. Abatacept, a fusion protein of 
CTLA4-Ig which selectively modulates T-cell co-stimulation by blocking the engagement of 
CD28, would theoretically be of benefit in AAV, although a multi-centre trial was 
terminated early due to slow recruitment. Other examples of potential strategies for 
immunomodulation include the use of blockade of IL-6 (Kawashiri et al., 2009) and IL-5 
(Rothenberg et al., 2008), which have been used in other autoimmune disorders and, with 
improved understanding of disease mechanisms, might have a role in AAV. 
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The work described in this thesis contributes to current understanding of the role of 
IL-17 in the pathogenesis of AAV and glomerulonephritis. Monoclonal antibodies blocking 
IL-17A and the IL-17 receptor are already available, and clinical trials of IL-17 blockade or 
manipulation of the Th17 axis have been carried out in a number of other autoimmune 
conditions. As yet, there have been no human trials of IL-17 blockade in AAV or renal 
disease.  Before moving in this direction, a more complete understanding of the role of IL-
17, both pathogenic and protective, in autoimmunity is required, with particular reference to 
AAV and glomerulonephritis, and it is to this end that the work in this thesis is directed. I 
will now outline the outcomes of some of the trials of IL-17 blockade in autoimmunity 
before going on to the final section of this introduction: the project hypotheses and aims. 
 
1.4.1 Clinical trials of IL-17 blockade 
 
There is evidence from clinical trials to support therapeutic blockade of the p40 
subunit of IL-12 and IL-23, which blocks both IL-12 from the Th1 axis and IL-23 from the 
Th17 axis, in a number of autoimmune conditions.  In psoriasis, a number of these trials 
using the anti-p40 monoclonal antibodies Briakinumab or Ustekinumab have successfully 
completed, including in psoriatic arthritis (Gordon et al., 2012; Gottlieb et al., 2009; Kimball 
et al., 2011; Papp et al., 2008). Additionally Ustekinumab was superior to TNFα blockade 
with Etanercept in moderate to severe plaque psoriasis (Griffiths et al., 2010). In Crohn’s 
disease, Briakinumab and Ustekinumab have both been successfully trialled (Mannon et al., 
2004; Sandborn et al., 2008). However, Ustekinumab produced no substantial therapeutic 
effects in a trial to treat patients with relapsing-remitting multiple sclerosis (Segal et al., 
2008). 
 
At present, the majority of evidence from clinical trials for Th17 modulation comes 
from these trials of dual IL-12/IL-23 blockade. However, clinical trials of IL-17A blockade 
are underway, or have completed, in autoimmune uveitis, psoriatic arthritis, ankylosing 
spondylitis, ulcerative colitis, polymyalgia rheumatic, multiple sclerosis, rheumatoid arthritis 
and Crohn’s disease (www.clinicaltrials.gov). The sometimes conflicting outcomes of these 
trials have been widely reviewed (Marwaha et al., 2012; Steinman, 2010). A phase I trial in 
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rheumatoid arthritis (Genovese et al., 2010) and results in two phase II psoriasis trials have 
been broadly favourable (Leonardi et al., 2012; Papp et al., 2012). The psoriasis trials used 
Brodalumab, a human anti-IL-17 receptor, and Ixekizumab (LY2439821), a humanised anti-
IL-17 monoclonal antibody, whilst the rheumatoid arthritis trial used Ixekizumab. Small 
trials of Secukinumab (AIN457), a fully human anti-IL-17 monoclonal antibody, in 
rheumatoid arthritis, uveitis and psoriasis have been variable but promising (Hueber et al., 
2010). However, in contrast, and unexpectedly, a recent phase II trial in Crohn’s disease of 
Secukinumab, was terminated early as it was inferior to placebo at the primary end point 
(Hueber et al., 2012). In particular, patients with inflammatory Crohn’s disease, as defined 
by elevated CRP or faecal calprotectin, did much worse, consistent with a protective role for 
IL-17.  
Overall it is clear that therapeutic modulation of IL-17A or the Th17 axis may be of 
benefit in some autoimmune diseases. However, this is not the case for all autoimmune 
diseases, and in some cases might even be harmful without further insight into pathogenesis. 
Additionally, the role of IL-17 with regard to host defence, particularly from fungal infection 
and bacterial infections such as S.aureus, should be borne in mind since some trials have 
seen an increase in infectious complications (Gordon et al., 2012; Hueber et al., 2012). 
Functional redundancy between IL-17A and IL-17F with regard to host defence may help to 
explain why these opportunistic infections have not been more frequent.  
 
1.5 Hypotheses and aims of the project 
 
 IL-17A and Th17 cells have been implicated in the pathogenesis of a number of 
autoimmune disorders. I have hypothesised that they are important in the development of 
glomerulonephritis and AAV. Therefore my original hypotheses were that mice deficient in 
IL-17 would be protected from NTN, and that patients with AAV would have increased 
serum levels of IL-17 or other markers of activation of the Th17 axis. By undertaking the 
work in this thesis I have aimed to: 
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 Define a role for IL-17 in the accelerated NTN model of immune-mediated 
glomerulonephritis, through a comparison of disease outcomes in IL-17-deficient and 
WT mice, and an assessment of the associated immune response (Chapter 3).  
As described in section 1.3.8 of this Introduction, during the course of this work 
similar results were also published by another group (Paust et al., 2009). 
 
 Determine whether disease susceptibility or resistance to NTN can be transferred.by 
transfer of WT or IL-17 deficient splenocytes, or CD4+ T cells (Chapter 3). 
 
 Assess the relative contribution of IL-17 from circulating leucocytes and intrinsic 
cells in NTN through the creation of bone marrow chimeras in WT and IL-17 
deficient mice (Chapter 4).  
 
 Consider potential aspects of the immune response that might contribute to novel 
results of the bone marrow transplant experiments including intra-renal cytokine 
expression and macrophage phenotype (Chapter 4). 
 
 Define a role for IL-17 in human disease, AAV, by measuring serum levels of IL-17 
and related cytokines in patients with AAV, compared to patients with other relevant 
diseases and healthy controls (Chapter 5).  
 
 Establish whether there is a memory Th17 population in patients with AAV that 
responds to stimulation with ANCA auto-antigen, MPO or PR3 (Chapter 5). 
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Chapter  2 
Materials and Methods 
 
 
2.1 Materials 
 
2.1.1 Animals 
 
 IL-17 deficient mice were generously donated by Professor Y Iwakura, Centre for 
Experimental medicine, University of Tokyo, Japan. IL-17 deficient mice were generated by 
a targeted mutation of the IL-17A gene in sv129 animals and backcrossed onto a C57BL/6 
background (Nakae et al., 2002). Homozygous mice were bred to provide experimental mice 
at the Central Biological Services Unit at Hammersmith Hospital. Mice used in this study 
were 8-12 weeks of age. Control age- and sex- matched C57BL/6 mice were obtained from 
Charles River laboratories. All mice were housed with free access to food and water and 
were kept in a specific pathogen free environment, according to institutional guidelines. 
Experiments were performed according to Home Office guidelines. 
 
2.2 Methods 
 
2.2.1 In vivo studies 
 
2.2.1.1 Genotyping of IL-17-/- mice by polymerase chain reaction (PCR) 
 
 Genomic DNA was isolated from a 2mm tail snip. Tissue samples were lysed 
overnight at 56°C with agitation in 250µl of DNA lysis buffer containing 100µg/ml 
proteinase K (Sigma-Aldrich) which was added immediately before use. For PCR, the DNA 
was diluted in three volumes of distilled H2O and heat inactivated at 75°C for 15 minutes. 
The following primer sequences were provided by Professor Iwakura:  
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1. IL-17 common primer: 5’-ACTCTTCATCCACCTCACACGA-3’ 
2. IL-17 wild-type primer: 5’-GTACACCAGCTATCCTCCAGATAG-3’ 
3. IL-17 mutant primer: 5’-GCCATGATATAGACGTTGTGGC-3’ 
 
Primers 1 and 2 are used to detect wild-type allele (0.7kb) and primers 1 and 3 are used to 
detect the mutant allele (0.5kb). A 25µl PCR was carried out using a PTC-200 Thermo 
Cycler (MJ Research). The reagents in each reaction tube comprised 1 PuRe Taq Ready-To-
Go PCR bead (GE Healthcare), 10pmol common primer, 10pmol wild-type primer, 10pmol 
mutant primer, 1 µl DNA and 21 µl H2O. Conditions for cycling were provided by Professor 
Iwakura and are detailed below: 
 
PCR conditions 
 
Denaturation  94°C 2mins 
 
Amplification  94°C 15 sec 
   64°C 30 sec   x40 cycles 
   72°C 1min 
 
Extension  72°C 10mins 
   25°C hold 
 
PCR products were analysed by gel electrophoresis. 3g of agarose (Sigma-Aldrich) 
were diluted in 150ml Tris Acetate EDTA (TAE), microwaved for 3 minutes and 5µl of 
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ethidium bromide (Sigma) was added to stain the DNA. The gel was left at room 
temperature for 1 hour to set. 15µl of each sample was mixed with 5µl of loading dye (New 
England BioLabs inc) and 15µl of this mixture was loaded on to the gel. A 100bp ladder 
(New England BioLabs inc) was used to size the PCR products. Samples were 
electrophoresed in TAE at 150V for 30-60 mins and the DNA was then visualised under 
ultraviolet light using a transilluminator. 
 
2.2.1.2 Induction of accelerated nephrotoxic nephritis 
 
 Mice were pre-immunised subcutaneously with 0.2mg of sheep IgG (Sigma-Aldrich) 
made up in PBS in a 50:50 mix with Complete Freund’s Adjuvant (CFA) (Sigma Aldrich). 
This mixture was prepared by repeatedly mixing the solution between two glass syringes 
joined by a double-luer lock (Sigma Aldrich). When fully homogenised, a droplet placed on 
water retained its form. Five days after immunisation, the animals were injected with 200µl 
sheep nephrotoxic globulin (NTS) diluted 1:1 in 0.9% NaCl, via the tail vein. Using 
absorbance spectrophotometry of ammonium sulphate precipitated serum, protein 
concentration of the NTS was quantified as 292mg/ml.  Mice were placed in metabolic cages 
for 24 hours one day before they were humanely killed 7-9 days after NTS injection, at 
which point kidneys and spleen were harvested, and urine and blood was collected. Blood 
was allowed to clot at room temperature before separating serum which was stored at -80°C 
 
2.2.1.3 T-cell isolation and cell transfer 
 
For cell transfer experiments, pre-immunised donor mice were sacrificed and spleens 
removed into RPMI-1640 medium (Gibco, Paisley, UK)) with 2% penicillin-streptomycin 
(5000u/ml penicillin, 5000µg/ml streptomycin, Gibco) on ice. Spleen tissue was 
homogenised using a 100µm cell strainer (BD Falcon). Homogenates were suspended in 
phosphate-buffered saline (PBS), centrifuged and the cell pellet re-suspended in ACK lysis 
buffer for 4 minutes. Cells were washed twice with PBS and counted. Subsequently T-cells 
were isolated using the MACS pan T-cell isolation kit (Miltenyi Biotech) as per 
manufacturer’s instructions. Briefly, the single cell suspension was re-suspended in buffer 
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(PBS, 2mM EDTA, 0.5% bovine serum albumin (BSA)) and biotin antibody cocktail was 
added. The mixture was left at 4°C for 10 minutes, when anti-biotin microbeads were added 
for an additional 15mins. Cells were then washed and re-suspended in buffer. Magnetic 
separation was performed using a MACS separator and MACS MS column (Miltenyi 
Biotech). Effluent represented the enriched T-cell fraction and retained cells represented the 
non-T-cell fraction. Purity of the enriched T-cells was evaluated by flow cytometry, as 
detailed below. 
 
In some experiments, T cell fractions were labelled with PKH26 red fluorescent cell 
linker kit (Sigma-Aldrich) after separation. Cells were washed in serum-free medium at 600g 
for 5 minutes,  re-suspended in 1ml of PBS and mixed with 1ml of dye solution (4µl dye in 
1ml PBS) before incubating at room temperature for 3 minutes. The reaction was stopped 
with an equal volume of foetal calf serum. The cell suspension was diluted with complete 
medium and washed 3 times before re-suspending and counting.  In order to visualise these 
labelled cells post mortem, frozen kidney sections were mounted in Vectashield mounting 
medium (Vector Laboratories, Burlingame, CA, USA) with 4,6-diamidino-2-phenylindole 
(DAPI) and analysed by indirect immunofluorescence using a wide-field microscope and a 
TRITC filter. 
 
Flow Cytometry of enriched splenocyte fractions 
 
Purity of the enriched T-cell and non T-cell fractions was assessed following pan T-
cell isolation by antibody staining and flow cytometry. On a 96 well V-shaped plate (Nunc, 
Denmark), 100µl cell suspension containing 1 million cells per well was added. Cells were 
stained with one of, FITC isotype control, PE isotype control, rat anti-mouse CD3 (FITC), 
anti-CD4 (FITC) or anti-CD8 (PE) which were added to individual wells (all BD 
biosciences). Cells were incubated at 4°C for 30 minutes and washed twice in 1% PBS/BSA. 
200µl 2% paraformaldehyde was added to all wells and the plate was stored at 4°C in the 
dark until analysis, performed within one week of staining. 
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2.2.1.4 Bone Marrow Transplantation 
 
 Female donor bone marrow was harvested from the femur and tibia by flushing with 
a 21G needle using sterile PBS, collected, spun down at 600g at 4°C for 5 minutes, re-
suspended then washed again and counted using a haemocytometer. The cells were 
centrifuged again and re-suspended in sterile PBS to a final concentration of 5x10
7 
cells/ml. 
Ten million cells (0.2ml) were injected intravenously per mouse. 
Recipient female mice were irradiated in an IBL 637 irradiator at CBS Hammersmith 
hospital at a dose of 8Gy which was optimised by Dr Ruth Tarzi in our laboratory. 
Following irradiation the mice were injected with the bone marrow cells via a tail vein. 
During the following eight weeks, the mice were housed in individually ventilated cages 
with free access to autoclaved food and acidified water. They were kept in a specific 
pathogen free environment according to institutional guidelines.  
 
2.2.1.5 Semi-quantitative PCR of circulating leucocyte DNA 
 
In order to assess genetic reconstitution of leucocytes following bone marrow 
transplantation, DNA was extracted from clotted blood isolated from all animals at the end 
of the bone marrow transplant experiments. About 100µl of blood was removed into an 
autoclaved Eppendorf tube and allowed to clot. 0.5ml lysis buffer containing proteinase K 
(100µg/ml) was added to each blood sample and the samples were incubated in the oven at 
56°C overnight. 
 
To extract DNA, 300µl of saturated NaCl was added to each lysed sample and 
vortexed. 200µl of chloroform was added in a fume hood and then vortexed again. The 
samples were spun in a micro-centrifuge at 14000g at room temperature. 0.5ml of the 
supernatant, containing the dissolved DNA, was removed avoiding the protein precipitate 
below. 50µl of 3M sodium acetate was added to the supernatant, followed by 550µl of 
isopropanol to precipitate the DNA. The samples were gently inverted a few times and 
centrifuged for 10 minutes at 8000g. The DNA pellet was washed twice in 70% ethanol 
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(Fisher Scientific) and allowed to dry.  The DNA was then dissolved in 20µl Tris-EDTA and 
stored at 4°C. For PCR to assess reconstitution, DNA concentration was measured using a 
NanoDrop spectrophotometer and diluted to 100ng/ml for all samples. For PCR, 1µl of this 
solution was added directly to the 25µl reaction mixture and PCR for the IL-17 wild-type 
and mutant alleles was carried out as described above. 
 
In order to define the sensitivity of the PCR for WT and recombinant DNA, a 
standard curve of known proportions of WT and recombinant DNA was prepared. The 
proportions used were: 100% WT, 0% IL-17
-/-
; 99.9% WT, 0.1% IL-17
-/-
; 99% WT; 90% 
WT; 75% WT; 50% WT; 25% WT; 10% WT; 1% WT; 0.1% WT and 100% IL-17
-/-
. The 
limit of detection of the WT band was 1% and the limit of detection of the IL-17
-/-
 band was 
0.1%. Due to the semi-quantitative nature of the PCR, it was not possible to quantitate the 
proportion of donor and recipient DNA precisely but the relative intensity of the donor and 
recipient bands was used to estimate the degree of donor reconstitution.  
 
2.2.1.6 Measurement of proteinuria, serum creatinine and serum urea 
 
Individual 24-hour collections of urine were performed using metabolic cages, in 
which the mice had free access to food and water. The concentration of protein in the urine 
of the mice was assessed using a Sulphosalicylic Acid Assay. On a 96 well ELISA plate 
(Nunc Maxisorb, Life Technologies, Paisley, UK), BSA standards and urine from individual 
animals (1:10 dilution) were added in triplicate. BSA standards were made up in six different 
dilutions (0, 0.02, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1mg/ml). 25% sulphosalicylic acid was 
added to two wells and 10µl/well water to the third well for each sample. After 6-8 minutes 
at room temperature, optical density was analysed using an Anthos Multiscan ELISA plate 
reader (Lab Tech International, UK) at a wavelength of 450nm. Proteinuria concentration 
was calculated with reference to BSA standards by linear regression. At the point of 
collection, urine was also analysed by dipstick urinalysis (Multistix 8 SG, Siemens), which 
grades the urine for protein (and blood) concentration by colour change. 
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Serum urea and creatinine were kindly measured in the department of Clinical 
Chemistry, Hammersmith hospital, under the direction of Mr John Meek. Creatinine was 
measured by the Jaffe method and urea was measured by the Urease method, both using an 
Abbott Architect Ci8200 general chemistry analyser and reagents from Abbott diagnostics. 
 
2.2.1.7 Processing of histological specimens 
 
For light microscopy, kidneys were fixed in neutral buffered formalin overnight, 
transferred to 70% ethanol and processed to paraffin blocks. Sections were stained with 
periodic acid Schiff (PAS) and haematoxylin-eosin (H&E) reagents (Leucocyte biology, 
Biological Sciences, South Kensington). 
For staining cell surface markers, kidneys were first fixed in paraformaldehyde-
lysine-periodate (PLP) fixative at 4°C for 4 hours, washed overnight in 7% sucrose in PBS, 
placed on cork boards embedded in OCT (Cellpath, Powys, UK) and snap frozen using 
isopentane cooled with liquid nitrogen. For immunofluorescence, half kidneys were simply 
placed on cork boards and snap frozen as above. 5µm sections were cut using a cryostat onto 
slides coated with Poly-L-lysine (Sigma). Slides were then air-dried and stored at -80°C until 
use. 
 
2.2.1.8 Immunofluorescence staining of frozen sections 
 
Direct immunofluorescence was used to detect mouse and sheep IgG on sections of 
mouse kidney. Frozen sections were fixed for 10 minutes in acetone and air-dried. Non-
specific background was blocked with 20% normal goat serum to block non-specific cross-
reactivity (Dako). Goat anti-mouse IgG FITC (Sigma) 1:200 or monoclonal anti-goat/sheep 
IgG FITC (Sigma) 1:200 in PBS/0.1%Tween (Sigma-Aldrich) was added for 1hour  at room 
temperature in a humidified chamber in the dark. Sections were washed 3 times in PBS/0.1% 
Tween and mounted in AF1 solution (Citifluor).  
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2.2.1.9  Immunoperoxidase staining for cell surface markers 
  
Immunoperoxidase staining was used to detect macrophages and CD4+ T-cells using 
the Polink-2 HRP Plus kit (Newmarket scientific) which provides all reagents other than the 
primary antibodies. 5µm sections of PLP-fixed kidney were used. Mouse spleen was stained 
in parallel as a positive control. Endogenous peroxidase was blocked with 3% hydrogen 
peroxide for 10mins. Sections were rinsed with distilled water and incubated with the 
primary antibody: rat anti-mouse CD68 (Serotec) or rat anti-mouse CD4 (Pharmingen), both 
diluted 1:100 in 10% goat serum/PBS, with PBS to negative controls at 4°C in a humidified 
chamber for 1 hour.  After 3 washes in PBS, 2 drops of Antibody Enhancer were added to 
each section for 10 minutes in a humidified chamber. Slides were washed 3 times again and 
2 drops of the Polymer-HRP incubated with the sections for a further 10 minutes. Slides 
were washed 3 times in PBS and the Detection Antibody made up by adding 2 drops of the 
DAB chromogen (3,3’diaminobenzidine chromogen solution) to 1ml of DAB substrate. 
Once brown colour development was obtained, slides were rinsed in distilled water and 
counterstained in filtered Harris’ haematoxylin (Cell Path PLC) for 30 seconds. After 
rinsing, slides were dipped in acid alcohol and washed for 5 minutes until the sections turned 
blue. Subsequently sections were dehydrated by serial immersions for 3 minutes each in 
100% ethanol twice and xylene twice, before mounting with DePeX Gurr mounting medium 
(BDH) and coverslips.  
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Antibody specificity 
 
    Source Host/Clone  Conc
n
  Dilution 
         (mg/ml) 
Immunofluorescence 
Sheep IgG FITC  Sigma  Mouse IgG1  1.7  1:200 
(Fc specific)     Clone GT34  
 
Mouse IgG FITC   Sigma  Goat polyclonal 5.2  1:200 
(Fc specific) 
 
Primary antibodies 
CD68    Serotec Rat FA11  0.1  1:100 
 
CD4    BD  Rat monoclonal 0.5  1:100 
    Pharmingen GK1.5 (L3T4)   
 
 
Table 1. Antibodies used for immunofluorescence and immunoperoxidase staining 
 
 
2.2.1.10 Histological Analyses 
 
All microscopic analysis was performed blinded to sample identity.  
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Glomerular crescents 
 
 Glomerular crescents were defined as glomeruli containing two or more layers of 
cells in Bowman’s space. 50 glomeruli were scored per kidney. 
 
Glomerular thrombosis 
 
Glomerular thrombosis was assessed by scoring individual glomeruli on PAS-stained 
kidney sections for the percentage area containing PAS positive material as follows: grade 0: 
no PAS positive material; grade 1: 1-25%; grade 2: 26-50%; grade 3: 51-75%; grade 4: 76-
100%. 25 glomeruli were scored per kidney and the mean glomerular thrombosis score 
calculated. 
 
Tubular Damage 
 
 Tubular damage was assessed by viewing the entire section under low power and 
assessing the presence of tubular dilatation and tubular casts. Each section was assigned a 
score based on the total area of the section involved: grade 1: 1-25%; grade 2: 26-50%; grade 
3: 51-75%; grade 4: 76-100%. 
 
Macrophages and CD4+ cells 
 
Macrophages and CD4+ cells were counted on immunoperoxidase stained sections. 
For intra-glomerular scoring, only macrophages or CD4+ cells inside glomeruli, as defined 
by Bowman’s capsule, were counted. 25 glomeruli were scored per kidney. For interstitial 
macrophage and CD4+ cell scoring, whole sections were inspected and all kidneys from a 
single experiment were ranked in order of increasing interstitial macrophage or CD4+ 
staining. A score was then assigned to each kidney, beginning at 1 for the least interstitial 
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staining, and ascending, with a maximum score equal to the number of animals in the 
experiment. 
 
Immunofluorescence 
 
 Immunofluorescence sections were examined at x200 magnification using an 
Olympus BX4 fluorescence microscope (Olympus Optical). Fluorescence for each 
glomerulus was scored using a quantitative visual fluorescence scale as follows: Grade 0 – 
no increase from background; Grade 1- minimally fluorescent; Grade 2- moderately 
fluorescent; Grade 3 – strongly fluorescent. 25 glomeruli were scored for each section. All 
sections from one experiment were stained at the same time and analysed in the same 
session. 
 
2.2.1.11 Assessment of the systemic immune response to sheep IgG 
 
Total mouse anti-sheep IgG and IgG sub-classes were measured in mouse serum by 
ELISA at the end of the experiment. For total IgG, ELISA plates were coated overnight at 
4°C with 100µg/ml of sheep IgG (Sigma) diluted in 100mM boric acid (BBS). Plates were 
washed and blocked with 3% BSA (Sigma) for 1hr at 37°C. Plates were washed 3 times in 
PBS/0.1% Tween 20, and dilute serum 1:10 with PBS/1%BSA/0.1% Tween 20 incubated for 
2hrs at 37°C. Plates were washed three times. The secondary antibody was Fc-specific goat 
anti-mouse IgG conjugated to alkaline phosphatase (Sigma), diluted 1:1000 in 1% 
BSA/0.1% Tween 20/PBS. 100µl were added to each well for 1hr at 37°C. For IgG 
subclasses, the same procedure was followed using the following secondary antibodies 
diluted 1:100: goat anti-mouse IgG1, IgG2a, IgG2b, IgG2c, IgG3 (all Southern 
Biotechnology, Birmingham, Alabama, USA). Plates were developed using p-nitrophenyl 
phosphate (Sigma) before determination of the optical density by the ELISA plate reader at 
405nm.  
 
 
Sally Hamour  PhD thesis 2012 
94 
 
2.2.1.12 RNA extraction 
 
Kidneys were removed from storage at -80°C and rapidly placed into ice. For each ½ 
kidney, 2ml Trizol (Invitrogen) was added at 4°C and the tissue was homogenised. The 
sample was allowed to stand at room temperature for 5 minutes to allow complete 
dissociation of the nucleoprotein complexes before transferring 1ml into each of 2 sterile 
Eppendorfs. To each tube, 0.2ml of chloroform (AnalaR) was added and the tube shaken by 
hand for 15 seconds and then incubated at room temperature for 2 minutes. The tube was 
centrifuged at 12 000g for 15 minutes at -4°C which separated the mixture into a lower red, 
phenol-chloroform phase containing DNA and an upper clear aqueous phase containing the 
RNA. The aqueous phase was transferred into a fresh tube and 0.5ml of isopropanol (VWR 
International) was added and the sample was stored at -20°C for a minimum of 1 hour. The 
tube was centrifuged at 12000g for 10 minutes at 4°C so that the RNA formed a gel-like 
pellet at the bottom of the tube. Supernatant was removed and the pellet washed with 1ml of 
75% ethanol and shaken by hand. After centrifugation at 8000g for 8 minutes at 4°C, the 
supernatant was again removed and the sample left to air-dry, taking care not to allow the 
pellet to dry out completely. 40µl of RNAse-free water (Gibco) was added and the sample 
incubated at 55°C for 5 minutes before spinning down briefly.  
 
In order to optimise the purity of RNA for quantitative PCR, the entire Trizol 
extraction protocol was carried out twice on all samples as this was found to significantly 
reduce genomic DNA contamination. RNA concentration for all samples was measured after 
the second extraction by UV absorption using a NanoDrop spectrophotometer and quality 
assessed using the absorption ratio at 260/280 nm. A ratio >1.7 was considered to represent 
good quality RNA, although in practice most ratios were >1.95. For certain experiments, 
RNA quality was also assessed using gel electrophoresis with observation for the definition 
and relative intensity of the 28S and 18S bands. For RNA electrophoresis, a 1.2% agarose 
gel was used. 5µl RNA was added to 10µl RNAse-free water and incubated at 70°C for 1 
minute. 1µl of this RNA was mixed with 15µl RNAse-free water and 5µl of loading dye and 
15µl of the mixture added to the gel which was run at 50V for 2 hours. Otherwise the 
procedure was the same as that detailed for DNA gel electrophoresis above.  
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2.2.1.13 Reverse-transcription polymerase chain reaction 
 
 Complementary DNA (cDNA) was synthesised from RNA by reverse transcription. 
1µl Oligo(dT)12-18, 1µl 10mM dNTP mix (all Invitrogen), a volume equivalent to 1µg RNA 
and 10µl RNAse-free water were heated in a sterile PCR tube at 65°C for 5 minutes using a 
thermal cycler, spun down briefly to collect the contents at the bottom of the tube, and 
incubated on ice for 1 minute. 4µl 5x1st strand buffer, 1µl 0.1M Dithiothreitol and 1µl 
RNAse out (all Invitrogen) were added to the tube, the contents spun down and incubated on 
ice.  3µl were removed into a separate PCR tube for use as a control without reverse 
transcription to assess for genomic DNA contamination. 1µl of SuperScript III Reverse 
Transcriptase (Invitrogen) was then added to the original tube and the contents pipetted up 
and down gently. The tube was incubated at room temperature for 5 minutes before being 
returned to the thermal cycler and heated at 50°C for 50 minutes to allow reverse 
transcription to take place. Finally the samples were heated at 70°C for 15 minutes to 
terminate the reaction. 
 
2.2.1.14 Real-time polymerase chain reaction 
 
 In order to compare gene expression between different experimental groups in the 
bone marrow transplant experiments, quantitative PCR was carried out for IL-17, IL-10, 
IFNγ, IL-4, IL-1β, IL-23, Tbet, TGFβ, mannose receptor, inducible nitric oxide synthase 
(iNOS) and arginase, using cDNA synthesised as above. For each sample, mRNA abundance 
was normalised to the amount of GAPDH. I am grateful to Clare Turner and Phoebe Sharp 
in the Renal Section for donation of in-house designed primer sequences and primers. 
Primers had GC content between 30 and 80%, a length of 10-40 bases and a melting 
temperature between 58 and 60°C. 
 
 PCR mastermix comprised 10µl Mesa Blue qPCR Mastermix plus for SYBR assay 
(Eurogentec Ltd, Southampton, UK), 8µl sterile distilled water, 5pmol forward primer and 
5pmol reverse primer and was prepared at 4°C. This was aliquoted using a white 96-well 
PCR plate (Abgene) before addition of 1µl of cDNA. The plate was sealed with a PCR 
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microseal (Biorad) and spun down briefly before being placed on the thermal cycler 
(Mastercycler realplex
2
, Eppendorf).  The following cycling parameters were used: 
 
DNA polymerase  95°C 2mins 
activation 
 
Denaturation   95°C 30sec 
 x40 cycles 
Annealing and extension 60°C 1min   
 
Melt Curve  95°C 15sec 
   60°C 15sec 
   Increase to 95°C over 20 mins, Hold 15 sec 
 
For each sample, the gene of interest and the control gene were run in parallel and 
cDNA synthesised from the same batch was used for all samples in an experiment. 3 cDNA 
samples synthesised using kidney RNA from 3 normal C57Bl/6 female mice were analysed 
in parallel each time, and the same controls were used for all the qPCR experiments. In 
addition, for each batch of cDNA, the RT negative control for each sample was analysed for 
GAPDH, to exclude genomic DNA contamination. A difference of at least 10 Ct between the 
RT positive and the RT negative samples for GAPDH was considered satisfactory. A blank 
sample without RNA was used to assess for the possibility of other contamination. For all 
samples, melt curve analysis was used to determine specificity of the PCR product and to 
identify unwanted by-products of the PCR reaction such as primer dimer. Ct results were 
analysed using the ΔΔCt method. All samples were assayed in triplicate, or in duplicate and 
repeated or excluded if there was any variation >0.99 Cycle thresholds (Ct) between 
replicates. 
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Gene Sequence Reference/Accession 
number 
GAPDH F: 5’GGGTGTGAACCACGAGAAAT-3’ 
R: 5’GTCTTCTGGGTGGCAGTGAT-3’ 
NM 008084.2 
IL-17 F: 5'ACCGCAATGAAGACCCTGAT-3' 
R: 5'TCCCTCCGCATTGACACA -3' 
NM 010552.3 
IL-10 F: 5’GGTTGCCAAGCCTTATCGGA-3’ 
R: 5’ACCTGCTCCACTGCCTTGCT-3’ 
NM 010548.2 
IL-1β F: 5’AACCTGCTGGTGTGTGACGTTC-3’ 
R: 5’CAGCACGAGGCTTTTTTGTTGT-3’ 
NM 008361.3 
IFNγ F: 5’ATCTGGAGGAACTGGCAAAA-3’ 
R: 5’TTCAAGACTTCAAAGAGTCTGAGG-3’ 
NM 008337.3 
IL-23p19 F: 5′-TGTGCCCCGTATCCAGTGT-3’  
R: 5′-CGGATCCTTTGCAAGCAGAA-3′ 
NM 031252.2  
IL-4 F: 5'ACAGGAGAAGGGACGCCAT-3' 
R: 5'GAAGCCCTACAGACGAGCTCA-3' 
NM 021283.2 
TGFβ F: 5’TGAGTGGCTGTCTTTTGACG-3’ 
R: 5’AGCCCTGTATTCCGTCTCCT-3’ 
NM 011577.1 
(Pang et al., 2010) 
Mannose Receptor F: 5’CAAGGAAGGTTGGCATTTGT-3’ 
R: 5’CCTTTCAGTCCTTTGCAAGC-3’ 
NM 008625.2 
(Lee et al., 2011) 
Arginase F: 5’CAGAAGAATGGAAGAGTCAG-3’ 
R: 5’CAGATATGCAGGGAGTCACC-3’ 
NM 007482.3 
(Lee et al., 2011) 
iNOS F: 5’CCAAGCCCTCACCTACTTCC-3’ 
R:5’CTCTGAGGGCTGACACAAGG-3’ 
NM 010927.3 
(Lee et al., 2011) 
Tbet F: 5’CCTGGACCCAACTGTCAACT-3’ 
R: 5’AACTGTGTTCCCGAGGTGTC-3’ 
NM 019507.2 
(Phoon et al., 2008) 
 
Table 2. Forward (F) and reverse (R) primer sequences used for quantitative RT-PCR.  
Those without a specified reference were designed in-house. 
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2.2.2 In vitro Studies 
 
2.2.2.1 In-vitro stimulation of splenocytes 
 
 Splenocytes were isolated from mice pre-immunised with sheep IgG and Complete 
Freund’s Adjuvant as previously described. Cell medium (RPMI 1640 medium containing 
10% foetal calf serum (FCS, Biosera) 100U/ml penicillin, 100μg/ml streptomycin and 2mM 
L-glutamine) was supplemented with mouse recombinant IL-6 10ng/ml (Sigma) and TGFβ 
10ng/ml (R&D Systems) to promote IL-10 production. Cells were cultured for 48hrs at 37°C 
in sterile 6-well plates at a concentration of 1 million cells/ml. Cells were then stimulated 
with Phorbol 12-myristate 13-acetate 100ng/ml (PMA, Sigma), ionomycin 500ng/ml 
(Sigma) and Brefeldin A 1:1000 (eBiosciences) for 4 hours prior to collection.  Cell solution 
was collected and the plate gently scraped to dislodge adherent cells, spun down and 
resuspended ready for FACS staining. 
 
 Simultaneously, splenocytes were also cultured at the same concentration in flat- 
bottomed 96-well plates for 48 hours at 37°C. Stimulation conditions were either (1) cell 
medium alone or (2) cell medium with TGFβ and IL-6 as above with 10µl CD3 CD28 co-
stimulation beads per million splenocytes (Dynabeads mouse T-activator CD3/CD28, Life 
Technologies). For the conditions described in (2), splenocytes were also cultured with IL-17 
5ng/ml or IL-17 50ng/ml added (eBioscience). After 48 hours, supernatants were aspirated 
and spun down to remove any cells, before storing at -80°C until analysis by ELISA.  
 
 
2.2.2.2 IL-10 ELISA 
 
 Splenocyte supernatants were analysed for IL-10 concentration by ELISA (IL-10 
Duoset, R&D systems). ELISA plates were coated with 4µg/ml of capture antibody in PBS 
overnight at room temperature. Plates were washed 3 times with 0.05% Tween 20/PBS and 
blocked with 300µl 1% BSA in PBS (reagent diluent) for 1 hour at room temperature. After 
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3 washes, samples and standards with a top concentration of 2000pg/ml diluted in reagent 
diluent were incubated for 2 hours at room temperature. After 3 further washes, detection 
antibody 300ng/ml was added for 2 hours. Plates were washed and streptavidin-horseradish 
peroxidase (strep-HRP) in reagent diluent added for 20 minutes. After washing again, 
peroxide-chromogen substrate was added until colour development and the reaction 
terminated with Stop Solution (1M H2SO4). Optical density readings were measured at 450 
nm. 
 
2.2.2.3 Flow cytometry cell staining 
 
On a 96 well V-shaped plate (Nunc), 100µl cell suspension containing 0.25-1x10
6
 
million cells per well was added. For extra-cellular staining, cells were washed twice in 
1%FCS/PBS before incubating with 2µl of rat anti-mouse CD3, CD11b, NK1.1, or 
Armenian hamster anti-mouse CD11c or IgG isotype control (all FITC-labelled antibodies, 
all Biolegend), or FITC rat anti-mouse IgG2bκ isotype control (BD Pharmingen), in 50µl 1% 
FCS/PBS for 30 minutes in the dark at 4°C.  For intra-cellular staining, cells were then 
washed twice in 1% PBS/BSA and fixed with 4% paraformaldehyde for 10 minutes at room 
temperature. Cells were washed twice in 0.05% Tween 20/PBS before adding 2µl of rat anti-
mouse IL-17A PE, rat IgG1 PE isotype control, or rat IgG1κ APC isotype control (all BD 
Pharmingen) or 2µl rat anti-mouse IL-10 APC (Biolegend), in 50µl 0.01% tween 20/PBS for 
30 minutes at room temperature in the dark. Finally cells were washed twice with 1% 
FCS/PBS and 200µl 2% paraformaldehyde was added to all wells and the plate stored at 4°C 
in the dark until analysis. Analysis of cell staining was performed on a FACS Calibur 
machine using Cell Quest software (BD Biosciences) within a week of staining. 
 
2.2.3 Human studies 
 
All work using clinical samples had received ethical approval from Queen 
Charlotte’s and Hammersmith hospital ethics committee and written consent was obtained 
from all patients and controls.  
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2.2.3.1 Serum cytokine ELISAS 
 
  For ELISA, 6 ml of venous blood was obtained from each subject in EDTA tubes 
and centrifuged within 2 hours. Plasma was aspirated and stored at -80°C until analysis. For 
all cytokine ELISAs, serum was diluted 1:1 with PBS. 
 
IL-1β and IL-6 ELISA 
 
IL-1β and IL-6 were analysed using Duoset ELISA Development System (R&D 
systems, Abingdon, UK). MaxiSorp-Immuno plates (Nunc, Denmark) were coated with 
monoclonal mouse anti-human IL-1β or IL-6 antibody at 3µg/ml and 2µg/ml respectively, 
blocked the following day for 2 hours and then incubated with serum samples and standards 
(1000-15.6pg/ml) in duplicate for a further 2 hours. A biotinylated goat anti-human IL-1β 
(0.1µg/ml) or IL-6 (0.2µg/ml) was added for 2 hours followed by Strep-HRP and peroxide-
chromogen substrate until colour development. Optical density readings were taken at 450 
nm. Both ELISAs were performed at room temperature. 
 
IL-17 and IL-23 ELISA 
 
Sandwich ELISA for IL-17A and IL-23 was performed using mouse anti-human IL-
17A and IL-23 p19 (eBiosciences, Insight Biotechnology Ltd, UK) at concentrations of 
1µg/ml and 3µg/ml respectively. Plates were coated overnight at 4°C and blocked for 2 
hours the following day. Samples and standards (2000-15.6pg/ml for IL-17A and 2000-
62.5pg/ml for IL-23) were added for 2 hours, followed by biotinylated anti-human IL-17A 
(0.5µg/ml) or IL-23 (0.1ug/ml) for 2 hours and 1 hour respectively. Strep-HRP and 
peroxide-chromogen substrate were subsequently added until colour development. Blocking, 
addition of samples/standards and biotinylated antibody incubations were performed at 37°C 
in the IL-17A assay and at room temperature in the IL-23 assay.   
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IFN-γ ELISA 
 
ELISA for serum interferon-gamma (INF-y) was measured using Human INF-y 
ELISA Ready-SET-Go (eBiosciences, Insight Biotechnology Ltd, UK) and performed 
following the manufacturer‘s instructions. ELISA plates were coated overnight with pre-
titrated capture antibody in Coating Buffer at 4°C. Plates were washed 5 times with 0.05% 
Tween 20/PBS and blocked with assay diluent for 1 hour at room temperature. After 
washing, samples and standards were incubated for 2 hours at room temperature. After 
repeat washing, pre-titrated detection antibody in assay diluent was incubated at room 
temperature for 1 hour. Plates were washed 5 times and strep-HRP diluted in assay diluent 
was added for 30 minutes. Substrate solution was added after 7 further washes until colour 
change and the reaction terminated with stop solution. Plates were read at 450nm.  
 
2.2.3.2 ELISPOT analysis  
 
For ELISPOT, 30ml of venous blood was collected in EDTA tubes. Peripheral blood 
mononuclear cells (PBMC) were isolated within 24hrs by Lymphoprep density 
centrifugation (Nycomed, Oslo, Norway). PBMC were analysed directly by ELISPOT.  
 
ELISPOT plates (Millipore) were pre-wetted with 35% ethanol and coated with 
4µg/ml human anti-IFN- coating antibody (Mabtech) or 2µg/ml anti-IL-17 (eBioscience) 
overnight at 4°C.  Plates were blocked with RPMI 1640 medium (Gibco), containing 10% 
FCS, 100U/ml penicillin, 100μg/ml streptomycin and 2mM L-glutamine for 1hr at 37°C. 
PBMCs (0.5 X 106/well) were incubated with stimuli in triplicate at 37°C for 48h. Cells 
were stimulated with: medium alone; Phytohaemagglutinin (PHA; Sigma, USA) at 1µg/ml; 
recall antigens (Diphtheria, tetanus and poliomyelitis marketed under Revaxis; Sanofi 
Pasteur MSD Limited, UK) 1:250; and 5µg/ml autoantigen PR3 (Athens Research & 
Technology) or MPO (Calbiochem) depending on patients’ ANCA specificity.  All cells 
from controls were stimulated with MPO. Subsequently, biotinylated anti-IFN- detection 
antibody (Mabtech) or anti-IL-17 detection antibody (eBioscience) at 0.5ug/ml in 0.5% 
FCS/PBS was added for 2.5 hours at room temperature. Strep-HRP (Mabtech) 1/500 in 0.5% 
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FCS/PBS for 1 hour at room temperature followed by TMB ELISPOT substrate (Mabtech) 
for 15 minutes enabled detectable spots to appear. Spots were counted by AID ELISPOT 
plate reader version 4.0. Control readings for stimulation with medium were subtracted from 
those for stimuli and mean values calculated. 
 
2.2.3.3 Measurement of ANCA titres and specificity 
 
ANCA positivity was determined by indirect immunofluorescence. ANCA antigenic 
specificity and titre were determined by Luminex-based technology, using the FIDIS 
vasculitis kit (Technoclone, Vienna, Austria), in the Hammersmith Hospital Immunology 
Laboratory. 
 
2.2.4 Statistical analysis  
 
All animal studies are expressed as median (range); clinical studies are expressed as 
mean (± standard deviation) (SD). All statistics were performed using GraphPad prism 4.0 
(GraphPad Software, San Diego California, USA). Non-parametric tests of significance were 
applied throughout as it could not be assumed that the distribution of the data was Gaussian. 
For comparing 2 groups, Mann-Whitney U test was used. One way analysis of variance 
(ANOVA) was carried out using non-parametric Kruskal-Wallis test and Dunn’s multiple 
comparison post test for groups of three or more. Paired data was analysed using the 
Wilcoxon matched pairs test. Two-way ANOVA was used to analyse differences between 
groups from more than one experiment. Correlations were assessed using the non-parametric 
Spearman rank correlation analysis.  Two tailed analysis was carried out with significance 
defined as P<0.05 with 95% confidence.  
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2.3 Buffers and Solutions 
 
2.3.1 Polymerase chain reaction 
 
Lysis buffer for tail lysis 
100mM Tris-HCL (pH 8.5), 5mM EDTA, 0.2% SDS, 200mM NaCl and 100µg/ml 
proteinase k (added immediately before use). 
 
Tris/EDTA (TE) buffer  
1M Tris-HCL (pH 7.5), 1 mM EDTA (pH 8.0) 
 
TAE buffer 50x 
40mM Tris-acetate, 1mM EDTA (pH 8.0). Diluted to 1x with distilled water for use in DNA 
electrophoresis. 
 
2.3.2 Tissue Fixation 
 
Neutral buffered formalin (pH 7.0) 
100ml full-strength formalin (37-40% formaldehyde), 6.5g Na2HPO4, 4g NaH2PO4 and 
900ml dH20. 
 
Paraformaldehyde lysine periodate (PLP) fixative 
 
Lysine stock solution: 0.2M lysine monohydrochloride (3.65g/100ml) and added to an equal 
volume of 0.1M disodium hydrogen orthophosphate (1.41g/100ml for anhydrous). The 
solution was adjusted to pH 7.4 and stored at 4°C.  
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4% Paraformaldehyde: Paraformaldehyde was dissolved in dH20 at 4g/100ml with stirring at 
60°C in a fume hood. The solution was cleared by adding a few drops of 1M NaOH and then 
stored at 4°C. 
Immediately prior to use, 1 volume of 4% paraformaldehyde was added to 3 volumes of 
lysine stock solution and sodium metaperiodate 0.214g/100ml (10mM) was added. 
 
2.3.3 Immunohistochemistry 
 
Phosphate buffered saline  
137mM NaCl, 0.27mM KCL, 8.1mM Na2PO4, 1.5mM KH2PO4, adjust to pH 7.2 
 
Acid alcohol 
1% HCL mixed with 70% ethanol 
 
2.3.4 ELISA 
 
Borate buffered saline (BBS) 
100mM boric acid, 25mM anhydrous sodium tetraborate, 75mM NaCl, pH8.3 
 
Wash buffer 
0.05% Tween 20 in PBS 
 
Blocking buffer 
3% BSA in PBS 
 
Reagent diluent 
1% BSA in PBS 
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Substrate solution 
1:1 mixture of Colour Reagent A (H2O2) and Colour Reagent B (Tetramethylbenzidine) 
(R&D systems) 
 
Stop solution 
1M H2SO4 diluted in dH2O 
 
2.3.5 Tissue culture 
 
Cell medium 
RPMI 1640 medium containing 10% FCS, 100U/ml penicillin, 100μg/ml streptomycin and 
2mM L-glutamine 
 
ACK lysis buffer  
150mM NH4Cl, 0.1mM Na2EDTA, 10mM KHCO3 
 
2.3.6 FACS solutions 
 
Wash buffer and antibody diluents 
Extracellular staining: 1% FCS diluted in PBS 
 
Intracellular staining: 0.05% Tween 20 in PBS for washing. 0.01% Tween 20 in PBS for 
antibody dilution. 
 
Fixation solutions 
4% paraformaldehyde and 2% paraformaldehyde diluted in dH2O. 
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Chapter 3 
The role of IL-17 in accelerated nephrotoxic nephritis 
 
 
3.1 Introduction 
 
 Accelerated nephrotoxic nephritis (NTN) is a well-established model of immune 
complex glomerulonephritis and is caused by the immune response to sheep anti-mouse 
antibodies planted in the glomerulus. Much of our understanding of the effectors of disease 
in human immune-mediated glomerulonephritis has come as a result of experiments carried 
out using NTN. The cellular and humoral mechanisms important in the development of renal 
injury in this model have been described in detail in chapter 1 (Couser, 1993, 1998). In the 
very early stages of disease, neutrophil influx in response to deposited antigen inflames the 
kidney and damages the glomerular basement membrane by release of lysosomal enzymes 
such as myeloperoxidase and serine proteases. Subsequently, resident renal cells such as 
mesangial cells and epithelial cells proliferate and monocytes and macrophages infiltrate the 
renal parenchyma and cause further injury.  
 
T-cells are central to the pathogenesis of NTN (Tipping and Holdsworth, 2006; 
Tipping et al., 1998) and, like many other models of autoimmunity, NTN has historically 
been considered to be a Th1-mediated condition. However, the discovery that IL-12 (a Th1 
cytokine) and IL-23 (a Th17 cytokine), share a common p40 subunit (Oppmann et al., 2000) 
prompted a re-thinking of this accepted dogma in other experimental models. The creation of 
genetically modified mice deficient in these subunits, or deficient in IL-17, has allowed 
investigation of the relative contribution of these lineages to disease. Therefore the 
pathogenesis in many mouse models of autoimmunity such as experimental autoimmune 
encephalomyelitis and collagen induced arthritis has been at least partially reattributed from 
Th1 to Th17 cells (Cua et al., 2003; Murphy et al., 2003).  
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Although IL-17 had thus been identified as a key cytokine in the pathogenesis of 
autoimmunity in a number of other animal models, at the starting point of this work no 
exploration of the role of IL-17 in immunological renal disease had been described.  My 
hypothesis was that, like some of these other animal models of autoimmunity, NTN was in 
fact a Th17 rather than a Th1 driven model; IL-17 produced by Th17 cells was central to the 
pathogenesis of nephrotoxic nephritis and IL-17 deficient mice would be protected from 
disease. Therefore I reproduced this model in WT and IL-17 deficient mice and compared 
disease outcomes using a variety of parameters. I also hoped to demonstrate that disease 
could be transferred by splenocyte or T-cell transfer from WT into IL-17 deficient mice, 
rather than by non-T cell splenocytes, consistent with the hypothesis that Th17 cells are the 
critical mediators of disease. During the course of this work, data on the role of IL-17 
deficient and p19 (IL-23) deficient mice in NTN, and p19 and p40 subunit deficient mice in 
EAG were published by other groups as detailed in the Introduction (Ooi et al., 2009; Paust 
et al., 2009) and will be discussed at the end of this chapter. The work which I describe 
below was carried out contemporaneous to this and provides further validation and 
corroboration of these findings.  
 
3.2 Aim 
 
The first chapter of this thesis describes an investigation into the role of IL-17 in the 
accelerated nephrotoxic nephritis model, based on a comparison of disease in wild-type and 
IL-17
-/- 
mice. Subsequently, a series of cell transfer experiments is described which 
attempted to induce disease susceptibility or confer resistance between these two strains. 
 
3.3 Experimental design 
 
 All experiments were conducted in the Central Biological Services department at the 
Hammersmith Hospital Campus of Imperial College, London. Animals were bred and 
housed according to institutional guidelines. IL-17 deficient mice were kindly donated by 
Professor Yoichiro Iwakura, University of Tokyo. Age and sex-matched WT (C57BL/6) 
Sally Hamour  PhD thesis 2012 
108 
 
mice were used as a comparator. Unless otherwise specified, all experiments were carried 
out in female mice between 8 and 12 weeks old.  
 
Firstly baseline parameters of WT and IL-17
-/- 
mice were established. The NTN 
model was optimized in WT mice. In total, 4 experiments inducing NTN in WT and IL-17
-/- 
mice were carried out with similar outcomes. For clarity, the results of two representative 
experiments are detailed below and, where appropriate, results from these two experiments 
are combined. 
 
Disease severity was assessed by urinalysis and quantification of proteinuria; 
measurement of renal function, based on serum urea and creatinine; and histological 
assessment on PAS and H&E stained sections with scoring of renal thrombosis. Incidence of 
glomerular crescents in this model was consistently <5% of glomeruli in all samples and 
therefore was not used in routine disease assessment. Humoral immune responses were 
measured by serum ELISA for mouse anti-sheep IgG and by immunofluorescence on frozen 
kidney sections for glomerular deposition of mouse and sheep IgG. Cellular immune 
responses were assessed by quantification of intra-glomerular CD68+ and CD4+ cells on 
PLP kidney sections. All data are represented as median (range). The data were analysed 
using Mann-Whitney U test (groups of mice) and two-way ANOVA to allow combination of 
different experiments.  
 
 
3.4 Results  
 
3.4.1 Confirmatory genotyping of IL-17-/- mice by PCR 
 
The genotype of the IL-17
-/- 
mice was confirmed by PCR analysis as described in the 
methods.  Genomic DNA was isolated from mouse tissue using 2mm tail snips and amplified 
by PCR using IL-17 specific primers. WT, mutant and common primer sequences for IL-17 
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were provided by Professor Iwakura, University of Tokyo. One band of 700bp and one band 
of 500bp were amplified from the wild-type and mutant alleles respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.2 Baseline parameters in WT and IL-17-/- mice   
 
In order to identify any important baseline phenotypic differences, unmanipulated 
WT and IL-17
-/-
 mice were characterised and compared. Weight, serum urea and creatinine 
as well as proteinuria were quantified in WT and IL-17
-/-
 male and female mice at 12 weeks 
old. 
 
Figure 6. Representative example of PCR genotyping of WT and IL-17
-/-
 mice. 
Two bands, 700bp and 500bp fragments, were amplified from the wild type and mutant 
alleles respectively (100bp DNA ladder). 
 
WT      IL-17
-/-
   IL-17
-/- 
500bp Mutant 
band  
700bp Wild type 
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 WT 
Male 
IL-17
-/- 
  
Male 
WT  
Female 
IL-17
-/-
 
Female 
Age (weeks) 12 12 12 12 
Weight (g) 28.0 
(27-29.5) 
26.0 
(25.8-26.2) 
21.0 
(20.2-22.0) 
21.0 
(20.0-22.5) 
Serum creatinine 
(μmol/L) 
37.1 
(34.4-40.4) 
41.1 
(37.1-46.5) 
41.0 
(40.0-52.0) 
45.0 
(41.3-48.7) 
Serum urea (mmol/L) 7.1 
(6.3-8.0) 
5.7 
(5.6-7.5) 
7.7 
(5.8-9.0) 
6.8 
(6.6-6.9) 
Proteinuria (mg/24hrs) 2.4 
(2.0-6.6) 
4.2 
(4.1-5.7) 
0.3 
(0.03-0.36) 
0.3 
(0.30-0.51) 
 
Table 3. Baseline characteristics of unmanipulated WT and IL-17
-/- 
mice using 3-5 mice per 
group.   
There were no statistically significant differences between WT and IL-17
-/- 
mice for either 
males or females. Males are recognised as having greater proteinuria than females (Alt et al., 
1985). 
 
 
3.4.3 Optimisation of the accelerated nephrotoxic nephritis model 
 
Since each batch of NTS shows slight variations in immunogenicity, it was necessary 
to first determine the optimal concentration of this batch of NTS in this model. An optimal 
concentration is that which induces measureable proteinuria and histological change by the 
end point of the experiment without mortality or undue severity. Using semi-quantitative 
mass spectrometry, the protein concentration of the NTS was measured as 290mg/ml. The 
first experiment was carried out using the standard protocol. 5 WT and 5 IL-17
-/-
 male mice 
were pre-immunised with 200μl 1:1 CFA:0.2mg sheep IgG in 0.9% NaCl s/c and 5 days 
later injected with 200μl of NTS diluted 1:7 with 0.9% NaCl. Animals were sacrificed at day 
7 after collection of urine using metabolic cages. 
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Figure 7. Schematic representation of the accelerated nephrotoxic nephritis model.  
Mice are pre-immunised s/c with complete Freund’s adjuvant and sheep IgG. 5 days later 
they receive an injection of nephrotoxic serum IV. Over the following 7-10 days they 
develop an immune-mediated glomerulonephritis. 
 
 
At 7 days there was proteinuria in both groups. WT mice had median proteinuria of 
10.05mg/24hrs (range 4.90-14.30) and IL-17
-/- 
mice had median proteinuria of 3.63mg/24hrs 
(1.44-9.96), p=ns. There was no statistically significant difference between the two groups. 
However, interestingly at this concentration of NTS, despite moderate amounts of 
proteinuria, there was no significant histological change with normal glomeruli on light 
microscopy demonstrating that proteinuria precedes histological change. Furthermore, 
mouse anti-sheep antibodies were detectable on ELISA indicating that there was an adequate 
immune response to pre-immunisation with sheep IgG. In WT mice, median optical density 
at 405nm was 0.35 (0.27-0.60) and in IL-17
-/- 
mice was 0.26 (0.11-0.54), p=ns, compared to 
median optical density of 0.10 (0.09-0.12) in normal mouse serum. 
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Figure 8. (A) Proteinuria and (B) ELISA for mouse anti-sheep IgG in WT and IL-17
-/-
 mice 
with NTN using a 1:7 dilution of NTS.  
Control represents normal mouse serum. Despite development of proteinuria, histology was 
normal by light microscopy. However, ELISA demonstrated an immune response to pre-
immunisation.  Lines represent median values. 
 
A 
 
 
 
 
 
 
A 
B 
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In view of these findings, the experiment was repeated using 2 higher concentrations 
of NTS: 1:4 and 1:1 dilutions with 0.9% NaCl. In this experiment, median proteinuria in WT 
animals was 1.97mg/24hr (0.87-7.94) and 11.84mg/24hr (1.04-21.00) at 1:4 and 1:1 
dilutions respectively. Histologically, WT mice with a 1:1 dilution of NTS had more 
hypercellularity, more thrombosis and occasional crescents compared with WT mice with 
NTS 1:4 dilution (data not shown). In summary, a 1:1 dilution of NTS resulted in greater 
proteinuria and more marked histological change in WT mice than a 1:4 dilution of NTS. 
Therefore 1:1 dilution was adopted as standard for all subsequent NTN experiments and the 
same batch of nephrotoxic serum was used throughout.  
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-/-
1:4 IL17
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Figure 9. Proteinuria in wild type and IL-17
-/- 
mice with NTN using NTS at 1:4 and 1:1 
dilutions.  
WT mice developed more proteinuria at the higher NTS concentration, whilst IL-17
-/-
 mice 
were protected at both concentrations. Lines represent median values. 
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3.4.4 IL-17-/- mice are protected from nephrotoxic nephritis as demonstrated by 
preserved renal function, less proteinuria and less histological change  
 
In total 4 experiments comparing NTN in WT and IL-17
-/-
 mice were performed. 
Two representative NTN experiments will be described. These were carried out using the 
optimised dilution of NTS 1:1. Mice were monitored for 9 days after disease induction and 
sacrificed thereafter. In both experiments, 200μl of NTS (diluted 1:1 with 0.9% NaCl) was 
administered intravenously via the tail vein 5 days after pre-immunisation with 0.2mg of 
sheep IgG in CFA. The first experiment comprised 5 WT mice and 4 IL-17
-/-
 mice, and the 
second experiment 3 WT mice and 6 IL-17
-/-
 mice. Results from the two experiments have 
also been analysed by 2-way ANOVA to determine whether there was significant difference 
between the experiments.  Where there is no significant difference between the experiments, 
results from these 2 experiments have been combined for clarity of presentation.  
 
3.4.4.1 Renal function 
 
IL-17
-/- 
mice have greater preservation of renal function in NTN as measured by 
lower serum urea at day 9. By two way ANOVA, there was no significant difference 
between the two experiments (p=0.08) but a significant difference between the two groups of 
mice (p=0.03). When the two experiments are taken together, in WT mice, median serum 
urea was 13.60mmol/L (9.80-86.70) and in IL-17
-/-
 mice median serum urea was 
9.00mmol/L (6.70-44.70); p<0.01.   
 
Serum creatinine is not as good a marker of renal injury in mice unless there is 
advanced disease, and consistent with this there was no significant difference in serum 
creatinine between the groups (WT 46.0µmol/L (39.0-76.0); IL-17
-/- 
45.5µmol/L (35.0-64.0), 
nor between the two experiments. 
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Figure 10. (A) Serum urea and (B) amalgamated results for serum urea for experiments 1 
and 2 in WT and IL-17
-/-
 mice at day 9 of NTN.  
IL-17
-/-
 mice demonstrated significantly lower serum urea. (A) Each experiment analysed 
separately by Mann Whitney-U test. (B) combined results analysed by Mann Whitney-U test 
after Two-Way ANOVA demonstrated no difference between experiments. Lines represent 
median values. * p<0.05; ** p<0.01; ***p<0.001.  
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Figure 11. Amalgamated results for serum creatinine in WT and IL-17
-/-
 mice at day 9 of 
NTN.  
IL-17
-/-
 mice demonstrated no difference in serum creatinine. Combined results analysed by 
Mann Whitney-U test after Two-Way ANOVA demonstrated no difference between 
experiments. Lines represent median values. * p<0.05; ** p<0.01; ***p<0.001.  
 
3.4.4.2 Proteinuria 
  Urine was collected overnight through the use of metabolic cages from all animals in 
the two experiments except two. One WT mouse from the first experiment did not produce 
sufficient urine for quantification. This was unlikely to have been due to severe renal disease 
and subsequent oligo-anuria, since in this animal serum urea was 10.5mmol/L and creatinine 
was 39μmol/L. There were insufficient metabolic cages to quantify proteinuria from one of 
the IL-17
-/-
 mice from the second experiment.  
 
IL17
-/- 
mice had significantly lower proteinuria in both experiments at day 9 as 
measured by the sulphosalicylic acid method. By two-way ANOVA analysis, there was no 
significant difference between the two experiments (p=0.37) but a very significant difference 
between WT and IL-17
-/-
 mice (p=0.001). When both experiments are taken together, in WT 
mice median proteinuria was 9.78mg/24hrs (1.04-21.00) and in IL-17
-/- 
mice it was 
0.21mg/24hrs (0.03-1.56); p<0.001. 
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Figure 12. Proteinuria in (A) experiments 1 and 2 and (B) amalgamated results for the two 
experiments in WT and IL-17
-/-
 mice at day 9 of NTN.  
IL-17
-/-
 mice are almost completely protected. (A) Each experiment analysed separately by 
Mann Whitney-U test. (B) combined results analysed by Mann Whitney-U test after Two-
Way ANOVA demonstrated no difference between experiments. Lines represent median 
values. * p<0.05; ** p<0.01; ***p<0.001 
 
WT IL-17
-/-
WT IL-17-/-
0
5
10
15
20
25 *
*
First experiment   Second experiment
P
ro
te
in
u
ri
a
 m
g
/2
4
h
rs
WT IL-17-/-
0
5
10
15
20
25 ***
P
ro
te
in
u
ri
a
 m
g
/2
4
h
rs
B 
A 
Sally Hamour  PhD thesis 2012 
118 
 
3.4.4.3 Renal histology 
 
WT mice with NTN demonstrated marked histological change with glomerular 
thrombosis, acute tubular dilatation and occasional crescents in the kidney. IL-17
-/- 
mice had 
significantly less glomerular thrombosis than WT mice and showed predominantly mild 
hypercellularity on histology with minimal acute tubular damage.  
By two-way ANOVA, there was no difference in thrombosis score between the two 
experiments (p=0.30), but a significant difference between WT and IL-17
-/-
 mice (p=0.02). 
When results from the two experiments are taken together, median thrombosis score in WT 
mice was 1.90 (0.72-2.80) and median thrombosis score in IL-17
-/- 
mice was 0.98 (0.40-
2.56); p<0.05.  
The frequency of crescents in the first experiment was quantified by counting 25 
glomerular cross-sections. In WT mice the median frequency of crescents was 4% (range 0-
12) and in IL-17
-/-
 mice was 2% (0-8), p=ns.  Overall the median frequency of crescents is 
low in this model using this batch of serum, and was very low (<5%) in both groups in this 
and subsequent experiments. Therefore, although the presence of crescents was noted, their 
frequency was not routinely quantified as a distinguishing feature of disease severity.  
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Figure 13. Representative PAS staining (A, C) and H&E staining (B, D) in (A, B) WT and 
(C, D) IL-17
-/-
 mice.  
WT mouse shows (A) extensive glomerular thrombosis and tubular dilatation with casts and 
(B) cellular crescent (*).  IL-17
-/- 
mouse shows only glomerular hypercellularity with 
preserved tubular architecture (C, D). Magnification x400. 
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Figure 14. Glomerular thrombosis scores in WT and IL-17
-/-
 mice with NTN. 
 (A) Each experiment analysed separately by Mann Whitney-U test and (B) combined 
results analysed by Mann Whitney-U test after Two-Way ANOVA demonstrated no 
difference between experiments. Lines represent median values. * p<0.05; ** p<0.01; 
***p<0.001 
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Figure 15. Frequency of glomerular crescents in experiment 1. 
Lines represent median values. There was no significant difference between the groups and 
median frequency of crescents was low. Analysis by Mann-Whitney U test. 
 
 
3.4.5 IL-17-/- mice with NTN have similar humoral immune responses to WT 
mice 
 
There was no significant difference in humoral immune responses between WT and 
IL-17
-/-
 mice with NTN as measured by levels of circulating mouse anti-sheep 
immunoglobulins and glomerular mouse immunoglobulins. In addition there was no 
difference in glomerular sheep NTS on the GBM between the groups.  
 
3.4.5.1 Glomerular IgG deposition 
 
Frozen kidney sections from both experiments were stained for deposited sheep and 
mouse IgG by direct immunofluorescence. Total glomerular sheep and mouse IgG were 
scored as described in the methods and the results expressed in visual fluorescence units 
(VFU). There was no difference between WT and IL-17
-/-
 mice in either experiment. Since 
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this unit of measurement is only comparable within and not between experiments, results for 
the two experiments are expressed separately.  
 
With regard to glomerular sheep IgG deposition, in experiment 1 median score/ 
glomerulus in WT mice was 3 VFU (range 3-3) and in IL-17
-/-  
mice was also 3 VFU (range 
3-3), indicating that deposition of sheep IgG was uniform and maximal throughout. In 
experiment 2, median score/ glomerulus in WT mice was 2.16 VFU (range 1.5-3) and in IL-
17
-/- 
mice was 2.95 VFU (range 1.56-3), p=ns. 
 
With regard to mouse IgG deposition, in experiment 1, median score/glomerulus in 
WT mice was 1.88 VFU (1.64-2.60) and in IL-17
-/-
 mice was 1.98 (1.44-2.8). In experiment 
2, median score/glomerulus in WT mice was 1.1 (1.0-1.2) and in IL-17
-/- 
mice was 1.0 (1.0-
1.5); p=ns. 
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Figure 16. Representative glomerular immunofluorescence due to deposition of sheep IgG 
in (A) WT and (B) IL-17
-/-
 mice.  
Magnification x400.  (C) Quantitative immunofluorescence of sheep IgG deposition for WT 
and IL-17
-/- 
mice with NTN at day 9. For Experiment 1, WT n=5, IL-17
-/-
 n=3. For 
Experiment 2, WT n=3, IL-17
-/-
 n=6. There was no significant difference between the groups 
in either experiment. Bars represent median and range. 
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Figure 17. Representative glomerular immunofluorescence due to deposition of mouse IgG 
in (A) WT and (B) IL-17
-/- 
mice. 
 (C) Quantitative immunofluorescence for WT and IL-17
-/- 
mice with NTN at day 9. For 
Experiment 1, WT n=5, IL-17
-/-
 n=4. For Experiment 2, WT n=3, IL-17
-/-
 n=5. There was no 
significant difference between the groups in either experiment. Bars represent median and 
range. 
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B B A 
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3.4.5.2 Serum anti-sheep IgG immune response 
 
Circulating levels of mouse anti-sheep IgG antibodies in the serum at the end of the 
experiment were measured by ELISA. In experiment 1, median optical density at 405nm was 
0.83 in WT mice (0.47-0.92) and 0.64 in IL-17
-/- 
mice (0.50-0.93), p=ns.  By comparison, 
median OD in serum from un-manipulated WT mice was only 0.30 (0.30-0.31), indicating 
that the pre-immunisation with sheep IgG was adequate and that the experimental mice had 
mounted an immune response as a result of this. In the second experiment, median OD in 
WT mice was 1.08 in WT mice (1.03-2.32); in IL-17
-/-
 mice it was 1.38 (1.05-1.80), while 
control serum demonstrated an OD of 0.11 (0.10-0.11). Again there was no statistically 
significant difference between the WT and IL-17
-/-
 mice in this experiment. By two-way 
ANOVA there was a significant difference between the two experiments (p=0.002) but no 
significant difference between the mice in each group (p=0.66).  
 
Serum mouse anti-sheep IgG subclasses (IgG1, IgG2a, IgG2b, IgG2c, IgG3) were 
also determined by ELISA from mice in the two experiments. Optical density was highest 
for IgG1 and IgG2b. Levels of IgG2a and IgG3 were very low. Levels of IgG2c were 
intermediate.  
 
For IgG1in the first experiment, median OD at 405nm was 1.37 (0.53-2.2) in WT 
mice and 1.57 (0.89-1.59) in IL-17
-/-
 mice, p=ns. For IgG1 in the second experiment, median 
OD at 405nm was 0.95 (0.75-1.97) in WT mice and 1.03 (0.42-2.43) in IL-17
-/-
 mice, p=ns. 
By two-way ANOVA, there was no difference in levels of IgG1 between the two 
experiments (p-0.80), nor between the groups of mice (p=0.99).  
 
For IgG2a, in the first experiment, median OD at 405nm was 0.19 (0.19-0.20) in WT 
mice and 0.22 (0.21-0.26) in IL-17
-/-
 mice, p=ns. For IgG2a in the second experiment, 
median OD at 405nm was 0.24 (0.18-0.73) in WT mice and 0.24 (0.19-1.08) in IL-17
-/-
 mice, 
p=ns. By two-way ANOVA, there was no difference in levels of IgG2a between the two 
experiments (p-0.31), nor between the groups of mice (p=0.92).  
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For IgG2b, in the first experiment, median OD at 405nm was 1.92 (0.86-2.98) in WT 
mice and 2.27 (1.37-2.43) in IL-17
-/-
 mice, p=ns. For IgG2b in the second experiment, 
median OD at 405nm in WT mice was 1.44 (1.20-2.87) and 1.65 (0.59-2.93), p=ns. By two-
way ANOVA there was no significant difference between the two experiments (p=0.76), nor 
between the mice in each group (p=0.99). 
 
For IgG2c, in the first experiment, median OD at 405nm was 0.61 (0.28-0.94) in WT 
mice and 1.10 (0.24-1.17) in IL-17
-/-
 mice, p=ns. In the second experiment, median OD of 
IgG2c in WT mice was 0.49 (0.27-1.20) and 0.71 (0.23-1.92) in IL-17
-/-
 mice, p=ns. By two-
way ANOVA there was no difference between the experiments (p=0.92), nor between the 
groups of mice (p=0.50).  
 
Overall therefore, there was no difference in humoral immune response as measured 
by production of serum mouse anti-sheep antibodies, either in total sheep IgG or when 
examining IgG subclasses. In terms of IgG subclasses, there was more IgG1 and IgG2b and 
low optical densities when measuring IgG2a, IgG2c and IgG3. 
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Figure 18. Total serum mouse anti-sheep IgG by ELISA in (A) experiment 1 and (B) 
experiment 2. 
There was no difference between WT and IL-17
-/-
 mice in either experiment, but there was a 
significant difference between the two experiments. Control represents serum from un-
manipulated WT mice. Bars represent median and range. 
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Figure 19. Serum mouse anti-sheep IgG in experiment 1 and 2 for (A) IgG1, (B) IgG2a, (C) 
IgG2b, (D) IgG2c, (E) IgG3.  
There was no significant difference between either groups of mice by Mann Whitney-U test 
for each experiment or between the two experiments by two-Way ANOVA. 
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3.4.6 IL-17-/- mice with NTN have similar cellular immune responses to WT 
mice  
 
Frozen kidney sections were stained for CD68+ and CD4+ cells to assess 
macrophage and T-helper cell infiltration respectively. Intra-glomerular CD68+ and CD4+ 
cells were quantified. Interestingly, there was no difference between WT and IL-17
-/- 
mice 
with regards to glomerular macrophage infiltration as assessed by anti-CD68 
immunoperoxidase on frozen sections. In the first experiment, median number of 
macrophages/glomerulus was 2.0 (1.68-2.72) in WT mice and 2.5 (1.72-3.28) in IL-17
-/-
 
mice, p=ns. In the second experiment, median number of macrophages/glomerulus was 1.84 
(1.5-2.1) in WT mice and 2.0 (1.32-2.76) in IL-17
-/-
 mice, p=ns. By two-way ANOVA there 
was no significant difference between the two experiments (p=0.15), nor between the mice 
(p=0.26).  
 
IL-17
-/-
 mice appeared to have a small tendency to fewer CD4+ T-cells/glomerulus 
compared to WT mice but this did not reach statistical significance. In experiment 1, median 
CD4+cells/glomerulus in WT mice was 2.34 (1.09-4.0) and in IL-17
-/-
 mice was 0.84 (0.52-
1.24), p=ns. In experiment two, median CD4+ cells/glomerulus was 0.56 (0.54-1.15) in WT 
mice and 0.82 (0.56-1.80) in IL-17
-/- 
mice, p=ns. By two-way ANOVA, there was no 
significant difference between the experiments (p=0.09), nor between the groups of mice 
(p=0.14). 
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Figure 20. Immunohistochemistry for the macrophage marker CD68 
(A) and (B) show intra-glomerular CD68+ cells in WT and IL-17
-/-  
mice respectively. 
Magnification x400. (C) Intraglomerular CD68+ cell quantification, experiment 1 and 2 
analysed separately by Mann Whitney-U test and (D) combined results analysed by Mann 
Whitney-U test after Two-Way ANOVA demonstrated no difference between 
experiments. Lines represent median values. There was no significant difference between 
groups of mice, nor between experiment 1 and 2. 
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Figure 21. Glomerular CD4+ T-cell infiltration on frozen sections in WT and IL-17-/- mice. 
Representative glomerulus from (A) WT and (B) IL-17
-/- 
mouse. Arrows show one positive 
cell in each. Magnification x400. (C) Intraglomerular CD4+ cell quantification, experiment 1 
and 2 analysed separately by Mann Whitney U test and (D) combined results analysed by 
Mann Whitney U test after Two-Way ANOVA demonstrated no difference between 
experiments. Lines represent median values. There was no significant difference in cell 
number between groups of mice or between experiment 1 and 2. 
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3.4.7 Transfer of WT cells to IL-17-/- mice does not consistently transfer 
disease susceptibility in this model 
 
3.4.7.1 Experimental method 
The preceding experimental results show that IL-17
-/- 
mice were protected from 
nephrotoxic nephritis, but no obvious difference was found in the humoral or cellular 
effectors. Therefore I went on to assess the effects of WT cell transfer into IL-17
-/- 
mice. 
Based on my original hypothesis that Th17 cells are an important source of IL-17 and 
important mediators of disease in this model, transfer of WT haematopoietic cells might at 
least partially restore disease susceptibility. Conversely, disease protection in IL-17
-/- 
mice 
could be due to another mechanism such as the reciprocal relationship between Th17 and 
Treg development resulting in increased numbers of Treg in IL-17
-/-
 mice.  In this case, 
transfer of cells from IL-17
-/- 
into WT mice might confer resistance to disease. Therefore I 
carried out a number of cell transfer experiments using splenocytes from WT or IL-17
-/-
 
donors and transferred cells into WT or IL-17
-/- 
recipients.  
 
Splenocytes from donor mice were isolated and transferred to recipient mice by 
intravenous tail vein injection prior to induction of nephrotoxic nephritis. Splenocytes were 
transferred either unfractionated, or as highly-purified T-cell or non-T-cell fractions, 
separated using a MACS pan T-cell isolation kit (Miltenyi Biotech) as described in the 
Methods. Cell fractions were assessed for purity by FACS prior to transfer. In some 
experiments these cells were also labelled with a red fluorescent cell linker (PKH26, Sigma 
Aldrich) prior to injection. The subsequent protocol was identical to that previously 
described for nephrotoxic nephritis. 
 
In order to try to induce disease in IL-17
-/-
 mice by cell transfer in this way, I 
manipulated a number of variables when there was no difference in experimental outcome. I 
altered the timing of cell-transfer in relation to pre-immunisation. Initially donor mice were 
pre-immunised with CFA and sheep IgG at day -5 and cells were transferred from these mice 
into pre-immunised recipients at day -3 or at day 0 with NTS injection. In later experiments, 
I transferred donor cells into recipients at day -5 and pre-immunised only the recipients. I 
also sequentially increased the total number of cells transferred. Finally, I also transferred 
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IL-17
-/- 
cells into WT animals in order to see whether this would confer protection from 
disease. The overall schema of this sometimes complex series of experiments is summarised 
below. 
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Cell transfer 
experiment 
Mice per 
group 
Sex Cells     
transferred 
Recipient Pre-
immunised 
Cell 
transfer 
(day) 
Result 
1 5  Female WT T cells 
3 million 
WT 
IL-17
-/-
 
Donors 
Day -5 
-3 No disease in 
IL-17
-/-
 mice 
with WT cell 
transfer 
 
2 4 Male     
donors 
Female 
recipients 
IL-17
-/- 
T cells 
3 million 
WT 
IL-17
-/-
 
Donors 
Day -5 
0 No protection 
of WT mice by 
IL-17
-/- 
cell 
transfer 
3 5 Female WT or IL-17
-/-
splenocytes 
8 million 
WT to WT      
WT to IL-17
-/- 
    
IL-17
-/-
 to IL-17
-/-
 
WT 
IL-17
-/-
 
Donors  
Day 5- 
0 No disease in 
IL-17
-/-
 mice 
with WT cell 
transfer. WT to 
WT cell 
transfer mice 
had disease. 
4 4 Female WT splenocytes 
18 million 
WT 
IL-17
-/-
 
Recipients 
Day-5 
-5 2/4 IL-17
-/- 
mice: disease 
with WT cell 
transfer 
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Table 4. Summary of schedule of cell transfer experiments prior to induction of NTN in WT and IL-17
-/-
 mice. 
Day 0 represents the day of IV NTS injection. Therefore for pre-immunisation and cell transfer, negative numbers represent the number of days 
prior to injection of NTS. 
5 4-5 Male  WT cells 
12 million 
splenocytes to 
WT & IL-17
-/-
 
5 million T cells 
to IL-17
-/-
 
8 million non T 
cells to IL-17
-/-
 
 
WT 
IL-17
-/-
 
Recipients 
Day -5 
-5 2/5 IL-17
-/- 
mice with WT 
T cells had 
some disease, 
but 0/4 IL-17
-/-
 
mice with WT 
splenocytes 
had disease 
 
6 5 Male WT and IL-17
-/-
 
splenocytes 
20 million IL-17
-/- 
to WT 
16 million WT to 
WT 
WT Donors 
Day -5 
0 No protection 
of WT mice by 
IL-17
-/- 
cell 
transfer 
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Purity of isolated cell fractions 
 
Separation of donor splenocytes into T-cell and non T-cell fractions in this series of 
experiments resulted in highly pure cell populations for transfer. For example in the first 
experiment, the T-cell fraction isolated from WT donor splenocytes was >95% CD3+, whilst 
in the non-T-cell fraction only 2.8% of cells were CD3+. Representative FACS analysis of 
donor splenocytes for CD3 in this experiment is shown in the figure below. Percentages of 
CD3, CD4 and CD8 cells are given in the following table and have been adjusted for Ig 
isotype controls. These data are representative of those in the subsequent experiments.  
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Figure 22. Representative FACS plots for separation of splenocytes from WT mouse 
spleen.. 
 (A) and (C): forward-scatter and side-scatter, and selected cell population, for T-cell and 
non-T-cell fractions respectively. (B) and (D): histograms of frequency of CD3+ cells 
(FITC) in T-cell and non-T-cell fractions respectively (red) compared to isotype controls 
(purple). T-cell fraction contains >95% CD3+ cells, whilst non-T-cell fraction contains 2.8% 
CD3+ cells. 
 
 
R1
R1
A B 
D C 
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 T cell fraction % Non T-cell fraction 
% 
CD3 95.5 2.8 
 
CD4 57.7 6.1 
 
CD8 41.8 1.8 
 
 
Table 5. Representative FACS analysis of purified T-cell and non T-cell fractions from WT 
mouse spleen  
 
 
3.4.7.2 Overview of findings from cell-transfer experiments 
 
Previous adoptive cell transfer experiments have used unfractionated splenocytes or 
purified T cells in numbers within this range (Eck and Turka, 2001; Hayashi et al., 1994; 
Morgan et al., 2005), although others have used much larger numbers. The first two 
experiments described in this series included control groups of WT and IL-17
-/- 
mice without 
cell transfer but with NTN. By comparison with these groups, transfer of 3 million WT T-
cells to IL-17
-/- 
mice did not result in disease, as demonstrated by minimal proteinuria and 
glomerular hypercellularity only on histology. Transfer of 3 million IL-17
-/-
 T-cells to WT 
mice did not protect from disease since this group developed disease comparable to that in 
normal WT with NTN in the same experiment. In the third experiment I transferred whole 
splenocytes rather than isolated T cells and increased the total number of cells transferred to 
8 million. IL-17
-/- 
mice were given WT or IL-17
-/-
 splenocytes and remained protected from 
disease in both cases whilst WT-WT cell transfer mice developed nephritis.  
 
In the fourth experiment, I increased the cell number again to 18 million and 
transferred WT splenocytes into WT and IL-17
-/- 
mice. Unusually in this experiment, the WT 
to WT mice did not develop significant disease and so the results are harder to interpret but 
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2/4 IL-17
-/-
 mice did develop renal impairment, proteinuria and thrombosis, perhaps 
providing proof of concept that it is possible to transfer disease susceptibility in this way. 
However, disappointingly, these results were not reproduced when repeated in the 5th 
experiment which I will outline in more detail below.  The 6
th
 and last cell transfer 
experiment was carried out to convincingly answer the question of whether transfer of IL-17
-
/-
 splenocytes could confer resistance to induction of NTN. I transferred high numbers 
(between 16 and 20 million) WT or IL-17
-/-
 splenocytes to WT mice. Both groups of mice 
developed disease and there was no protective effect of IL-17
-/- 
splenocytes. 
 
Detailed results of cell transfer experiment number 5 
Experimental outline 
 
 Since in the 4
th
 cell transfer experiment, 2/4 IL-17
-/- 
mice developed disease after 
receiving WT splenocytes, I carried out a further experiment to reproduce these findings and 
also to include groups of IL-17
-/-
 mice which received WT T-cell and non-T-cell fractions 
only, to establish which cell type was capable of transferring disease susceptibility. Hence 
there were 3 groups of IL-17
-/-
 mice and a positive control group of WT mice which received 
WT splenocytes.  
 
 This experiment was carried out in male mice. Splenocytes were isolated by standard 
protocol as described in the Methods. Following column separation into T-cell and non-T-
cell fractions of a proportion of the cells, FACS analysis was carried out to ensure adequate 
purity of these fractions as described above. Whole splenocytes, T-cells and non-T-cells 
were then labelled with PKH26 red fluorescent cell linker dye as described in the Methods; 
subsequently cells were washed and an aliquot stained with Trypan blue for counting cell 
number and viability. Recipient animals received 12 million whole splenocytes, 5 million T-
cells or 8 million non-T-cells. Recipient mice were also pre-immunised for NTN with sheep 
IgG:CFA s/c as per standard protocol (day -5) on the same day as cell transfer.  At day 0 
mice were given 200mcl NTS 1:1 dilution IV via tail vein and sacrificed at day 8 after 
overnight collection of urine in metabolic cages.  
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Results 
 
Frozen kidney sections from experimental animals were counter-stained with DAPI 
and visualised using a wide-field fluorescence microscope using a TRITC filter. PKH26-
labelled cells were detectable in kidney sections demonstrating that some of the cells 
transferred intravenously had been able to traffic to the kidney. Additionally, FACS on 
splenocytes from recipient mice in another cell transfer experiment showed that about 0.5% 
of splenocytes in recipients at sacrifice were labelled cells (data not shown). 
 
Data for this experiment for proteinuria, urea and creatinine and thrombosis is given 
below. The WT positive control group which received WT splenocytes developed disease as 
expected with proteinuria, some renal impairment and thrombosis. None of the IL-17
-/- 
mice 
which received WT splenocytes developed disease, contradicting the results of the previous 
experiment. However, of the IL-17
-/- 
mice which received WT purified T cells , 1 mouse did 
develop significant proteinuria (8.3mg/24hrs) and this mouse and one other developed 
thrombosis (thrombosis scores 1.56 and 1.72).  
 
Overall, there was no progressively consistent or robust evolution in the ability of 
these experiments to induce disease in IL-17
-/-
 animals. The possible causes for this are 
considered in the discussion for this chapter below. As a result of this, I went on to perform 
bone marrow transplantation in these animals and these experiments are outlined in the next 
chapter. 
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Figure 23.  Wide-field fluorescence of frozen kidney sections from a cell transfer 
experiment stained with DAPI.  
Nuclei are blue and PKH26-labelled transferred cells are pink-red using a TRITC 
filter. (A) shows a wide-field view with a number of TRITC-positive cells in an IL-
17
-/- 
mouse which received T-cell transfer and (B) shows a single glomerulus at high 
magnification in an IL-17
-/-
 mouse which received whole splenocytes with a single 
intra-glomerular PKH26-positive WT splenocyte (arrow). 
A 
B 
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Figure 24. (A) Serum urea, (B) serum creatinine, (C) proteinuria and (D) thrombosis score 
in WT and IL-17
-/-
 mice from cell transfer experiment number 5.  
It can be seen that transfer of WT splenocytes, or splenocyte fraction, did not consistently 
induce renal damage in IL-17
-/- 
mice by any of these measured parameters. Of note, one IL-
17
-/-
 mouse did develop considerable proteinuria. 
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3.5 Discussion 
 
These experiments demonstrate that IL-17
-/- 
mice are markedly protected from 
accelerated nephrotoxic nephritis compared to WT mice. IL-17
-/-
 mice had lower levels of 
serum urea and therefore greater preservation of excretory renal function than WT mice. 
They had lower levels of proteinuria and less glomerular thrombosis on histology. However, 
there was no difference between the two groups of mice in humoral immune responses, nor 
in glomerular cellular infiltration. Circulating levels of mouse antibodies to sheep IgG were 
similar between WT and IL-17
-/-
 mice as was glomerular deposition of sheep and mouse 
IgG. Intra-glomerular macrophage numbers were the same for both groups of mice and, 
although there was a trend towards fewer numbers of intra-glomerular CD4+ cells in IL-17
-/-
 
mice, this did not reach statistical significance.  
 
Thus these outcomes support my original hypothesis that IL-17 is an important 
cytokine in the pathogenesis of immune-mediated glomerulonephritis, with protection from 
disease in the absence of IL-17. This is in keeping with the pleiotropic and potent pro-
inflammatory functions of IL-17. In the introduction, I have described the role for IL-17 
which has been defined in many other models of autoimmunity such as EAE (Cua et al., 
2003), CIA (Murphy et al., 2003) and EAU (Luger et al., 2008). In some cases, protection 
from disease has also been correlated with decreased numbers of IL-17 producing CD4+ T 
cells (Murphy et al., 2003). T cells infiltrate the kidney in both human disease and 
experimental glomerulonephritis (Kurts et al., 2007). Historically, as in other models of 
autoimmunity, Th1 cells were thought to be responsible for much of the renal injury in these 
examples, as a result of experiments in genetically modified animals which elucidated the 
contribution of different elements of the Th1 pathway to disease (Kitching et al., 1999a; 
Kitching et al., 1999b; Kitching et al., 2005; Phoon et al., 2008).  The data in this chapter 
suggests that, since CD4+ T cells are known to play a critical role in disease (Tipping et al., 
1998), Th17 cells as major producers of IL-17 also have an important contribution to 
pathogenesis.  
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In addition, during the course of my work two other groups also published the first 
data on the role of IL-17 in autoimmune renal disease. Two papers were published 
concurrently in JASN in 2009 with an accompanying editorial (Hamour and Salama, 2009). 
Firstly Paust and colleagues induced NTN in IL-23 p19
-/-
 mice and in IL-17 deficient mice 
(Paust et al., 2009). IL-23 is an important cytokine in the stabilisation and maintenance of 
the Th17 population. Of note, their experimental protocol differs slightly from that in our 
laboratory: nephrotoxic serum is injected intraperitoneally rather than IV and animals were 
sacrificed a little later at day 10.  In keeping with my findings, both of these strains were 
protected from NTN compared with WT nephritic mice, as demonstrated by less proteinuria, 
fewer crescents and preserved renal function. Again similarly, both groups of mice had no 
difference in humoral immune response although they found reduced CD3+ T cell and 
monocyte infiltration. In addition they found that IL-23 deficient mice had reduced 
infiltration of Th17 cells. Lastly Paust and colleagues found that IL-17 in vitro can stimulate 
mouse mesangial cells to produce CCL2 (MCP1), CCL3 (MIP-1α) and CCL20 (LARC), 
chemokines which contribute to the pro-inflammatory milieu in glomerulonephritis by 
recruiting T cells and monocytes. 
 
In a complementary study in the same issue of the journal, Ooi and colleagues used 
the EAG model of anti-GBM disease to examine the contribution of the Th1 and Th17 
lineages in disease (Ooi et al., 2009). They immunised IL-12p35
-/-
 (IL-12 deficient, IL-23 
intact), IL-12p40
-/-
 (IL-12 and IL-23 deficient) and IL23p19
-/-
 (IL-23 deficient, IL-12 intact) 
animals with recombinant α3(IV)NC1, the Goodpasture antigen, which in WT mice leads to 
the development of autoreactivity to α3(IV)NC1 and immune-complex glomerulonephritis. 
They showed that deficiency of IL-23 is necessary and sufficient to protect from disease 
regardless of IL-12 status. Furthermore, given the reciprocal nature of Th17 and Treg 
development, they also showed that there was no increase in CD4+ CD25+ FOXP3+ 
regulatory T cells in the draining lymph nodes of IL-23p19
-/-
 or IL-12p40
-/- 
mice at day 19, 
demonstrating that the attenuation of disease in IL-23
-/-
 mice is mediated by a mechanism 
other than an increase in Treg. Overall, whilst IL-23 deficient animals expressed less IL-17 
as would be expected, they also expressed less IFNγ, IL-4, TNF, IL-10 and MCP-1, leading 
the authors to conclude that IL-23 deficiency additionally leads to a non-selective deficit in 
T-cell cytokine production and a more general effect on immune responses in this model. Of 
note, the EAG model requires a much longer time course for the development of disease than 
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NTN, 7 months in this case, and the nature of renal injury was much milder than that in the 
NTN model with 30% abnormal glomeruli and modest interstitial infiltrates. This is in 
marked contrast to the nature of human anti-GBM disease which is usually of sudden onset 
and affects almost 100% of glomeruli. However, these data provide further supportive 
evidence for the importance of the Th17 lineage in another model of immune-mediated 
glomerulonephritis. 
 
The following year a further study by the same group examining the effects of IL-17 
deficiency in renal disease was published, this time using an MPO-ANCA vasculitis model 
in mice (Gan et al., 2010). In this model, mice are pre-immunised with MPO to induce 
autoimmunity and then a low dose of nephrotoxic serum is injected to localise neutrophils 
and MPO deposition in the kidney. MPO is directly injurious and also is thought to act as a 
planted autoantigen. Subsequent recruitment of T cells and macrophages results in a focal 
necrotising glomerulonephritis. IL-17 deficiency did not alter autoantibody production but 
reduced MPO-specific dermal footpad DTH response. IL-17 deficient mice were 
substantially protected from renal injury and had decreased infiltration of neutrophils, 
macrophages and T cells. In a separate experiment where anti-GBM antibodies were injected 
into WT and IL-17
-/-
 mice and maximal neutrophil infiltration at 2 hours was observed, they 
also showed that neutrophil influx is decreased in IL-17
-/- 
mice and therefore that this is one 
mechanism for protection in this model. To study the effect of T cell responses to MPO in 
the kidney and to circumvent the lack of infiltration of neutrophils and therefore decreased 
MPO deposition in IL-17
-/-
 mice, they injected MPO directly into the kidney of MPO pre-
immunised mice. Macrophage infiltration was reduced in IL-17
-/-
 mice and levels of the 
monocyte-attracting chemokine CCL5 (but not CCL2) were reduced, suggesting a role for 
antigen-specific T cells in monocyte/macrophage recruitment in this model.  
 
I did not identify any significant difference in the number of intraglomerular CD4+ 
cells in my experiments although it tended to be lower in the IL-17
-/-
 mice. Paust and 
colleagues identified lower numbers of CD3+ cells, and Gan and colleagues identified lower 
numbers of CD4+ cells in IL-17
-/-
 mice in the MPO-model but the overall order of 
magnitude in all these experiments is similar, often <1 CD3+ or CD4+ T cell/glomerular 
cross section. Not only are intra-glomerular T cell numbers rather low but in WT nephritic 
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mice in the study by Paust, only 3-7% of renal CD3+ T cells produced IL-17 after 
stimulation with PMA and ionomycin. Given that IL-17 deficiency results in a profound 
amelioration of disease, the fact that that so few T cells are able to secrete IL-17 perhaps 
underscores the potent pro-inflammatory amplification of IL-17 signalling. This also raises 
questions as to the nature of the remaining 97% of renal T cells, and what their role is in 
interacting with Th17 cells. This could also contribute to the lack of consistency seen in the 
cell transfer experiments. Purified T cells were transferred but only a small proportion of 
these may have been Th17 cells. It would also have been useful to polarise Th17 cells in 
vitro and then transfer these to see whether disease could be restored.  An alternative 
explanation could be that the important source of IL-17 is non T cell-derived, given that 
many other immune cells can also produce IL-17. There are rather less data about the role of 
non T cell IL-17 producers in renal disease but recently neutrophils have been identified as a 
more significant source of IL-17 in human kidney biopsies (Velden et al., 2012). Finally it 
could also be that the spleen or the draining lymph node rather than the kidney are more 
important sites for the effector function of pathogenic Th17 cells or that the peak number of 
intra-glomerular T cells occurred before the end of the experiment, since it has been shown 
that there is a closely defined temporal nature of IL-17 responses in NTN (Odobasic et al., 
2011). 
 
Taken together, these 3 studies along with data in this chapter define a role for IL-17 
in the pathogenesis of the NTN, EAG and MPO-ANCA models of immune-mediated 
glomerulonephritis. In the introduction and earlier in this discussion I have highlighted some 
of the conflicting, but potentially complementary data regarding the role of Th1 cells in 
glomerulonephritis, and more generally in autoimmunity. Overall it is likely that both the 
Th1 and Th17 lineages contribute to disease in autoimmune glomerulonephritis. In RAG
-/- 
mice with ovalbumin as a planted antigen on the GBM, both Th1 and Th17 polarised 
ovalbumin specific CD4+ cells could induce proliferative glomerulonephritis (Summers et 
al., 2009) (although a similar study found that only Th17 and not Th1 could induce 
glomerulonephritis (Tulone et al., 2011)); and Th1 and Th17 cells have been suggested to 
counter-regulate each other during the course of disease (Odobasic et al., 2011). There is 
precedent for this in other models of autoimmunity, for example in both EAE and EAU both 
Th1 and Th17 cells can transfer disease although the pattern of disease is different (Kroenke 
et al., 2008; Luger et al., 2008).  
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Macrophages are another critical cellular mediator of injury in glomerulonephritis 
and NTN is characterised by macrophage infiltration. While some of the above studies have 
described decreased intra-glomerular macrophage infiltration in IL-17
-/-
 mice, I did not find 
any difference in macrophage number in my experiments despite different degrees of disease 
severity, although it would also be interesting to consider numbers of interstitial rather than 
intra-glomerular macrophages which were not routinely quantified. However, it is 
recognised that macrophage function rather than number usually dictates the severity of 
tissue damage (Kluth et al., 2004). Macrophages evolved to combat microbial infection and a 
range of receptors on their cell surface recognise pathogen associated molecular patterns 
(PAMPS) including toll-like receptor (TLR) 4 and mannose receptor. Classically activated 
macrophages require two signals: engagement of TLR and secondly IFNγ from T helper 
cells or NK cells. This leads to production of nitric oxide, reactive oxygen species and pro-
inflammatory cytokines including IL-12 and TNFα. Increased expression of MHC class II 
and other co-stimulatory molecules enhances antigen presentation (Weidenbusch and 
Anders, 2012). These effects enable the activation of adaptive immunity and optimise 
microbial killing.  Alternatively activated macrophages develop after exposure to IL-4 or IL-
13 and show increased expression of mannose receptor and MHC class II. They manifest 
increased endocytosis and decreased nitric oxide production and have a decreased role in 
killing of intracellular organisms but increase matrix production and have a role in tissue 
repair. Type II activated macrophages secrete more IL-10 and less IL-12 (Anderson and 
Mosser, 2002) and favour the development of Th2 type immune responses with increased T 
cell IL-4 production and IgG class switching by B cells.  
 
Thus macrophage number does not inform us about function and the mechanisms 
that cause macrophages to accumulate in glomerulonephritis may be separate from those that 
activate them for injury. In WKY rats with NTN, administration of IL-4 after disease was 
established promoted resolution of renal injury without altering macrophage numbers, 
suggesting that administration of IL-4 might in part serve to reduce the inflammatory 
properties of macrophages (Cook et al., 1999). Therefore, it is not possible to draw any 
definite conclusions regarding the significance of infiltrating macrophages in my 
experiments, or the fact that the numbers were similar. It would be useful to compare 
macrophage activation status in the different groups in these experiments by phenotyping.  
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In terms of humoral immunity, and in keeping with the study by Paust, I did not find 
any difference in immune responses between WT and IL-17
-/-
 mice. There was no difference 
in deposition of either heterologous (sheep anti-mouse) or autologous (mouse anti-sheep) 
antibody in the glomerulus, demonstrating that deposition of immunoglobulin is separate 
from the trigger for glomerular injury. For a precise assessment of antigen-specific humoral 
immunity, I also assessed serum levels of total mouse anti-sheep IgG and the isotype pattern 
of IgG subclasses in nephritic mice by ELISA. Again there was no difference between WT 
and IL-17
-/-
 mice in total anti-sheep IgG. Th1 responses which classically result in CD4 T 
cell/macrophage mediated cellular responses drive IgG subclass switching toward 
complement-fixing and macrophage-recruiting subclasses. However, analysis of IgG 
isotypes revealed no bias for either Th1 (IgG2a) or Th2 type (IgG1) antibody production in 
IL-17
-/-
 mice compared with WT. 
 
The next set of results in this chapter detailed a series of cell transfer experiments 
designed to demonstrate whether resistance to disease or increased disease susceptibility 
could be transferred by transfer of IL-17
-/-
 or WT splenocytes respectively. Cells were 
transferred either as whole splenocytes or by separation into T cell or non T cell fractions. I 
was able to demonstrate the relative purity of these fractions by FACS and also, after 
labelling the cells with a fluorescent dye, to demonstrate by FACS that some cells were able 
to traffic to the spleen and by immunofluorescence on frozen sections to demonstrate that 
some cells had trafficked to the kidney. However, despite this, the results of cell transfer 
were inconsistent, although they do suggest that restoring IL-17+ cells may restore disease 
susceptibility. Transfer of 18 million WT splenocytes did induce disease in 2/4 IL-17
-/-
 mice 
but this result was not replicated in the following experiment where this group remained 
protected, although there was a suggestion of disease in 2/5 IL-17
-/-
 mice which received T 
cell transfer. However, transfer of high numbers of IL-17
-/-
 splenocytes did not protect WT 
mice from disease. 
 
It is one of the limitations of the NTN model that there can be considerable 
variability in outcome between mice in the same group and between different experiments 
(Robson et al., 2003). However, these experiments had 4-5 mice per group which this should 
have been sufficient to detect any real differences in severity of disease. It is theoretically 
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possible that despite identical housing conditions, unidentified intercurrent infection or the 
presence of LPS may have contributed to pathogenesis in the IL-17
-/-
 mice which did 
develop disease since it is known that endotoxin contamination can aggravate disease in this 
model (Karkar and Rees, 1997). I made a number of protocol modifications during the 
course of these experiments to try to induce disease in IL-17
-/-
 mice. Priming of the host 
immune response by pre-immunisation was also performed in donor mice and primed donor 
cells transferred into recipients at day -3 or day 0; or naïve cells were transferred into 
recipients at day -5 and then the recipients were pre-immunised. This was coupled with a 
progressive increase in cell numbers transferred. However, these changes had an inconsistent 
effect on disease outcome in IL-17
-/-
 mice. 
 
Adoptive cell transfer is a long-established and well-recognised method for 
investigation of the contribution of different cell lineages to disease (Mitchison, 1955) and a 
multitude of studies in different models of autoimmunity have been carried out. Historical 
work done in our laboratory using the EAG rat model used high numbers of splenocytes 
from donors immunised with CFA and GBM into WT Brown Norway recipients. EAG was 
not transferred by sensitised splenic lymphocytes but at doses of splenocyte transfer above 
1x10
8 
cells, recipients were primed for antigenic challenge and showed an enhanced anti-
GBM antibody response (Reynolds et al., 1993). These cell transfer numbers are 
considerably higher than those used in my experiments. However, disease was not 
transferred and due to only low levels of albuminuria and inconsistent glomerular damage, 
the authors were unable to compare these variables between the groups. In contrast, in my 
cell transfer experiments, I have analysed markers of glomerular damage for outcome and so 
it would be useful to also analyse the immune response in the different groups to see whether 
differences exist.  Other groups have used the transfer of much lower numbers of specific T 
cell subsets to transfer disease, for example, Wolf and colleagues used the transfer of only 
0.5 million Tregs to attenuate disease in NTN (Wolf et al., 2005). 
 
More recently, cell transfer studies have generally utilised in vitro polarised antigen-
specific cells deployed in highly artificial genetically-modified models. For example, 
Summers and colleagues used ovalbumin bound to the GBM in RAG
-/- 
mice which lack 
intrinsic adaptive immunity and found that transfer of 5 million antigen specific Th1 or Th17 
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polarised CD4+ cells could transfer disease and cause glomerulonephritis (Summers et al., 
2009).  It is an interesting question as to how closely in vitro transfer of high numbers of 
antigen specific T cells mirrors in vivo pathogenesis. Although it provides valuable proof of 
concept of pathogenic effector ability, this scenario may not reflect the mechanisms in 
glomerulonephritis in human or animal disease. In an alternative method, using the CIA 
model, splenocytes were transferred from primed DBA/1J donors into SCID mice, which are 
prone to autoimmunity. Therefore the donor and recipient are not of the same strain and in 
this case 50 million splenocytes were injected intraperitoneally for disease transfer 
(Kadowaki et al., 1994). 
 
In both of these examples, cell numbers transferred were much higher than those 
which I used. Additionally cells were either antigen-specific or transferred into a more 
susceptible host. Therefore, perhaps my cell numbers were insufficient for disease transfer. 
However, it is also the case that no other group has published a demonstration of successful 
adoptive cell transfer in this model using in vivo primed cells without further in vitro 
manipulation. Finally it is also worth considering that, although the Th17 subset has been 
considered as the most important source of IL-17 in many of these models, disease may also 
be partly due to non-T cell production of IL-17. IL-17 is a pivotal cytokine in the interaction 
between innate and adaptive immunity and thus the critical source of IL-17 in the context of 
this complex in vivo pathogenic process has not been defined. It has been surprising as this 
field has evolved that in fact few renal T-cells in situ are actually IL-17 producing and other 
cell types such as neutrophils have been identified as the most significant IL-17 producing 
population (Paust et al., 2009; Velden et al., 2012). Therefore in the next experimental 
chapter I describe bone marrow transplantation experiments between WT and IL-17
-/-
 mice 
to address more definitively the ability of haematopoietic cells to transfer disease 
susceptibility, and also to investigate the contribution of non-haematopoietic cells in this 
model. 
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3.5.1 Summary 
 
 IL-17-/- mice are protected from proteinuria, thrombosis and renal impairment in 
accelerated nephrotoxic nephritis consistent with contemporaneous findings by other 
groups 
 
 There was no measured difference in the humoral or cellular immune response 
between WT and IL-17
-/-
 mice, although there was a tendency to fewer CD4+ cells in 
IL-17
-/-
 mice 
 
 Transfer of IL-17-/- splenocytes to WT mice did not protect them from developing 
disease 
 
 Transfer of WT T cells or splenocytes to IL-17-/- mice did  transfer disease 
susceptibility to some recipients, but this was not consistently reproducible 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
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The role of IL-17 from circulating leucocytes and intrinsic cells in 
glomerulonephritis 
 
 
4.1 Introduction 
 
 In both humans and mice, I hypothesised that IL-17 is important in the pathogenesis 
of glomerulonephritis, and in the previous chapter I have demonstrated that IL-17
-/-
 mice are 
protected in NTN. Th17 cells are an important source of IL-17 and part of my original 
hypothesis relates to their significance as mediators of disease in glomerulonephritis. In 
addition, much of the literature relating the Th17 axis to experimental nephritis has focused 
on transfer of Th cells of different lineages, which have often been polarised in vitro. Based 
on these results, T helper cells, including Th17 cells, do seem to have a role in pathogenesis. 
However, importantly, IL-17 is also secreted by a much wider variety of immune cells than 
Th17 cells alone. It is notable that in psoriasis for example, IL-23-responsive dermal γδ T 
cells are the most significant source of IL-17 in the skin (Cai et al., 2011) and in human renal 
biopsies, neutrophils have recently been shown to be important producers of IL-17 (Velden 
et al., 2012). Similarly in ischaemia reperfusion injury, neutrophils, iNKT cells and γδTcells 
have all been shown to be significant sources of IL-17 (Li et al., 2010; Sharma et al., 2011; 
Shichita et al., 2009). Therefore it cannot be assumed that a role for IL-17 in NTN is 
necessarily mediated by Th17 cells. 
 
In many autoimmune conditions, including nephritis, it is likely that IL-17 secretion 
from both intrinsic and bone-marrow derived cells may play a role in pathogenesis. In order 
to test this hypothesis in NTN, bone marrow chimeric mice were created with an intact IL-17 
gene in bone marrow-derived cells but not in tissue cells or vice versa. The susceptibility of 
these mice to NTN was compared to WT mice transplanted with WT bone marrow.  
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4.2 Aim 
 
 To define the role of IL-17 derived from haematopoietic cells or intrinsic cells in the 
development of disease in NTN. 
 
4.3 Experimental design 
 
In order to investigate the role of IL-17 from intrinsic cells and haematopoietic cells, 
bone marrow transplantation experiments were performed. Initially, WT and IL-17
-/-
 female 
mice aged 6-8 weeks received whole body gamma irradiation in a single dose of 8Gy to 
ablate the bone marrow in an IBL irradiator at CBS, Hammersmith hospital. The optimal 
irradiation dose for elimination of recipient bone marrow, with minimum mortality and 
somatic tissue damage has previously been defined in experiments by Dr Ruth Tarzi in our 
laboratory. Immediately following irradiation, mice received an intravenous injection of 10 
million whole bone marrow cells from female donors. IL-17
-/-
 mice received bone marrow 
cells from WT animals and vice versa. As a control, WT bone marrow was transplanted to 
WT mice. During the following 8 weeks, mice were housed in individually ventilated cages, 
with acidified water and autoclaved diet. After allowing 8 weeks for haematopoietic 
reconstitution, NTN was induced and disease was assessed in WT and IL-17
-/-
 mice as 
previously described in chapter 3. 
 
4.4 Results 
  
 Two bone marrow transplant experiments (BMT1 and BMT2) were carried out. 
Following bone marrow reconstitution, NTN was induced using the same method as that 
described in chapter 3 with a 1:1 dilution of the same batch of nephrotoxic serum. In the first 
experiment, animals were sacrificed at day 9 of NTN and unexpectedly some were found to 
have very severe disease. Two mice died before the end of the experiment, one from the WT 
to IL-17
-/-
 transplant group and one from the WT to WT group. Therefore the second 
experiment was terminated earlier at day 8. However, despite close monitoring, 2 mice in the 
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most severely affected WT to IL-17
-/-
 group still died before the end of the experiment. 
Therefore the numbers available for analysis at the end of the experiments were: 
 
IL-17
-/-
 to WT  WT to IL17
-/-
    WT to WT 
BMT1   8   7   7 
BMT2   6   4   6   
 
Results for each experiment were analysed by Kruskal-Wallis test and Dunn’s multiple 
comparisons post-test. Results from the two experiments were also analysed by two-way 
ANOVA and where there was no difference between the two experiments, these results were 
combined.  
 
4.4.1 Reconstitution of bone marrow chimeras 
 
 All mice were bled at the termination of the NTN experiment. DNA was extracted 
from blood as described in the Methods chapter. DNA concentration was standardized to 
100ng/ml and PCR for WT and IL-17
-/-
 alleles was carried out on all samples. Product band 
and intensity were compared to a DNA ‘ladder’, made of sequential proportions of WT and 
IL-17
-/-
 DNA, in order to determine the degree of reconstitution. The limit of detection of the 
WT band was 1% and the limit of detection of the IL-17
-/- 
band was 0.1%. All animals 
reconstituted bone marrow adequately (>90%). Representative genotyping results from the 
first bone marrow transplant experiment are shown below.  
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Figure 25. Representative reconstitution genotyping from BMT1. 
(A) DNA ‘ladder’ demonstrating PCR results for WT and IL-17-/- alleles after combining 
fixed fractions of WT and IL-17
-/- 
DNA. (B) Reconstitution genotyping results for BMT1. It 
can be seen that WT to IL-17
-/-
 and IL-17
-/-
 to WT bone marrow transplant resulted in a 
minimum of 90% reconstitution.  
A 
B 
WT%    100    99.9     99     90     75      50     25      10      1        0.1     0       H2O 
WT band 
700bp 
IL-17
-/-  
band  
 
500bp 
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4.4.2 Transfer of WT bone marrow to IL-17-/- mice restores disease 
susceptibility to NTN, and results in augmented disease compared to WT to 
WT bone marrow transplant mice  
 
Eight weeks after bone marrow transplantation, NTN was induced in the mice using 
the same method as that described in chapter 3. Disease outcomes were analysed by 
measurement of serum urea and creatinine, assessment of glomerular thrombosis and 
measurement of proteinuria. Disease susceptibility was restored to the previously resistant 
IL-17
-/-
 mice by transfer of WT bone marrow. Unexpectedly, this group developed 
significantly more severe disease than that in the WT to WT positive control group and this 
suggests an unexpected protective role for IL-17 production by intrinsic cells which is 
lacking in this group. The third experimental group consisting of WT mice which received 
IL-17
-/-
 bone marrow developed less disease than the other two groups in the bone marrow 
transplant experiments.  
 
4.4.2.1 Renal function 
 
 In BMT1, median serum urea was 6.8 mmol/L (range 5.6-80.0) in the IL-17
-/-
 to WT 
group; 93.0 (9.5-158.0) in the WT to IL-17
-/- 
group and 7.4 (5.3-91.5) in the WT to WT 
group. By Dunn’s multiple comparison test, WT to IL-17-/- mice had significantly higher 
urea than both IL-17
-/-
 to WT and WT to WT groups (p<0.05). For creatinine, median results 
was 32.7μmol/L in the IL-17-/- to WT group (range 26.7-45.2); 38.4 (24.9-59.6) in the WT to 
IL-17
-/- 
group and 28 (23.7-33.9) in the WT to WT group. There was no significant 
difference between any of the groups.  
 
 In BMT2, median serum urea was 12.2 mmol/L (range 6.4-65.8) in the IL-17
-/-
 to 
WT group; 109.8 (94.4-151.0) in the WT to IL-17
-/- 
group and 12.4 (8.1-80.2) in the WT to 
WT group. WT to IL-17
-/-
 mice had significantly higher urea than both IL-17
-/-
 to WT mice 
(p<0.001) and WT to WT mice (p<0.05). For creatinine, median creatinine was 39.9μmol/L 
in the IL-17
-/-
 to WT group (range 31.6-48.7); 45.4 (32.9-69.3) in the WT to IL-17
-/- 
group 
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and 42.8 (25.8-61.5) in the WT to WT group. There was no significant difference between 
any of the groups.  
 
 By two-way ANOVA for urea for BMT1 and BMT2, there was no significant 
difference between the two experiments, but a very significant difference between the 
experimental groups (p<0.001). Thus, urea results for the two experiments were combined, 
and demonstrated that WT to IL-17
-/- 
mice had significantly higher urea than both IL-17
-/- 
to 
WT mice (p<0.001), and WT to WT mice (p<0.01). There was no difference in serum 
creatinine between any of the groups. 
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Figure 26. Combined results for (A) serum urea and (B) serum creatinine for the two bone marrow 
transplant experiments. 
WT to IL-17
-/-
 bone marrow transfer mice had significantly higher urea than the other two 
experimental groups, but no difference in serum creatinine. Analysis by two-way ANOVA and 
Kruskal-Wallis test with Dunn’s post-test. Bars represent medians. *p<0.05; **p<0.01; ***p<0.001.  
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4.4.2.2 Proteinuria 
 
 In the first experiment, total proteinuria in the 24hrs before the end of the experiment 
was measured after collection of urine using metabolic cages as previously described. Due to 
the number of cages available, 6 IL-17
-/- 
to WT, 6 WT to IL-17
-/-
 and 7 WT to WT mice had 
urine collected. However, some of the mice had severe oliguria and therefore, of these, one 
mouse in each group did not produce enough urine to quantify proteinuria. Median 
proteinuria was 0.04mg (0-3.1) in the IL-17
-/- 
to WT group; 1.33 (0.78-13.59) in the WT to 
IL-17
-/-
 group and 0.30 (0.09-1.77) in the WT to WT group. WT to IL-17
-/-
 mice had 
significantly more proteinuria than IL-17
-/- 
to WT mice (p<0.05) and tended to have more 
proteinuria than the WT to WT group, although due to small numbers this did not reach 
statistical significance.  
 
 In the second BMT experiment, metabolic cages were used at the end of the 
experiment in the same way. However, presumably due to profound renal impairment, this 
time the mice produced even smaller volumes of urine. In particular, 3 out of 4 mice in the 
WT to IL-17
-/-
 group produced urine volumes that were too small for quantification of total 
proteinuria. Therefore, for this experiment it was not possible to formally compare 
proteinuria between the groups, although they clearly had significant proteinuria since on 
dipstick urinalysis, 11 out of 16 mice had +++ or ++++ proteinuria.  
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Figure 27. Proteinuria in BMT mice from experiment 1.  
WT to IL-17
-/-
 mice had significantly more proteinuria than IL-17
-/-
 to WT mice. Due to small 
numbers, other comparisons were not statistically significant but WT to IL-17
-/-
 mice also tended to 
greater proteinuria than WT to WT mice. Analysis by Kruskal-Wallis test and Dunn’s post test. Bars 
represent medians. *p<0.05; **p<0.01; ***p<0.001.  
 
 
 
4.4.2.3 Renal histology 
 
Renal histology was assessed using PAS and H&E stained paraffin sections for 
glomerular thrombosis and tubular damage. As in the experiments in chapter 3, the 
frequency of crescents was again very low, <5% in all groups, and therefore this was not 
formally quantified. 
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Figure 28. Representative renal histology from PAS sections in BMT1 for the three 
experimental groups.  
IL-17
-/- 
to WT image shows glomerular hypercellularity with preserved tubular architecture. 
WT to IL-17
-/-
 image shows glomerular thrombosis with gross tubular dilatation and casts.  
WT to WT image shows abnormal glomeruli with thrombosis but relatively preserved 
tubular structure. Magnification x400. 
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Glomerular thrombosis 
 
 Glomerular thrombosis was scored for all mice as previously described. In the first 
BMT experiment, median thrombosis was 0.1 (0-1.7) in the IL-17
-/-
 to WT group; 2.2 (1.7-
2.6) in the WT to IL-17
-/-
 group and 0.4 (0-1.9) in the WT to WT group. WT to IL-17
-/- 
mice 
had significantly more thrombosis than WT to WT mice (p<0.05). In the second BMT 
experiment, median thrombosis was 1.4 (0.3-2.2) in the IL-17
-/-
 to WT group; 1.9 (1.5-2.4) in 
the WT to IL-17
-/-
 group and 1.6 (0.7-2.6) in the WT to WT group. Although the WT to IL-
17
-/-
 group also tended to have greater glomerular thrombosis than the other groups in this 
experiment, this did not reach statistical significance. When results for the two groups were 
analysed by two-way ANOVA, there was a significant difference between the experimental 
groups (p<0.01), but also a significant difference between the two experiments (p<0.01). 
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Figure 29. Glomerular thrombosis in (A) BMT1 and (B) BMT2.  
Both experiments showed greater thrombosis in the WT to IL-17
-/-
 group, although this was only 
statistically significant in BMT1 (p<0.05). Analysis by Kruskal-Wallis test with Dunn’s post-test. 
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Tubular Injury 
 
 Tubular injury was defined as the presence of tubular dilatation and tubular casts. 
Sections were examined under low power and assigned a score from 0-4 depending on the 
degree of tubular damage. Scoring was as follows: 0: 0% of section showing tubular injury; 
1: 1-25%; 2: 26-50%; 3: 51-75%; 4: 75-100%. 
In BMT1, median tubular injury score for the IL-17-/- to WT group was 0 (range 0-
4); for WT to IL-17
-/- 
median 4 (2-4); for WT to WT median 1 (1-3). The WT to IL-17
-/- 
group had significantly more tubular injury than the WT to WT group (p<0.05). 
In BMT2, median tubular injury score for the IL-17
-/-
 to WT group was 1 (range 0-4); 
for WT to IL-17
-/- 
median 3.5 (3-4); for WT to WT median 1 (0-4). Although the WT to IL-
17
-/-
 group again tended towards the most severe tubular injury, this did not reach statistical 
significance (p=0.1).  
Results for the two experiments were analysed by two-way ANOVA. There was no 
significant difference between the experiments (p=0.5), but a very significant difference 
between the experimental groups (p<0.001). When the two experiments were combined, the 
WT to IL-17
-/-
 group had significantly more tubular injury than the WT to WT group 
(p<0.01). 
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Figure 30. Tubular injury scores for (A) BMT1, (B) BMT2 and (C) combined results for 
BMT1&2 after analysis by two-way ANOVA. 
The WT to IL-17
-/-
 group had more tubular injury than the WT to WT group (p<0.01). Bars 
represent medians. Analysis by Kruskal-Wallis test. * p<0.05; ** p<0.01; *** p<0.001 
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4.4.3 Humoral immune responses  
 
4.4.3.1 Glomerular sheep IgG deposition 
 
 Frozen kidney sections were stained for sheep IgG by immunofluorescence and 
scored as described in the Methods chapter using visual fluorescence units. There was no 
significant difference in the amount of sheep IgG deposited on the glomerular basement 
membrane between any of the groups. In the first BMT experiment, median score was 2.2 
(1.9-2.9) in the IL-17
-/-
 to WT group; 2.5 (1.4-3.0) in the WT to IL-17
-/-
 group and 2.6 (1.4-
3.0) in the WT to WT group. In the second BMT experiment, median score was 2.8 (1.7-3.0) 
in the IL-17
-/-
 to WT group; 2.0 (0.7-2.8) in the WT to IL-17
-/-
 group and 2.2 (1.1-3.0) in the 
WT to WT group. 
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Figure 31. (A) Representative glomerular immunofluorescence for sheep IgG for each 
experimental group in BMT1. 
(B,C) Scores for glomerular immunofluorescence for BMT1 and BMT2 respectively. There 
was no significant difference between any of the groups. Bars represent medians. Analysis 
by Kruskal-Wallis test. 
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4.4.3.2 Glomerular mouse IgG deposition 
 
Frozen kidney sections were also stained for mouse IgG by immunofluorescence and 
scored using visual fluorescence units as described in the Methods chapter. There was no 
significant difference in the amount of mouse IgG deposited on the glomerular basement 
membrane between any of the groups. In the first BMT experiment, median score was 1.6 
(0.8-3.0) in the IL-17
-/-
 to WT group; 2.0 (1.4-2.7) in the WT to IL-17
-/-
 group and 1.2 (1.0-
3.0) in the WT to WT group. In the second BMT experiment, median score was 1.5 (0.8-1.8) 
in the IL-17
-/-
 to WT group; 1.5 (0.8-2.5) in the WT to IL-17
-/-
 group and 1.1 (0.7-1.6) in the 
WT to WT group. 
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Figure 32. (A) Representative glomerular immunofluorescence for mouse IgG for each 
experimental group in BMT1.  
(B,C) Scores for glomerular immunofluorescence for BMT1 and BMT2 respectively. There 
was no significant difference between any of the groups. Bars represent medians. Analysis 
by Kruskal-Wallis test. 
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4.4.3.3 Serum antibodies to sheep IgG 
 
 Mouse anti-sheep antibody production was also measured by ELISA as previously 
described in the Methods chapter. Total IgG and IgG subclasses IgG1, IgG2a, IgG2b, IgG2c 
and IgG3 were measured in serum for all experimental animals. Overall there was a 
tendency for lower total IgG, IgG1, IgG2a and IgG2b  levels in the WT to IL-17
-/-
 group, 
although this was only statistically significant for IgG2a and IgG2b.  
 
Total IgG 
 
All serum samples for this ELISA are usually diluted 1 in 100. However, in 
experiment 2, antibody levels were higher than usual and reached saturation for optical 
density in some cases. Therefore the ELISA was repeated for experiment 2 and samples 
further diluted to 1 in 200 in order to obtain measurable results. In experiment 1, total sheep 
IgG median (range) results for optical density were: normal mouse serum 1.5 (1.5-1.5); IL-
17
-/-
 to WT 2.3 (1.7-2.7); WT to IL-17
-/-
 1.7 (1.1-2.3); WT to WT 2.0 (1.8-2.5). There was no 
significant difference between the experimental groups, although there was a tendency to 
less IgG in the WT to IL-17
-/-
 group.  In experiment 2, total sheep IgG median (range) results 
for optical density were: normal mouse serum 0.43 (0.41-0.44); IL-17
-/-
 to WT 1.8 (1.3-2.6); 
WT to IL-17
-/-
 1.1 (0.7-1.7); WT to WT 1.7 (0.6-2.6). There was no significant difference 
between the experimental groups in BMT2 either, although again there was a tendency to 
lower levels in the WT to IL-17
-/-
 group.  
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Figure 33. Serum total sheep IgG levels by ELISA from (A) BMT1 and (B) BMT2. 
Although there was no statistically significant difference between the groups, in both 
experiments IgG levels in the WT to IL-17
-/-
 group tended to be lower. Bars represent 
medians. Analysis by Kruskal-Wallis test.  
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IgG subclasses 
 For IgG subclass analysis, all samples were diluted 1 in 100 except for IgG1 and 
IgG2b which were diluted to 1 in 200, due to high OD readings at 1 in 100. 
IgG1 levels were: BMT1; IL-17 to WT, median 1.3 (range 0.4-1.5); WT to IL-17
-/-
, 
0.4 (0.2-1.4); WT to WT, 1.2 (0.5-1.4); For BMT2; IL-17 to WT, median 1.4 (range 1.0-
2.7); WT to IL-17
-/-
, 1.3 (0.4-1.8); WT to WT, 1.8 (0.6-2.9). There was no significant 
difference between the groups in either experiment although IgG1 levels had a tendency to 
be lower. 
IgG2a levels were: BMT1, IL-17 to WT, median 1.2 (range 0.8-1.3); WT to IL-17
-/-
, 
0.7 (0.3-1.1); WT to WT, 1.0 (0.7-1.2). There was significantly less IgG2a in the IL-17
-/-
 to 
WT group compared to the WT to IL-17
-/-
 group (p<0.01). IgG2a levels were not analysed 
for BMT2. 
IgG2b levels were: BMT1, IL-17
-/-
 to WT, median 1.0 (range 0.3-1.6); WT to IL-17
-/-
, 0.2 (0.1-1.0); WT to WT, 0.9 (0.3-1.6). There was significantly less IgG2b in the WT to IL-
17
-/-
 group compared to the IL-17
-/-
 to WT group (p<0.05); For BMT2, IL-17
-/-
 to WT, 
median 2.1 (range 0.5-2.2); WT to IL-17
-/-
, 0.4 (0.2-2.1); WT to WT, 1.0 (0.3-3.0). Although 
these also tended to be lower in the WT to IL-17
-/-
 group, this was not statistically 
significant. 
IgG2c levels were: BMT1, IL-17 to WT, median 0.3 (range 0.1-0.5); WT to IL-17
-/-
, 
0.1 (0.1-0.8); WT to WT, 0.2 (0.1-0.7); For BMT2, IgG2c levels were: IL-17 to WT, median 
0.4 (range 0.3-2.1); WT to IL-17
-/-
, 0.6 (0.3-0.8); WT to WT, 0.4 (0.2-1.1). Levels were low 
throughout and there was no difference between any of the groups in either experiment. 
 IgG3 levels were: BMT1, IL-17 to WT, median 0.2 (range 0.1-0.5); WT to 
IL-17
-/-
, 0.1 (0.1-0.3); WT to WT, 0.1 (0.1-0.3). For BMT2, IL-17 to WT, median 0.3 (range 
0.2-2.8); WT to IL-17
-/-
, 0.2 (0.1-0.4); WT to WT, 0.2 (0.1-0.3). There was no significant 
difference between the groups in either experiment and levels throughout were low. 
In summary, levels of IgG1 tended to be lower in the WT to IL-17
-/-
 group but did 
not reach statistical significance. Levels of IgG2a and IgG2b were also lower in the WT to 
IL-17
-/-
 group and reached statistical significance in BMT1 when compared to the IL-17
-/-
 to 
WT group. There was a similar trend for IgG2b in BMT2.  Levels of IgG2c and IgG3 were 
very low throughout and were not different between groups. 
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Figure 34. IgG subclasses for BMT1 and BMT2 
(A) IgG1, (B) IgG2a and (C) IgG2b levels for BMT1 (left) and BMT2 (right) respectively.  
Bars represent medians. Analysis by Kruskal-Wallis test. Differences are non-significant 
unless stated. * p<0.05, ** p0.01, *** p<0.001 
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Figure 35. IgG2c and IgG3 for BMT1 and BMT2 
(A) IgG2c and (B) IgG3 levels for BMT1 (left) and BMT2 (right) respectively. Bars 
represent medians. Analysis by Kruskal-Wallis test. Differences are non-significant. 
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4.4.4 Cellular immune responses 
 
4.4.4.1 Macrophages 
 
 Frozen PLP kidney sections were stained by immunohistochemistry for CD68, and 
numbers of intraglomerular macrophages were counted for 25 glomeruli as previously 
described. As in the NTN experiments in chapter 3, there was no difference in the number of 
intraglomerular macrophages between the groups for either bone marrow transplant 
experiment. In BMT1, median macrophage number/glomerulus for IL-17
-/-
 to WT mice was 
1.0 (range 0-2.6); WT to IL-17
-/-
 1.2 (0.6-2.1); WT to WT 1.4 (0.4-5.0), p=0.6. For BMT2, 
median macrophage number/glomerulus for IL-17
-/-
 to WT mice was 0.7 (0.3-1.0); WT to 
IL-17
-/-
 was 0.4 (0.4-1.0); WT to WT was 0.5 (range 0-0.8), p=0.6. 
 The amount of interstitial macrophage infiltration was too great to allow counting of 
individual cells. In order to assess whether interstitial, rather than intraglomerular, 
macrophage infiltration was different between the bone marrow transplant groups, all 
sections for each experiment were inspected blind and ranked in order of increasing 
interstitial macrophage infiltration. Sequential scores were assigned for each experiment, 
with a score of 1 for the least number of interstitial macrophages, 2 for the next fewest and 
so on. In BMT1, median interstitial macrophage score for IL-17
-/-
 to WT mice was 6 (range 
1-16); WT to IL-17
-/-
 11 (8-21); WT to WT 13 (4-20), p=0.6. For BMT2, median interstitial 
macrophage score for IL-17
-/-
 to WT mice was 7.5 (range 3-16); WT to IL-17
-/-
 11.5 (9-13); 
WT to WT 6.5 (1-15), p=0.6. When these results were combined by two-way ANOVA, there 
was no significant difference between the experiments (p=0.25), nor the experimental groups 
(p=0.27). However, when data from both experiments was combined, there was a non-
significant tendency to a greater number of interstitial macrophages in the WT-IL-17
-/- 
group.  
 
 
 
 
Sally Hamour  PhD thesis 2012 
176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36. CD68 staining showing representative intra-glomerular and interstitial 
macrophage infiltration in the three experimental groups in BMT1. 
Note the marked periglomerular macrophage infiltrate in the WT to IL-17
-/-
 mouse. 
Magnification x400 
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Figure 37. Renal macrophages in BMT1 and BMT2 
(A) Intraglomerular macrophages and (B) Interstitial macrophages in (left) BMT1 and (right) 
BMT2 respectively. There was no difference in numbers of intra-glomerular macrophages 
between the groups in either experiment. For interstitial macrophages, there was a tendency 
for the WT to IL-17
-/- 
group to have a greater number in both experiments, but this did not 
reach statistical significance. Analysis by Kruskal-Wallis test.  
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4.4.4.2 CD4+ T cells 
 
Frozen PLP kidney sections were stained by immunohistochemistry for CD4, and the 
numbers of intraglomerular CD4+ cells were counted for 25 glomeruli as previously 
described. As in the NTN experiments in chapter 3, there was no difference in the number of 
intraglomerular CD4+ cells between the groups for either bone marrow transplant 
experiment. In BMT1, median CD4+ number/glomerulus for IL-17
-/-
 to WT mice was 0.2 
(range 0-0.8); WT to IL-17
-/-
 0.2 (0-0.5); WT to WT 0 (0-2.3), p=0.8. For BMT2, median 
CD4+ number/glomerulus for IL-17
-/-
 to WT mice was 0.1 (range 0.1-1.4); WT to IL-17
-/-
 
0.1 (0-0.2); WT to WT 0.2 (0-0.3), p=0.8. 
In order to retain the same methodology for assessment of interstitial cell infiltration, 
Interstitial CD4+ cells were also ranked for the second BMT experiment. There was no 
statistically significant difference between the groups. Median ranking for interstitial CD4+ 
cells for IL-17
-/-
 to WT mice was 7.5 (range 1-14); WT to IL-17
-/-
 10 (4-16); WT to WT 7.5 
(2-15), p=0.8.  
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Figure 38. Renal CD4+ cells in BMT1 and BMT2 
(A) Representative kidney CD4+ staining for each of the experimental groups in BMT1. (B) 
and (C) Quantification of intraglomerular CD4+ cells for BMT1 and BMT2 respectively. (D) 
Interstitial CD4+ cells for BMT2. Lines represent medians. There is no statistically 
significant difference between the groups. Analysis by Kruskal-Wallis test.  
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4.4.5 Differences in cytokine expression and macrophage phenotype between 
the experimental groups may contribute to disease outcomes 
 
 In order to explore why the WT to IL-17
-/-
 bone marrow transplant group had more 
severe disease than the WT to WT group with nephrotoxic nephritis, and the mechanisms by 
which intrinsic IL-17 in the WT to WT group might be mediating a protective effect, I 
carried out quantitative PCR on RNA from whole kidneys for a number of relevant immune 
mediators. RNA was extracted from snap frozen kidneys as described in the Methods 
chapter. RNA quality and concentration was verified by spectrophotometry using a 
Nanodrop bioanalyser and by gel electrophoresis. cDNA was then synthesised and qPCR 
performed as described in the Methods chapter, using the primer sequences given. All 
sample concentrations were standardized and run in duplicate. Any sample with a 
discrepancy >1Ct value between duplicates was rejected and repeated. Normal levels of 
expression were determined as the average value from 3 non-nephritic WT kidneys. 
Expression levels were calculated using the delta delta Ct equation and expressed relative to 
the housekeeping gene GAPDH. 
 
 
 
 
 
 
 
 
 
Figure 39. Representative RNA gel using RNA extracted from mice in BMT2. 
28S and 18S bands of ribosomal RNA are clearly demarcated. Note that the intensity of the 
28S band is greater than that of the 18S band. The last lane demonstrates RNA that has been 
partially degraded. 
28S 
18S 
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4.4.5.1 IL-17 
 
 There was no significant difference in fold-change in IL-17 expression between the 
difference experimental groups in either bone marrow experiment, although levels were 
higher overall in BMT1. 
 
 
 
 
 
 
 
 
 
 
Figure 40. Fold change in gene expression of IL-17. 
(A) BMT1 and (B) BMT2. Lines represent medians. There was no significant difference 
between groups in either experiment. Analysis by Kruskal-Wallis test.  
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there was a significant difference between the experimental groups (p=0.005). Median fold 
change in IL-10 expression was 2.7 (range 0-16.6) for the IL-17
-/-
 to WT group; 1.9 (0-6.8) 
for the WT to IL-17
-/-
 group and 6.9 (0-44.3) for the WT to WT group. Combined results 
were analysed by Kruskal-Wallis test and WT to IL-17
-/- 
mice had significantly less IL-10 
than WT to WT mice (p<0.01).  
 
 Similarly, for IL-1β by two-way ANOVA there was no significant difference 
between the experiments (p=0.8) but there was a significant difference between the 
experimental groups (p=0.04). Median fold change in IL-1β expression was 2.1 (range 1.2-
5.6) for the IL-17
-/-
 to WT group; 0.6 (0.2-1.2) for the WT to IL-17
-/-
 group and 2.8 (1-23.6) 
for the WT to WT group. By Kruskal-Wallis test and Dunn’s multiple comparison post-test, 
WT to IL-17
-/-
 mice had significantly less IL-1β than WT to WT bone marrow transplant 
mice (p<0.001). 
 
  For IL-23 by two-way ANOVA there was no significant difference between the 
experiments (p=0.6) but there was a significant difference between the experimental groups 
(p=0.004). Median fold change in IL-23 expression was 0.5 (range 0.1-1.0) for the IL-17
-/-
 to 
WT group; 0.2 (0-1.0) for the WT to IL-17
-/-
 group and 0.7 (0.2-1.5) for the WT to WT 
group. By Kruskal-Wallis test and Dunn’s multiple comparison post-test, WT to IL-17-/- 
mice had significantly less IL-23 than WT to WT bone marrow transplant mice (p<0.01).  
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Figure 41. Quantitative PCR showing fold change in gene expression for (A) IL-10, (B) IL-
1β and (C) IL-23 for bone marrow transplant experiments 1 and 2. 
In each case, the WT to IL-17
-/- 
group has significantly lower levels than the WT to WT 
group. Bars represent medians. Analysis by Kruskal-Wallis test and Dunn’s multiple 
comparison post-test. * p<0.05, ** p0.01, *** p<0.001. 
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4.4.5.3 Other immune mediators 
 
 Quantitative PCR was also carried out for the cytokines IFNγ, IL-4, and TGFβ and 
the transcription factor Tbet. There was no difference in levels of any of these between the 
WT to IL-17
-/-
 group and the WT to WT group. Levels of IL-4 were measured only for the 
2
nd
 BMT transplant experiment and were low in all groups with no significant differences 
(data not shown).  
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Figure 42. Quantitative PCR results for both bone marrow transplant experiments combined 
for (A) IFNγ, (B) Tbet, (C) TGFβ expression.  
Lines represent medians. Differences are non-significant unless otherwise stated. Analysis 
by Kruskal-Wallis test and Dunn’s multiple comparison post-test. * p<0.05, ** p0.01, *** 
p<0.001. 
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4.4.5.4 Markers of macrophage phenotype 
 
 Since macrophages have been shown to be critical for induction of NTN and there 
was no difference in macrophage numbers between the groups, quantitative PCR was also 
carried out to assess macrophage phenotype. Specifically, I measured the macrophage 
markers mannose receptor, arginase and inducible nitric oxide synthase (iNOS) in the 
kidneys of the three bone marrow transplant groups. 
 
 Results for mannose receptor for the two experiments were analysed by two-way 
ANOVA and there was no significant difference between the experiments (p=0.8) but a 
significant difference between the groups (p=0.03). For the combined data set, median fold 
change in expression of mannose receptor for the IL-17
-/-
 to WT group was 0.9 (range 0.1-
3.2), for the WT to IL-17
-/-
 group 0.8 (0.3-2.3) and for WT to WT mice was 1.7 (0.4-4.4). 
The WT to IL-17
-/-
 group had significantly less mannose receptor than the WT to WT group 
(p<0.05). 
 
Results for arginase for the two experiments were analysed by two-way ANOVA and 
there was no significant difference between the experiments (p=0.5) nor the interaction 
(p=0.1), nor the experimental groups (p=0.1). For the combined data set, median fold change 
in expression of arginase for the IL-17
-/-
 to WT group was 18.6 (range 0.4-86.2), for the WT 
to IL-17
-/-
 group 6.5 (1.2-41.1) and for WT to WT mice was 41.3 (0.2-213.8). Although there 
was no statistically significant difference between the groups, the WT to IL-17
-/-
 tended 
towards less arginase expression than the WT to WT group. 
 
Results for iNOS for the two experiments were analysed by two-way ANOVA. Due 
to smaller numbers in the second experiment due to insufficient cDNA from that particular 
batch, the test was unable to detect any significant difference between the experiments 
(p=0.1) nor the interaction (p=0.1), nor between the groups (p=0.08). However, when both 
experiments were analysed separately by Kruskal-Wallis test, the WT-IL-17
-/-
 group had 
significantly less iNOS than the WT-WT group in both experiments (p<0.01). For the 
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combined data set, median fold change in expression of iNOS for the IL-17
-/-
 to WT group 
was 0.6 (range 0.2-9.7), for the WT to IL-17
-/-
 group 0.1 (0-0.7) and for WT to WT mice was 
3.0 (0.2-57.3). The WT to IL-17
-/-
 group had significantly less iNOS than the WT to WT 
group (p<0.001) and less than the IL-17
-/-
 to WT group (p<0.05). 
 
Thus, the most severely affected WT to IL-17
-/-
 group had a different macrophage 
phenotype to the WT to WT group, with less mannose receptor and a tendency to less 
arginase which are both associated with a more anti-inflammatory phenotype. Perhaps 
surprisingly, this group also had significantly less iNOS which is usually associated with a 
more pro-inflammatory state. 
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Figure 43. Fold change in gene expression for mice from bone marrow transplants 1 and 2 
for the macrophage markers (A) mannose receptor, (B) arginase and (C) iNOS. 
Lines represent medians. Analysis by Kruskal-Wallis test and Dunn’s multiple comparison 
post-test. * p<0.05, ** p0.01, *** p<0.001. 
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4.4.5.5 There was no proven intrinsic defect of IL-10 production in IL-17-/- mice, 
although renal expression was lower in the WT to IL-17-/- bone marrow 
transplant group 
 
 Since IL-10 is an important anti-inflammatory cytokine which has been associated 
with the regulation of NTN, and was found at significantly lower levels in the severely 
diseased WT to IL-17
-/-
 transplant group, it was important to establish whether there was any 
intrinsic defect of IL-10 production in IL-17
-/- 
mice. Therefore I went on to measure IL-10 
production from WT and IL-17
-/-
 splenocytes by FACS and to measure IL-10 levels in 
supernatants from stimulated splenocytes.   
 
 Pairs of WT and IL-17
-/-
 mice were immunized with complete Freund’s adjuvant and 
sheep IgG as per the NTN experiments. Five days later, splenocytes were isolated as 
previously described in the Methods chapter. They were then cultured in complete media 
with 10ng/ml TGFβ and 10ng/ml IL-6 for 48 hrs to promote IL-10 production. Splenocytes 
were then stimulated with 500ng/ml ionomycin, 100ng/ml PMA and brefeldin A 1:1000 
(eBioscience) for 4 hours prior to staining for FACS.  Cells were stained intra-cellularly for 
IL-10 and IFNγ and for the extracellular markers CD3, CD11b, CD11c and NK1.1.  
 
The proportion of IL-10 producing cells using this protocol was frequently quite low 
and surprisingly varied. Using a Wilcoxon matched pairs test, there were no statistically 
significant difference overall between WT and IL-17
-/-
 mice in the proportion of cells 
producing IL-10. However, I did observe that when there was more IL-10 production, the 
WT mice seemed to have a higher proportion of IL-10 producing cells than the IL-17
-/-
 mice. 
When IL-10 production was very low, for example around 1%, then it was not possible to 
detect a difference between WT and IL-17
-/- 
mice. Therefore future work could include 
optimization of the stimulation protocol before collecting more paired data as I feel that at 
present this data is inconclusive. 
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 Simultaneously, splenocytes were also cultured with (1) normal media or (2) media 
with TGFβ, IL-6 and CD3 CD28 co-stimulation beads either (i) alone, (ii) with IL-17 5ng/ml 
or (iii) IL-17 50ng/ml as described in the Methods. IL-17 was added to see whether any 
potential deficit in IL-10 production would be corrected by restoring IL-17.  Levels of IL-10 
in the supernatant were measured by ELISA. However, again using this stimulation protocol, 
levels of IL-10 were low in all the groups and were not significantly different between WT 
and IL-17
-/-
 mice.  
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Figure 44. IL-10 production from WT and IL-17
-/-
 splenocytes. 
(A) FACS plots from WT and IL-17
-/-
 splenocytes for CD3 and IL-10 following culture with 
TGFβ and IL-6. In this experiment, there was more IL-10 production from the WT than the 
IL-17
-/-
 splenocytes.  (B) Amalgamated paired results showing % of IL-10 producing WT 
and IL-17
-/-
 splenocytes following culture. (C) ELISA for IL-10 on paired supernatants from 
splenocytes stimulated with TGFβ, IL-6 and CD3 CD28 co-stimulation beads for 48hrs. For 
(C) and (D) bars represent medians. Analyses by Wilcoxon matched pairs test. Differences 
are non-significant. 
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4.5 Discussion 
 
In chapter 3 I demonstrated that IL-17 is pathogenic in nephrotoxic nephritis. In this 
chapter I have performed bone marrow transplantation in WT and IL-17
-/- 
mice in order to 
investigate the relative contribution of haematopoietic cells and intrinsic cells to disease in 
this model.  The results shown here demonstrate that disease in murine accelerated 
nephrotoxic nephritis is dependent on IL-17 from circulating cells since transfer of WT bone 
marrow to IL-17
-/-
 mice restored their susceptibility to disease as measured by serum urea, 
glomerular thrombosis, tubular injury and proteinuria. A further unexpected observation in 
these experiments is that, not only did bone marrow transfer restore disease susceptibility, 
but the WT to IL-17
-/-
 bone marrow transfer group developed significantly more severe 
disease than the WT to WT group. Therefore normal haematopoietic cells in the absence of 
local or intrinsic production of IL-17 results in augmented disease. This indicates that while 
circulating IL-17 may play a pathogenic role in nephrotoxic nephritis, local production of IL-
17 may also play a protective role in disease. Due to limitations in the availability of IL-17
-/- 
mice and logistical constraints, I was unable to include an IL-17
-/-
 to IL-17
-/- 
bone marrow 
transplant group in these two sets of experiments. This would have been a helpful negative 
control group, since I have demonstrated that IL-17
-/-
 mice are protected from NTN. In 
addition, it would have revealed any unexpected effect of radiation or of the experimental 
protocol on the susceptibility of the IL-17
-/-
 mice to NTN, which might need to be 
considered when interpreting the outcomes of experiment as a whole.  
 
Although a protective role for IL-17 in nephrotoxic nephritis has previously been 
suggested by Odobasic and colleagues (Odobasic et al., 2011), this is the first time that a 
protective role for IL-17 production by intrinsic cells in this model has been proposed. 
Odobasic and colleagues found that in non-accelerated nephrotoxic nephritis, although IL-
17
-/-
 mice were protected early on in disease at day 6, by day 21 the IL-17
-/-
 mice had worse 
disease and enhanced Th1 responses. This suggests that IL-17 attenuates disease in the later 
phase of disease. IL-23
-/-
 mice also had worse disease in the later phase. Conversely, IL-12 
deficient mice had less Th1 response, more Th17 response and less disease. The authors 
point out that IL-27 has a similar biphasic role in disease (Summers et al., 2011), and suggest 
that pathology related to the Th17 mediated phase could be due to the role of IL-17 in 
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neutrophil recruitment which is important early on in NTN.  Day 21 is later than the end 
point used in most other studies of non-accelerated NTN, and using the accelerated model 
my experiments have been terminated between days 7 and 9, which may explain why this 
observation has not previously been demonstrated. In addition, since it seems to require an 
interaction between the Th1 and Th17 responses, experiments which have relied upon 
transferring either Th1 or Th17 cells alone would have obscured this role for IL-17. This is 
partially in keeping with data from Paust and colleagues (Paust et al., 2012) who described a 
sequential role for Th17 and Th1 cells in the pathogenesis of NTN. This time-dependent 
function began with a Th17-mediated immune response predominating in the early phase, 
peaking at day 7, while Th1 cells were critical architects of renal injury in the later phases. 
However, while Odobasic found that Th1 effects were exaggerated as Th17 responses 
diminished, Paust and colleagues did not find increased Th1 responses in the absence of 
Th17, nor did they observe the same protective effect of IL-17 in the later stages.  
  
In other models of autoimmunity, the vast majority of the literature on IL-17 or Th17 
cells has focused on characterising its pathogenic role. However, there have also been a few 
indications in non-renal models of a protective role for IL-17. In graft versus host disease, 
disease induced by IL-17 deficient cells is more severe than that with WT cells (Yi et al., 
2008). In asthma, although IL-17 is required for disease initiation, IL-17 is suppressive in the 
effector phase (Schnyder-Candrian et al., 2006). In addition, exogenous IL-17 in the effector 
phase reduced pulmonary eosinophil recruitment and bronchial hyper-reactivity. In 
experimental models of colitis the evidence for a protective role for IL-17 has been mixed. In 
the CD45RBhi model, transfer of IL-17
-/-
 CD45RBhi cells into RAG
-/-
 mice resulted in 
worse disease than transfer of WT cells, demonstrating that IL-17 is protective (O'Connor et 
al., 2009). Furthermore, transfer of IL-17RA
-/-
 CD45RBhi cells also resulted in worse 
disease demonstrating that, as well as producing IL-17, T cells can also respond to IL-17 
which effects changes in function. In keeping with my findings in the BMT experiments, this 
group did not find any difference in cellular infiltration, and concluded that disease outcomes 
were due to differences in T cell effector function.  Similarly, in the dextran sodium sulphate 
model of colitis, blockade of IL-17 resulted in a mild worsening of disease (Ogawa et al., 
2004), but in trinitrobenzenesulfonic acid induced colitis IL-17 was pathogenic (Zhang et al., 
2006). In EAE, Almolda and colleague showed that in the recovery phase in the acute model 
in Lewis rats, there was an increase of Th17 and Treg in the spinal cord (Almolda et al., 
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2011). Lastly in experimental uveitis, the protective effect of IL-17 has also been 
demonstrated. Whilst the use of anti-IL-17 antibodies blocked the development of disease, 
injection of recombinant human IL-17 significantly attenuated disease, and cytokine 
production by autoreactive T cells was diminished (Ke et al., 2009) 
 
Thus, these bone marrow transplant experiments suggest a novel protective role for 
IL-17 production by intrinsic cells in glomerulonephritis. However, at a simpler level, they 
also confirm the original hypothesis that pathogenesis is at least in part due to circulating 
production of IL-17 by haematopoietic cells, since the IL-17
-/-
 mice are no longer protected 
from NTN once WT bone marrow is transplanted.  These results are supported by work from 
other groups using more complex antigen-specific cell-transfer models, which has also 
demonstrated that Th17 cells can cause disease in nephrotoxic nephritis. Tulone and 
colleagues used ovalbumin bound to the glomerular basement membrane in RAG
-/-
 mice and 
transferred antigen-specific, in vitro polarised Th17 and Th1 cells. They found that only 
Th17 cells but not Th1 cells could cause disease (Tulone et al., 2011). In contrast, Summers 
and colleagues in a broadly similar experiment transferred 5 million antigen-specific cells 
and demonstrated that both Th1 and Th17 cells could cause disease. However, they found 
that Th17 cells caused earlier disease (day 3 rather than day 5) and were associated with 
more neutrophil infiltration, while only Th1 cells were associated with crescent formation 
(Summers et al., 2009).  Overall, these experiments probably suggest that either Th1 or Th17 
cells can induce disease under the right circumstances, albeit with slightly different patterns 
of injury. However, to date, no group has published outcomes from a classical bone marrow 
transplant experiment between WT and IL-17
-/-
 mice as I have described in this chapter. My 
results are arguably much closer to reflecting changes to the original disease process in vivo, 
and fully reflect the contribution of both intrinsic and circulating IL-17-producing cells to 
pathogenesis. For example, the role of circulating WT bone marrow cells in restoring disease 
susceptibility to IL-17
-/-
 mice may not exclusively be due to Th17 cells, since other 
haematopoietic cells such as neutrophils have also been proposed as an important source of 
IL-17 in glomerulonephritis (Velden et al., 2012). 
 
There appeared to be subtle differences in humoral immune response between the 
groups in these bone marrow transplant experiments.  There was no difference in deposition 
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of sheep or mouse IgG in the glomerulus by immunofluorescence. However, by ELISA, 
measurement of serum anti-sheep antibodies did show lower levels of IgG2b in the WT to 
IL-17
-/-
 group and a tendency to lower total mouse anti-sheep IgG and IgG1 in the WT to IL-
17
-/-
 group, although this was not statistically significant. IL-17 is recognised to have a role 
in humoral immunity and IL-17
-/-
 mice have been characterised as having lower levels of 
total IgG and IgG subclasses (Nakae et al., 2002). This does not fully explain why levels 
were lower in the WT to IL-17
-/-
 group than in the IL-17
-/-
 to WT group. However, since 
there were also significantly attenuated levels of IL-10 in the WT to IL-17
-/- 
transplant group, 
and IL-10 is associated with IgG class-switching to IgG2b (Hu et al., 2005; Tongren et al., 
2005), this may further explain why levels of IgG2b were consequently reduced.  
 
It is noteworthy that despite differences in the degree of renal injury, the different 
groups in the bone marrow transplant did not have different numbers of intra-glomerular or 
interstitial macrophages or CD4+ cells at the end-point of the experiment. However, it is 
well recognised that macrophage function rather than number may dictate injury (Kluth et 
al., 2004), and work in our laboratory has previously shown that there may be no difference 
in macrophage number using this model despite different disease outcomes (Tam et al., 
1997). There are a number of possible explanations for this. Firstly, it may be that there are 
differences earlier on in the time course of the experiment which have been missed by 
terminating the experiment on day 9, and indeed it has been shown that Th17 cells peak 
early in disease (Paust et al., 2012) or there may also be differences in the number of 
interstitial immune effector cells at an earlier time point. Alternatively, it may be that 
important variations in cell number (or effector function) are reflected in lymphoid tissue 
rather than in the kidney itself. For example, significant macrophage trafficking to the 
kidney draining lymph node during experimental glomerulonephritis has been demonstrated 
(Lan et al., 1993). Therefore it is likely that differences in T cell effector function or 
macrophage activation status are responsible for the difference in outcome in the different 
groups in the absence of a difference in cell numbers.  
 
In keeping with this hypothesis, by qPCR on kidney RNA, significant differences 
were observed in cytokine levels between the groups. There were significantly lower levels 
of IL-10 in the most severely affected group of WT to IL-17
-/-
 mice which is in keeping with 
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the disease outcomes since the anti-inflammatory cytokine IL-10 is known to have a 
protective effect in NTN, and IL-10 deficient mice are more susceptible to disease (Kitching 
et al., 2000). Furthermore, Th17 cells which have been matured in the presence of TGFβ and 
IL-6 can secrete IL-17 but acquire a more suppressive phenotype and also co-secrete IL-10 
(McGeachy et al., 2007). Recently, human T cells have also been shown to be capable of co-
secreting IL-10 and IL-17 or IL-17 and IFNγ depending on the nature of the pathogen 
(Zielinski et al., 2012). Therefore lower levels of IL-10 in the WT to IL-17
-/-
 BMT group 
could contribute to an explanation as to why this group develops more disease than the WT 
to WT group. In the WT to WT group, this could either be as a result of a single intrinsic cell 
co-secreting IL-17 and IL-10 as has been described, or by IL-17 secretion triggering IL-10 
production. There is considerable evidence that harmful Th17 responses can be regulated by 
IL-10. The data in this chapter demonstrate that there may be a counter-regulatory feedback 
loop whereby IL-17 is required for IL-10 production and therefore helps to modulate disease. 
Additionally, levels of renal IL-17 were not significantly different between the groups and 
this again underscores the importance of IL-17 production by intrinsic cells. The FACS data 
did not show any difference in IL-10 levels in stimulated splenocytes from IL-17
-/-
 mice 
compared to WT, although I feel that this data is at present inconclusive. However, it may be 
that differences in IL-10 levels in the kidney in NTN occur as a result of the local cytokine 
milieu and microenvironment rather than an intrinsic defect in IL-10 production.  
 
Levels of IL-1β and IL-23, which are both part of the Th17 axis, were also 
significantly lower in the WT to IL-17
-/-
 group. However, there was no difference in the 
levels of IFNγ or IL-4, nor the transcription factor Tbet. Together with the IL-10 results, this 
may suggest that the protective effect of IL-17 in these experiments is not mediated by 
suppression of the Th1 axis in contrast to results from other groups (Odobasic et al., 2011). 
In human T cells, IL-1β has recently been proposed as a pro-inflammatory regulator of Th17 
cells that can inhibit IL-10 production in differentiating and memory Th17 cells (Zielinski et 
al., 2012). However, the results in this chapter suggest that low levels of IL-1β (together with 
IL-10) were associated with worse disease. Significantly, these two sets of results differ in 
that my experiments were carried out in mice and the difference in disease outcomes in 
unlikely to be due exclusively or directly to T cells since both WT-IL-17
-/-
 and WT-WT 
groups retained the ability to differentiate Th17 cells.  
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There was also a difference in macrophage markers, possibly reflecting a difference 
in phenotype in the WT to IL-17
-/-
 group with less mannose receptor and less iNOS and an 
overall trend towards less arginase expression. Whilst mannose receptor and arginase might 
be considered to be associated with an ‘alternatively activated’ or more reparative 
phenotype, iNOS expression is associated with classically activated ‘pro-inflammatory’ 
macrophages. However, it has become clear that there is no absolute dichotomy between 
these phenotypes and it is probably sufficient to conclude more broadly that the differences 
in macrophage markers between the experimental groups are enough to lead to differences in 
effector function. It should also be noted that cells other than macrophages can contribute to 
these results such as mannose receptor-expressing mesangial cells (Chavele et al., 2010a) 
and iNOS-expressing endothelial cells.  
 
Overall, the experimental outcomes are consistent with a protective role for IL-17 by 
intrinsic cells. The important IL-17 producing cells which confer protection in this model 
must be non-bone marrow derived cells and resistant to radiation. I have described other 
models where IL-17 appears to be protective, but the data in this chapter cannot fully explain 
the exact mechanism by which IL-17 production by intrinsic cells mediates protection in 
NTN, nor the exact cell type. The fact that, using qPCR, there was no difference in the levels 
of IL-17 in the kidney in the experimental groups in the bone marrow transplant underscores 
the importance of production of IL-17 by intrinsic cells in this model. The IL-17
-/-
 to WT 
group did not have significantly less IL-17 than the other two groups, despite lacking the 
ability to produce IL-17 from haematopoietic cells. As the FACS data shows, a significant 
amount of IL-17 production in mouse splenocytes is by non CD3+ cells and small numbers 
of CD11b+ and CD11c+ cells can produce IL-17. As described previously, a wide variety of 
other immune cells are known to produce IL-17: macrophages, iNKT cells, neutrophils, LTi-
like cells, CD8 cells and γδ T cells. Furthermore, it has recently been observed that radio-
resistant follicular dendritic cells in the spleen produce IL-6 and are important in a murine 
model of chronic viral infection (Harker et al., 2011). Therefore there is also precedent for 
the role of radio-resistant spleen cells in secreting cytokines and modulating disease, and the 
key cell in this model could be resident in the kidney or in the lymphoid tissue.  
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Interestingly, rather like the evidence in animal models, results from trials of IL-17 
receptor blockade or monoclonal antibodies to IL-17 have been mixed. Two recent phase II 
trials in psoriasis have had broadly favourable outcomes using Brodalumab, a human anti-
IL-17 receptor, and Ixekizumab, a humanised anti-IL-17 monoclonal antibody (Leonardi et 
al., 2012; Papp et al., 2012). In contrast, Secukinumab is a fully human anti-IL-17 
monoclonal antibody which has previously been used successfully in rheumatoid arthritis 
and psoriasis phase I and II trials. The most recent phase II trial in Crohn’s comprised 59 
patients with moderate to severe disease and was terminated early with Secukinumab less 
effective than placebo at the primary end point (Hueber et al., 2012). In particular, patients 
with inflammatory Crohn’s disease, as defined by elevated CRP or faecal calprotectin, did 
much worse. 1/3 of patients discontinued treatment prematurely and in 21% of patients on 
Secukinumab this was due to insufficient therapeutic effect. There was also an excess of 
infections in the treatment arm, particularly localised fungal infections. In contrast, when 
Ustekinumab, a human IL-12/23 antibody which modulates both Th1 and Th17 pathways, 
was used in Crohn’s disease, this had a modest positive effect (Sandborn et al., 2008). In 
view of the results of the Secukinumab trial, another group has subsequently shown that 
numbers of IL-17 producing CD45RO+CD4+ cells increase in quiescent disease compared 
to active disease, after treatment with the TNF-inhibitor Adalimumab, which further points 
to an anti-inflammatory role for Th17 cells in Crohn’s disease (Dige et al., 2012e). Overall it 
is clear that the role of IL-17, or therapeutic modulation of the Th17 axis, in many 
autoimmune diseases is not straightforward and its effects are likely to differ both according 
to the disease, and even to the time-point within the disease.  
 
4.5.1 Summary 
 
 IL-17-/- mice are protected from NTN. Disease susceptibility is restored by 
transplantation of WT bone marrow, demonstrating that bone-marrow derived cells 
are required for disease. 
 
 Increased severity of disease in WT to IL-17-/- mice compared to WT to WT mice 
also suggests a novel protective role for production of IL-17 by intrinsic cells. 
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 WT to IL-17-/- mice have a different cytokine profile to WT to WT control mice 
including less IL-10, and differences in macrophage phenotype which are likely to be 
important in the increased severity of disease 
 
 These results have implications for the potential use of IL-17 blockade in renal 
disease 
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Chapter 5 
The Th17 axis in ANCA-associated vasculitis 
 
5.1 Introduction 
 
 Anti-Neutrophil Cytoplasm Antibody (ANCA)-associated vasculitis (AAV) refers to 
a group of heterogeneous multi-system autoimmune disorders characterised by the 
production of ANCA targeted against myeloperoxidase (MPO) or proteinase 3 (PR3), which 
are constituents of neutrophil granules or monocyte lysosomes. Within the spectrum of AAV 
are several clinically and pathologically defined disease entities: granulomatosis with 
polyangiitis (Wegener’s) (GPA), microscopic polyangiitis (MPA), renal-limited vasculitis 
(RLV) and Churg-Strauss syndrome (CSS) (Jennette et al., 1994). These rare chronic 
disorders, which relapse and remit, result in inflammation of small calibre vessels. Although 
any organ system can be involved, the most serious complications result from pulmonary 
haemorrhage or renal failure. Renal involvement is the most significant prognostic factor. 
Over 70% of patients with AAV will have some degree of renal involvement, with over 20% 
of patients developing end-stage renal failure at 5 years (Booth et al., 2003). Treatment 
requires long-term immunosuppression, usually involving agents such as cyclophosphamide, 
at least in the early induction phase which aims to induce remission. The long-term 
complications of immunosuppression such as malignancy and infection continue to 
contribute considerably to morbidity and mortality and, despite the toxicity of treatment, 
relapse rates remain high at about 50% over 5 years (Westman et al., 1998).  
 
Although there is good evidence that ANCA are pathogenic (Bansal and Tobin, 
2004; Little et al., 2005; Xiao et al., 2002), both cellular and humoral arms of the immune 
system are involved in disease in AAV. In particular, there appears to be a role for T cells 
(Griffith et al., 1996; Lamprecht and Gross, 2007; Schmitt et al., 2004). The identification of 
the Th17 subset as a distinct CD4+ Th cell lineage (Harrington et al., 2005; Park et al., 
2005), and the discovery that IL-12 (a Th1 cytokine) and IL-23 (a Th17 cytokine) share a 
common p40 subunit (Oppmann et al., 2000), prompted a reanalysis of a body of evidence 
from experimental animal models which had implicated the Th1 pathway in the pathogenesis 
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of autoimmunity.  Consequently it is now recognised that in many of these models, Th17 
cells are in fact the primary requirement for disease (Cua et al., 2003; Murphy et al., 2003), 
although Th1 cells may also still play an important role. In humans, it is much more difficult 
to be definitive about causation but work in a number of autoimmune conditions such as 
rheumatoid arthritis (Chabaud et al., 1999) and SLE (Wong et al., 2000) has identified a role 
for Th17 cells in disease pathogenesis. Similarly, serum levels of IL-17 are elevated in 
multiple sclerosis (Matusevicius et al., 1999) and myelin antigen-reactive Th17 cells are 
enriched in patients (Venken et al., 2010). IL-17 has also been found to be over-expressed in 
psoriasis (Teunissen et al., 1998), inflammatory bowel disease (Nielsen et al., 2003) and 
systemic sclerosis (Kurasawa et al., 2000).  
 
Prior to publication of the work in this chapter, there were only two small human 
studies which had investigated the role of IL-17 in AAV. These had described an increased 
frequency of Th17 cells in patients with GPA after stimulation with PR3 (Abdulahad et al., 
2008) or an increase of Th17 cells in patients with CSS (Saito et al., 2009). Therefore there 
was a need to further define the role of the Th17 axis more broadly in AAV and, with this in 
mind, the following work in this chapter was carried out. In view of the high morbidity and 
mortality related to treatment of AAV, and the high frequency of relapse, there remains an 
imperative to identify equipotent but less toxic treatment regimens for patients. Since IL-17 
blockade is now being trialled in autoimmunity (www.clinicaltrials.gov), confirmation of the 
role of IL-17 in AAV could potentially present a new therapeutic target for 
immunomodulation.  
 
5.2 Aims 
 
The aim of this work was to determine the role of Th17 cells and IL-17 in the 
pathogenesis of human AAV. Serum ELISAs for IL-17A and the Th17-related cytokines IL-
23, IL-1β and IL-6 were carried out on 28 acute and 65 convalescent patients with AAV. 
Serum levels of IFNγ were also measured by ELISA to assess the Th1 response. Results 
were compared to healthy controls, patients with sepsis and patients with anti-GBM disease. 
To determine whether there was an antigen-specific memory Th17 population that persisted 
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in patients during remission, PBMCs from convalescent patients and healthy controls were 
stimulated with ANCA autoantigens (MPO or PR3), and IL-17 or IFNγ responses measured 
by ELISPOT to assess the presence of antigen-specific Th17 or Th1 cells respectively. 
Clinical data was correlated with cytokine results. 
 
5.3 Experimental Design 
 
 I would like to acknowledge the contribution of Dr Estela Nogueira, a visiting 
Portuguese research fellow to our laboratory, who began the process of patient sample 
collection for this work, and performed some of the ELISA assays. We are jointly named as 
principal authors on the related publication (Nogueira et al., 2010), for which I wrote the 
manuscript. Ethical approval for this work was sought and received from the Hammersmith, 
Queen Charlotte’s and Chelsea hospitals research ethics committee. In total, blood samples 
were obtained from 28 acute and 65 convalescent patients under follow-up at the 
Hammersmith hospital multi-disciplinary vasculitis clinic. All patients gave informed 
consent. Patients who had concurrent infection or malignancy were excluded. Disease 
classification was based on the Chapel Hill Consensus Conference criteria (Jennette et al., 
1994). Patients were classified as having either GPA; MPA, which included renal-limited 
vasculitis or CSS.  Acute patients were those presenting either de novo with vasculitis, or 
with a major relapse which involved organ or life-threatening disease. Samples were 
collected from these patients within 10 days of presentation. Convalescent patients were 
those with quiescent disease as assessed clinically and biochemically, and with a 
Birmingham Vasculitis Activity Score (BVAS) of 0, who were under routine outpatient 
follow up. BVAS is a validated method of assessing disease activity (Mukhtyar et al., 2009) 
and scores were calculated on all patients at the time of sample collection, or occasionally 
retrospectively.  
 
 Patient results were compared with 3 control groups. 28 healthy volunteers made up 
the negative control group. Two positive control groups comprised, firstly, a cohort of 
patients with sepsis, either with confirmed infection or meeting the criteria for the systemic 
inflammatory response syndrome (Levy et al., 2003), all with c-reactive protein >100mg/dl 
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and, secondly, a historical cohort of serum from patients with anti-GBM disease. These 
historical sera were available due to the long-standing interest in this condition in our 
laboratory, and provide an interesting comparison with another renal autoimmune disease. 
 
Demographic and clinical data were collected on all patients. The immunology 
laboratory at the Hammersmith hospital performed determination of ANCA positivity by 
indirect immunofluorescence and ANCA specificity and titre by luminex technology as part 
of routine clinical practice. Serum was separated as described in the Methods and stored at -
80°C until analysis by ELISA. PBMC were isolated from blood using Lymphoprep density 
centrifugation and analysed immediately by ELISPOT.  
 
ELISA for IL-17, IL-23, IL-1β, IL-6 and IFNγ were carried out according to 
manufacturers’ instructions as described in the Methods. IL-1β and IL-6 are cytokines which 
are upstream of IL-17 in the developmental pathway of Th17 cells. IL-23 is required for 
stabilisation and maintenance of the Th17 population and IFNγ is produced predominantly 
by Th1 cells which may be antagonistic to the development of Th17 cells (Harrington et al., 
2005). ELISPOT was carried out as described in the Methods. Briefly, isolated PBMCs were 
stimulated for 48hrs in triplicate on ELISPOT plates with medium alone, 
phytohaemagglutinin (PHA), diphtheria, tetanus and pertussis antigens (DTP), and PR3 or 
MPO in accordance with the patients’ ANCA specificity. Stimulation for 24-48 hours 
appears to be the optimum duration to elicit recall responses, whilst longer time periods may 
elicit a primary immune response(Gebauer et al., 2002). All control patients were stimulated 
with MPO rather than PR3. PHA is a plant lectin which induces mitosis and is used to 
stimulate lymphocytes to assess immune function. DTP was used to assess recall responses 
since most individuals have a history of exposure to these antigens as a result of childhood 
immunisation programmes. Response to antigenic stimulation by production of IL-17 or 
IFNγ was assessed. Spots were counted by AID ELISPOT plate reader version 4.0. Results 
were expressed as absolute numbers and also as a proportion of the mitogen response (to 
PHA) or the recall response (to DTP) for each individual as a way of controlling for different 
degrees of immunosuppressive therapy. 
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GraphPad prism 4.0 (GraphPad Software, San Diego California, USA) was used for 
all statistical analyses. One way analysis of variance (ANOVA) was carried out using non-
parametric Kruskal-Wallis test and Dunn’s multiple comparison post test, and Mann-
Whitney-U test for ELISPOT analysis. Correlations were assessed using the non-parametric 
Spearman rank correlation analysis.  Two tailed analysis was carried out with significance 
defined as P<0.05 with 95% confidence. 
  
5.4 Results 
 
5.4.1 Demographics 
 
 Relevant demographic and clinical data were collected from all patients. The mean 
age of the patients was 54 years (range 19 to 84), reflecting the fact that AAV is 
predominantly a disease of older people. 39% of patients were female and 61% were male. 
Patients were categorised according to their clinical syndrome (GPA, MPA or CSS), degree 
of organ involvement (whether disease was limited or systemic), and on MPO- or PR3- 
ANCA specificity. 17 acute patients had GPA and 11 had MPA. Of the convalescent 
patients, 42 had GPA, 20 MPA and 3 had CSS. A significant proportion of patients had renal 
disease. Of the acute patients, 21/28 had acute renal failure and 8 required haemodialysis. Of 
the convalescent patients, 29/65 had chronic kidney disease stage 2-4. As expected, BVAS 
scores were elevated in acute patients with a mean of 15.6 (range 7- 27). In convalescent 
patients mean BVAS was 1.25, median 0 (range 0-5). Two patients scored >0 for long-
standing symptoms which were thought unlikely to be related to new or acute disease, 
although under current BVAS guidelines these should not in fact have attracted a score 
(Mukhtyar et al., 2009). These demographics are summarised in Table 6 below. 
 
5.4.1.1 Treatment regimens 
 
The life-threatening nature of acute AAV requires urgent treatment and consequently 
it is often not possible to obtain samples from patients who are entirely naïve to 
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immunosuppression. Two of the acute patients in the study had received no treatment at the 
time of blood sampling. The others had been given a variety of initial treatments: 16 had 
received one dose of cyclophosphamide (CYP) and prednisolone (P), 10 of these 
additionally received plasma exchange (PEX) and 3 also received rituximab (RTX). Of the 
acute patients, 10 were patients already on treatment who had suffered a major relapse. Their 
previous immunosuppression regimens were: three on P and Mycophenolate mofetil (MMF); 
five P and azathioprine (AZA); 1 P and methotrexate (MTX) and 1 P alone. Maintenance 
immunosuppressive regimens in the 65 convalescent patients were P+AZA (n=27); P+MMF 
(n=7); P+MTX (n=4); P+tacrolimus (n=2); AZA only (n=12); P only (n=4); MTX only 
(n=1); no treatment (n=8).
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Table 6. Clinical and demographic characteristics of patients and control 
AAV patients 
 
patients 
(n) 
male female 
mean 
age (yrs) 
GPA MPA CSS 
limited 
disease 
systemic 
disease 
ARF \ HD 
  1. Acutes 28 16 12 55 17 11 0 0 28 20\8  
PR3 + \  MPO+ 17\ 11 10\6 7\5 53\59 16\1 1\10 0\0 0\0 17\11   
                    CKD 2-4 \ HD 
  2.Convalescent 65 32 33 53 42 20 3 12 53 29 \ 0 
PR3 + \  MPO+ 43\22 21\10 22\11 48\62 39\3 4\16 0\3 10\2 33\20   
  
 
patients 
(n) 
male female 
mean 
age (yrs) 
CKD 2-4 
\ HD 
NIDDM         
Healthy controls 28 14 14 36             
Septic patients 9 5 4 70 2\2 3         
Anti-GBM + 
patients 
10 7 3 43             
Years (yrs); Granulomatosis with polyangiitis (Wegener’s) (GPA);  Microscopic Polyangiitis (MPA); Churg Strauss Syndrome (CSS), Acute renal failure  (ARF); 
Haemodialysis  (HD);   Chronic  Kidney disease stage 2 to 4  (CKD 2-4) Non-insulin dependent diabetes mellitus (NIDDM) 
Sally Hamour  PhD thesis 2012 
207 
 
5.4.2 Acute and convalescent patients with AAV have higher serum levels of 
IL-17 and IL-23 than healthy controls 
 
In keeping with the hypothesis that the Th17 axis was involved in the pathogenesis of 
AAV, both acute and convalescent patients with AAV had significantly higher serum levels 
of IL-17 than healthy controls (acutes: mean IL-17 3,581pg/ml, median 64 pg/ml, range 0-
72,940; convalescent: mean 329pg/ml, median 0, range 0-2,732; healthy controls: mean 
21pg/ml, median 0, range 0-252, p<0.01). The upper limit of the normal range was defined 
as mean + 2 standard deviations (SD) of the healthy control population (133pg/ml). In 
comparison with this level, 36% of acute patients and 34% of convalescent patients with 
AAV had increased IL-17 levels.  Importantly, overall, patients with AAV demonstrated a 
wide variation in serum levels of IL-17: the range in acute patients was between 0pg/ml and 
72,940pg/ml.  
 
IL-23 is a Th17-related cytokine which plays a role in the division and maintenance 
of IL-17 producing cells.  Serum levels of IL-23 in the different groups demonstrated a 
similar pattern to those of IL-17.  Acute and convalescent patients with systemic disease had 
significantly higher IL-23 levels than healthy controls (acutes: mean IL-23 941pg/ml, 
median 282, range 0-5,950; convalescent: mean 775pg/ml, median 155, range 0-11,033; 
healthy controls: mean 66pg/ml, median 0, range 0-645, p<0.001). The upper limit of the 
normal range was defined as mean + 2SD of the healthy control population (373pg/ml). In 
comparison with this level, 43% of acute patients and 25% of convalescent patients with 
AAV had increased IL-23 levels.  The range of serum levels of IL-23 in patients was 
narrower than that for IL-17 but was still broad (0- 11,033pg/ml) and was higher in some 
convalescent patients than in the acute patients. 
 
 IL-17 levels were significantly lower in patients with sepsis (mean 45pg/ml, median 
0, range 0-407) than acute AAV patients, p<0.05. Although IL-17 levels also tended to be 
lower in patients with anti-GBM disease (mean 176pg/ml, median 35, range 0-1325) this 
was not statistically significant. Levels of IL-23 in patients with sepsis were not significantly 
different to those in patients with AAV (mean 198pg/ml, median 22, range 109-294, p>0.5) 
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but patients with anti-GBM disease had significantly lower levels of IL-23 (mean 56pg/ml 
median 0, range 0-563) than acute (p<0.01) or convalescent (p<0.05) AAV patients. 
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Figure 45. Serum cytokine levels in acute and convalescent AAV patients compared to 
control groups. 
 (A) IL-17, (B) IL-23. IL-17 and IL-23 levels were significantly higher in both acute and 
convalescent patients with AAV, than in disease and healthy controls. Abbreviations: 
Healthy controls (HC), septic patients (septic), anti-GBM disease (Anti-GBM+).  Bars 
represent medians.  *(p<0.05); **(p<0.01); ***(p<0.001). 
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5.4.3 High levels of IL-17 and IL-23 at acute presentation may remain elevated 
even in remission and are not inhibited by immunosuppression 
 
In order to prospectively assess changes in levels of IL-17 and IL-23 with the 
resolution of acute disease, serial measurements of IL-17 and IL-23 were carried out. In one 
patient with systemic AAV in whom it was possible to obtain repeated measurements of IL-
17 and IL-23, it can be seen in this case that very high levels of IL-17 at presentation fell by 
month 4, and then remained at levels of between 18 and 50pg/ml during remission. Five 
acute AAV patients with systemic disease and elevated cytokine levels had levels measured 
at acute presentation and between 1 and 4 months later when in disease remission.  Levels of 
both cytokines fell following treatment, but only returned to normal levels in 3/5 patients. It 
is of note that the two patients in whom levels remained elevated above normal had major 
relapses (at 13 and 15 months), while the other three maintained disease free remission (at 
18, 20 and 23 months of follow up, p=0.04 by Chi-squared test). One simple explanation for 
the suppressed levels found in some patients is the effect of immunosuppressive medication, 
however, when levels of IL-17 and IL-23 were compared between those patients on or off 
treatment, IL-17 and IL-23 levels were equivalent.  
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Figure 46. Sequential measurements of IL-17 in 1 patient with systemic acute AAV. 
There is a persistent fall in levels of IL-17 with the onset of disease remission. 
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Figure 47. Changes in IL-17 and IL-23 levels following remission induction.  
Box and whisker plots of (A) Levels of IL-17 and (B) Levels of IL-23 in 5 patients from 
their acute presentation to disease remission. Dotted lines represent upper limit of normal 
range. (C) Influence of immunosuppression on IL-17 and (D) IL-23 cytokine levels in all 
patients. No difference between patients taking (n=80) or not taking (n=11) 
immunosuppressive medication is seen (p>0.05). 
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5.4.4 Levels of IL-17 correlated significantly with levels of IL-23, IL-1β and IL-6 
but not with IFNγ 
 
In this group of patients with AAV, IL-17 levels correlated significantly with the 
related cytokines IL-23 (r = 0.54, p<0.0001), IL-1β (r =0.56, p<0.0001) and IL-6 (r = 0.59, 
p<0.0001). In contrast, no correlation was found for the Th1 cytokine IFNγ (p>0.05). 
However, when cytokine data was analysed for the other experimental groups, containing 
those patients with sepsis or anti-GBM disease, there was no such correlation between IL-17 
production and any of the other cytokines (p>0.05). 
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Figure 48. Correlation of IL-17 with related cytokines.  
Levels of (A) IL-23, (B) IL-1β and (C) IL-6 all correlated strongly with levels of IL-17. 
There was no correlation with levels of IFNγ (D). 
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5.4.5 Patients with elevated levels of IL-23 had more active disease as 
measured by BVAS and higher ANCA titres 
 
Patients with elevated levels of IL-23 (> mean+2SD of healthy controls) had 
significantly more active disease (mean BVAS 9.5, median 7.0) than patients with levels of 
IL-23 within the normal range (mean BVAS 4.5, median 1.0, p<0.05). Patients with elevated 
levels of IL-23 also had higher levels of ANCA titre (mean 268, median 82) compared to 
patients without elevated levels of IL-23 (mean 88, median 31 p<0.05).   
 
There did not appear to be a correlation for IL-23 or IL-17 with any other clinical 
parameters such as disease extent, number of previous relapses, current renal function, 
proteinuria or renal biopsy findings. Similarly, in this cross sectional cohort, neither levels of 
IL-17 nor any of the other measured cytokines apart from IL-23 correlated with BVAS score 
or any of the clinical parameters described above.  
 
There was no significant difference between MPO-ANCA and PR3-ANCA patients, 
either in the acute or the convalescent group, in levels of any of the cytokines (IL-17, IL-23, 
IL-1β, IL-6 and IFNγ).  
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Figure 49.  (A) BVAS score and (B) ANCA titre in patients with normal and elevated levels 
of IL-23.  
Patients with elevated levels of IL-23 had higher BVAS scores compared to patients with IL-
23 levels within the normal range. Patients with elevated levels of IL-23 had higher ANCA 
titre than patients with normal levels. Median and interquartile range shown. 
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5.4.6 Levels of IL-1β and IFNγ were not elevated in AAV patients. Levels of IL-6 
were only elevated in acute patients. 
 
IL-6 and IL-1β are critical in the developmental pathway of Th17 cells and so, as 
important upstream elements for Th17 generation, levels of these cytokines were assessed in 
this group of AAV patients.  IL-1β levels in acute patients (mean 63 pg/ml, median 0, range 
0-562) and convalescent patients (mean 242 pg/ml, median 0, range 0-5,124) did not vary 
statistically from healthy controls (mean 12 pg/ml, median 0, range 0-113) or from disease 
controls. In septic patients, levels ranged from 0-375, mean 45 pg/ml, median 0 and in anti-
GBM patients, levels ranged from 0-726, mean 83 pg/ml, median 0.  
 
IL-6 levels in acute patients (mean 35 pg/ml, median 6.8, range 0-358) were higher 
than those of healthy controls (mean 11.5 pg/ml, median 0, range 0-113, p<0.05). Although 
levels of IL-6 in convalescent patients (mean 161 pg/ml, median 0, range 0-4,278) had a 
tendency to be higher than those in healthy controls, this result was not statistically 
significant. In septic patients levels ranged from 0-102 pg/ml, mean 58, median 64 and in 
anti-GBM patients the range was 0-1049, mean 177 pg/ml, median 27. Levels in these two 
groups did not differ significantly from any of the other groups.  
 
Compared to the other measured cytokines, the Th1 cytokine IFNγ was found at low 
levels in all the groups. In acute AAV patients, mean 12 pg/ml, median 0, range 0-75; 
convalescent patients mean 5.6 pg/ml, median 0, range 0-89; healthy controls mean 8.3 
pg/ml, median 0, range 0-208.  In the disease control groups, patients with sepsis had IFNγ 
levels mean 26.4 pg/ml, median 0, range 1-122 and patients with anti-GBM disease had 
mean values of 20 pg/ml, median 0, range 0-105. Levels in acute or convalescent patients 
with AAV were not significantly different from those in healthy volunteers or disease 
controls. 
 
 
 
Sally Hamour  PhD thesis 2012 
216 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50. Serum IL-1β, IL-6 and IFNγ levels in acute and convalescent AAV patients. 
Serum cytokine levels in acute (n=28) and convalescent (n=50) AAV patients compared to 
control groups. (A) IL-1β, (B) IL-6 and (C) IFN-γ. IL-6 levels were higher in acute AAV 
patients than healthy controls (p<0.05) but there were no other statistically significant 
associations with these cytokines. Abbreviations: Healthy controls (HC), n=28, septic 
patients (septic), n=9, anti-GBM disease (Anti-GBM+), n=10.  Bars represent medians. 
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5.4.7 Patients with AAV have antigen-specific memory T cells which secrete 
IL-17  
 
It is recognised that a population of persistently activated T cells does exist in AAV 
(Marinaki et al., 2006). Work by our group has previously shown that frequencies of IFNγ-
producing autoreactive cells were equivalent in convalescent patients and controls (Chavele 
et al., 2010b). This may make a role for activated Th1 cells in these patients unlikely. 
However, if Th17 cells are important in the pathogenesis of AAV, then memory Th17 cells 
which are antigen-specific for MPO or PR3 might be expected to persist in the circulation of 
convalescent AAV patients. Such a population of Th17 cells could have a role in disease 
relapse. Therefore I determined whether there is a predominant IL-17-producing memory T 
cell response to the ANCA autoantigens in convalescent patients.  
 
These experiments were performed on a subgroup of the AAV cohort consisting of 
17 convalescent patients and 12 healthy volunteers. 12 patients were PR3-ANCA positive 
and 5 were MPO-ANCA positive. 14 patients had systemic disease, and 3 patients had 
localised disease. The mean patient age was 55 years and 42% were male. ELISPOT is a 
technique which allows determination of the frequency of cells producing a particular 
cytokine following antigen stimulation by counting spots on a plate. Each spot on the assay 
represents a single reactive cell. PBMC were isolated and ELISPOT for IL-17 and IFNγ was 
carried out. Cells were stimulated in triplicate for 48hrs as this duration allows determination 
of recall responses rather than primary responses (Gebauer et al., 2002). Cells were 
stimulated with medium alone, PHA, DTP, and PR3 or MPO in accordance with the 
patients’ ANCA specificity. All control patients were stimulated with MPO rather than PR3. 
Spots were counted using an AID ELISPOT plate reader. Background readings for 
stimulation with medium alone were subtracted and results expressed as mean number of 
spots/million PBMC for each stimulant. 
 
Control subjects tended to have higher response to PHA stimulation (median 226 
spots/million PBMC, range 0-404) compared to patients (median 43, range 0-318), but this 
was not statistically significant, and is likely to be as a result of patients’ immunotherapy. 
However, no difference was found between the groups in response to recall antigens (DTP) 
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(controls: median 47 spots/million PBMC, range 0-131; patients: median 20, range 0-195). 
In order to try to control for different levels of immunosuppression between the different 
patients and the absence of immunosuppression in healthy controls the number of IL-17 
secreting cells was also expressed as a percentage of the total PHA (mitogen) or DTP (recall) 
response. 
In absolute terms, it was striking that 53% (9/17) of convalescent patients had IL-17-
producing cells in response to stimulation with ANCA autoantigen, compared to none of the 
controls (p<0.05). Of the 9 patients who had a positive ELISPOT for IL-17, mean number of 
spots was 8/million PBMC, median 7, range 1-21 and for all the patients, mean number of 
spots was 4, median 1, range 0-21. Even after results were expressed as a percentage of the 
PHA or DTP response, this difference between convalescent patients and healthy controls 
still persisted: (% autoantigen specific T cells relative to DTP response: controls 0%; 
patients mean 22%, median 0, range 0-143%, p<0.05) or relative to PHA response (controls 
0%; patients mean 11.2%, median 4%, range 0-63%, p<0.01). Overall there was no 
difference in the proportion of patients producing IL-17 in response to autoantigen between 
patients with MPO-ANCA and PR3-ANCA (7/12 with PR3-ANCA and 2/5 with MPO-
ANCA). With respect to IFNγ, there was no difference in numbers of IFNγ-producing cells 
in response to autoantigen between patients and controls, confirming the previous work by 
our group.  
Interestingly, there was no direct correlation between serum IL-17 levels and 
isolation of antigen specific autoreactive Th17 cells. 63% of patients with a positive 
ELISPOT had a detectable serum IL-17 level at the time of blood sampling (mean level 133 
pg/ml), with only 25% expressing significantly elevated levels compared to that defined by 
the control population as previously described. In contrast, 40% of patients who did not have 
ANCA autoantigen T cell reactivity on ELISPOT did have detectable levels of IL-17 (mean 
level of 35pg/ml), with 20% expressing significantly elevated levels. There was a similar 
outcome to the analysis of IL-23 levels and IL-17 ELISPOT reactivity in response to 
autoantigen. There was no correlation between the detection of serum IL-23 and a positive 
IL-17 response on ELISPOT and vice versa. Overall there was also no correlation between 
ELISPOT IL-17 response to autoantigen and clinical parameters such as CRP, WCC, ANCA 
titre or MPO/PR3 positivity. 
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Figure 51. IL-17 and IFNγ T cell frequencies in convalescent patients and healthy controls. 
 (A) Absolute number of IL-17 producing cells in response to autoantigen stimulation 
(patients versus controls, p<0.05). (B) Number of IL-17 producing cells as % DTP recall 
response (patients versus controls, p<0.05). (C) Number of IL-17 producing cells as % PHA 
mitogen response (patients versus controls, p<0.01). (D) Absolute number of IFNγ 
producing cells in response to autoantigen (not significant). Bars represent medians. 
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Figure 52. Levels of serum IL-17 in patients who were positive and negative for IL-17 
production in response to stimulation with ANCA antigens by ELISPOT. There was no 
significant difference in levels of IL-17 production between the two groups. Bars represent 
medians.  
 
5.5 Discussion 
 
These data show that a proportion of both acute and convalescent patients with AAV 
have significantly higher IL-17 and IL-23 levels than healthy controls. After treatment, there 
is a reduction in IL-17 and IL-23 levels in some, but not all patients. High IL-23 levels 
correlated with higher levels of clinical disease activity as defined by BVAS, and with 
higher ANCA titres. In addition, over half of the convalescent patients had circulating 
memory T-cells which are reactive to ANCA autoantigen and produce IL-17. These findings 
are in keeping with a role for the Th17 axis in the pathogenesis of AAV in at least some 
patients.   
 
The range of IL-17 and IL-23 found in AAV patients was extremely wide, 
reminiscent of other cytokine studies performed in AAV patients (Ohlsson et al., 2004). The 
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highest levels of IL-17 and IL-23 were found in acute patients, although this was not 
statistically different from levels in convalescent patients. For IL-17 the range was between 0 
and 72,940 pg/ml in the acute cohort, with 36% of patients demonstrating levels above the 
normal range and for IL-23 in acute patients this was 0-5,950 pg/ml, and 43% had levels 
above the normal range. Thus, there are a significant proportion of acute patients with 
extremely high cytokine levels, and another group in which IL-17 and IL-23 were not 
elevated at the time of sampling. 
 
Overall in both cytokine and ELISPOT data, between 47% and 66% of patients did 
not have elevated levels of IL-17 or evidence of autoantigen specific IL-17 cells. There are a 
number of possible explanations for this. Since many patients with acute presentations 
received some initial immunosuppressive treatment in the first ten days, IL-17 levels could 
have dropped quite rapidly due to the effect of therapy.  Indeed in the patients followed 
sequentially, immunosuppressive treatment was coincident with a reduction in levels, albeit 
not always back to within normal range. However, since the analysis of cytokine levels and 
immunotherapy showed no difference in levels between those on and off 
immunosuppression, the data do not support treatment as an important reason why some 
patients had low or undetectable levels. Alternatively, the Th17 population has been shown 
to be unstable and, at least in experimental systems, Th17 cells may undergo phenotype 
switching depending on the cytokine milieu (Bending et al., 2009; Shi et al., 2008). 
Therefore, levels of IL-17 may only be high transiently at particular time-points in the 
pathogenesis of disease. Lastly, whilst IL-17 may be important for pathogenesis in some 
patients, this may not apply to all, in the same way that not all patients with AAV will have 
high titres of ANCA.  
 
Importantly, IL-17 and IL-23 levels remained significantly elevated during 
convalescence in a proportion of patients and there was no significant difference between 
levels in acute and convalescent patients in this cross-sectional study. Some convalescent 
patients also had persistent autoantigen-specific IL-17 producing memory T-cells. Increased 
percentages of circulating CD4+ effector memory T cells in GPA in remission have 
previously been identified (Abdulahad et al., 2006). Based on the data in this chapter, this 
population might constitute CD4+ Th17 cells. Taken together with the fact that regulatory T 
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cells are functionally defective in WG in remission (Abdulahad et al., 2007), these data 
demonstrate that many of these convalescent patients have underlying immunological 
activity. Therefore, despite being in clinical and biochemical remission, persistent low levels 
of IL-17 in convalescent patients might be a reflection of on-going immune activation and 
could explain grumbling disease activity or the high incidence of relapse.  
 
Some ELISPOT positive patients lacked detectable circulating IL-17 and conversely, 
some ELISPOT negative patients had detectable serum levels of IL-17. It is possible that 
other antigens could also be responsible for stimulating a T cell IL-17 response at the time of 
sample collection, or other immune cells could contribute to circulating IL-17 levels (as has 
been suggested for neutrophils, macrophages and NK T cells (Coquet et al., 2008; Hoshino 
et al., 2008; Velden et al., 2012)). There are as yet little data about the contribution of non T 
cells to circulating IL-17 levels in AAV. Additionally, Th17 cells may sequester in inflamed 
tissue (Pene et al., 2008; Pido-Lopez et al., 2011) and therefore measurement of serum 
cytokine levels or peripheral T cell activity may only be a distant proxy for inflammation in 
affected organs. This may also partially explain the wide range in serum levels of IL-17.  
 
The sequential data showed that persistently high levels of IL-17 and IL-23 over time 
may be associated with worse outcome than in those patients in whom levels return to 
normal. 2/5 patients in whom IL-17 and IL-23 levels were persistently elevated had major 
relapses while 3/5 patients whose levels returned to normal did not have a relapse during the 
course of follow up (p<0.05). However, clearly a larger prospective cohort is required before 
it is possible to draw any conclusions about the role of IL-17 and IL-23 in disease relapse.    
Amongst AAV patients, IL-17 production correlated closely with the levels of IL-1β, IL-6 
and IL-23 (p<0.0001), but not with IFNγ, which is consistent with the role of IL-1β, IL-6 
and IL-23 in Th17 population development and survival. Serum levels of IFNγ were not 
elevated in patients and ELISPOT data demonstrated no increase in IFNγ-producing cells in 
response to autoantigen in convalescent patients, as our group has previously described 
(Chavele et al., 2010b). Since the Th17 lineage was characterised, it has been recognised that 
IFNγ is inhibitory to differentiation of Th17 cells (Harrington et al., 2005; Park et al., 2005). 
Therefore, in keeping with these findings, low levels of IFNγ are consistent with a role for 
Th17 cells in pathogenesis. 
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Despite correlating closely with levels of IL-17, levels of IL-1β were not 
significantly elevated in acute patients with AAV. However, IL-6 levels were higher in acute 
patients with AAV and tended to be higher in those with PR3-ANCA, the group with the 
highest incidence of relapse, although this did not reach statistical significance (data not 
shown). Since both IL-1β and IL-6 are important in the differentiation of Th17 cells, it is 
possible that the peak in levels of IL-1β and IL-6 preceded that of IL-17 and would have 
fallen by the time of sampling. As might be expected, IL-6 levels were highest in patients 
with sepsis. A role for septic episodes preceding episodes of AAV has historically been 
proposed (Pinching et al., 1980) and has received more attention recently with a proposed 
model of molecular mimicry between ANCA targets and bacterial fimbrial proteins (Kain et 
al., 2008; Kain et al., 2012). Therefore, potentially, elevated IL-6 levels may have preceded 
the rise in IL-17 and disease initiation.  
 
The patient group in this work is typically heterogeneous in terms of pattern of organ 
involvement, degree and duration of disease activity as well as immunosuppression regime.  
There are other practical limitations such as the use of historical sera in the anti-GBM 
disease positive control cohort, although this is virtually unavoidable in rare diseases, and 
the fact that BVAS scores occasionally had to be calculated retrospectively. There was no 
correlation of IL-17 with CRP, ANCA specificity or ANCA titre.  However, IL-23 was 
associated with clinical disease severity, as assessed by BVAS, and with ANCA titre. Since 
this study is limited by being retrospective, it would be useful to further assess clinical 
correlations prospectively. It is intriguing that IL-23 levels but not IL-17 levels appeared to 
correlate with disease severity and a similar observation has since been made in patients with 
rheumatoid arthritis (Rasmussen et al., 2010). IL-23 may modulate disease by mechanisms 
which are broader than those through IL-17 alone, as IL-23 deficient mice with experimental 
glomerulonephritis were protected from disease and produced less IL-17 but also produced 
less IFNγ, IL-4, TNF and MCP-1 (Ooi et al., 2009).  
 
These data are in keeping with, and extend, those of Abdulahad and colleagues 
(Abdulahad et al., 2008) who analysed only patients with GPA and PR3-ANCA, and found 
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increased PR3-specific IL-17 and IL-4 producing T-cells in convalescent GPA patients. 
Unlike the data I have shown, they did not address the role of IL-23, but similarly found no 
significant difference in IFNγ production, confirming a relative skewing toward Th17 (and 
Th2) cells in GPA. Following stimulation with PR3 they found an increase in Th17 cells in 
ANCA-positive compared to ANCA-negative patients and healthy controls which also 
supports my findings in this chapter. Similarly, Saito and colleagues found an increase in 
Th17 cells in the peripheral blood of patients with active CSS compared to those with 
inactive disease and healthy controls, however they did not look for antigen specificity (Saito 
et al., 2009).  
 
Although these data are not proof of causation, it is notable that IL-17 or IL-23 
deficiency has been reported as protective in several mouse models of immune-mediated 
glomerulonephritis including an MPO vasculitis model (Gan et al., 2010; Ooi et al., 2009; 
Paust et al., 2009). The pro-inflammatory nature of IL-17 is consistent with the disease 
process in vasculitis and the data in this chapter is in keeping with a role for Th17 cells in the 
pathogenesis of AAV and a Th17 memory cell population in disease convalescence. 
Similarly, accumulating evidence from human studies has also begun to define a role for the 
Th17 axis in the pathogenesis of other related autoimmune diseases such as Behcet’s disease 
(Hamzaoui, 2011); Henoch Schonlein purpura (Jen et al., 2011) and Kawasaki disease (Jia et 
al., 2010). 
 
As understanding of the mechanisms of pathogenesis in AAV grows, one approach to 
treatment is the use of more targeted immunotherapy in order to reduce harmful side-effects 
and improve relapse rates. Trials evaluating the role of newer agents such as the anti-CD20 
monoclonal antibody rituximab (Jones et al., 2010; Stone et al., 2010) are likely to lead to 
modification of standard treatment regimens to ones with less obvious toxicity, although 
long-term follow-up data are still required. A range of other therapeutic approaches in AAV 
are being considered and have been extensively reviewed (Hamour et al., 2010). The 
identification of the Th17 subset and its proposed role in autoimmunity has opened up 
further potential new avenues for immune modulation. In several autoimmune conditions 
such as inflammatory bowel disease, rheumatoid arthritis and uveitis, blockade of IL-17 or 
IL-23 has been used in preliminary trials (www.clinicaltrials.gov). Randomised phase 1 trials 
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of IL-17 blockade in rheumatoid arthritis (Genovese et al., 2010) and phase 2 trials in 
psoriasis (Leonardi et al., 2012; Papp et al., 2012) have been published. Although the 
experimental findings from the previous chapter describing an unexpected protective role for 
IL-17 should be borne in mind,  the data in this chapter suggest that the IL-23 and IL-17 axis 
could also represent a potential future target for therapeutic intervention in some patients 
with AAV.  
 
5.5.1 Summary 
 
 Serum levels of IL-17 and IL-23 are elevated in acute and convalescent patients with 
AAV 
 
 High serum levels of IL-23 are associated with more severe disease as measured by 
BVAS and with higher ANCA titre 
 
 
 Some convalescent patients with AAV have memory T-cells which secrete IL-17 in 
response to stimulation with ANCA autoantigen 
 
 Higher levels of IL-17 and IL-23 in convalescence may be associated with relapse 
 
 
 
 
 
 
 
 
Sally Hamour  PhD thesis 2012 
226 
 
Chapter 6 
Discussion 
 
6.1 Summary of results 
 
In Chapter 3, I showed that IL-17
-/-
 mice were protected from NTN, even though they 
mounted similar immune responses. This demonstrates a role for IL-17 and the Th17 axis in 
the pathogenesis of NTN and corroborates results by other groups published during the 
course of this work. Through a series of cell transfer experiments, I then demonstrated that 
transfer of WT splenocytes or WT CD4+ T cells to IL-17
-/-
 mice was able to restore disease 
susceptibility in a proportion of animals, implicating circulating leucocytes as critical 
mediators of disease. 
 
 In Chapter 4, I performed bone marrow transplantation from WT mice to IL-17
-/- 
mice and vice versa in order to investigate the relative contribution of circulating leucocytes 
and intrinsic (radio-resistant) cells producing IL-17 in the development of disease. I was able 
to confirm clearly that IL-17 production from circulating leucocytes was critical to 
pathogenesis, since transplantation of WT bone marrow to IL-17
-/-
 mice restored disease 
susceptibility. However, in a seemingly contradictory finding, I also showed that IL-17 
production from radio-resistant cells plays an important protective role in the pathogenesis of 
NTN: transplantation of WT bone marrow to IL-17
-/-
 mice resulted in significantly more 
severe disease than that in WT to WT bone marrow transplants. I went on to examine the 
immune response in the different experimental groups. There were no differences in cellular 
infiltration of macrophages or CD4+ cells. However, there was less serum IgG2b in the WT 
to IL-17
-/-
 group, in keeping with less IL-10, as well as reduced levels of IL-1β and IL-23 
than in the other groups. The WT to IL-17
-/-
 mice also had an altered macrophage phenotype 
with less expression of mannose receptor, iNOS and arginase than the other groups.  
 
 In Chapter 5, I showed that patients with AAV have significantly elevated serum 
levels of IL-17 and IL-23, both acutely and when in remission, compared to healthy controls 
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and compared to patients with sepsis or anti-GBM disease. These findings point to a role for 
IL-17 and Th17 cells in the pathogenesis of AAV. Furthermore, serum levels of IL-17 
correlated closely with serum levels of IL-23, IL-6 and IL-1β, which are required for Th17 
differentiation, but did not correlate with serum levels of the Th1 cytokine IFNγ. Serum 
levels of IL-23 correlated clinically with disease activity as measured by BVAS and with 
ANCA titres. I went on to show that convalescent patients with AAV have memory T cells 
that respond to stimulation with ANCA autoantigens by producing IL-17, but not IFNγ, 
which further suggests a role for IL-17 in pathogenesis and the possibility of a role for 
memory Th17 cells in disease relapse. 
 
The discussion at the end of each experimental chapter has addressed the specific 
implications of data presented, set within the context of the current literature. I will now go 
on to address the broader relevance and limitations of the work within this thesis, and 
consider the future direction of any subsequent related studies.  
 
6.2 Thesis limitations 
 
6.2.1 Limitations of the use of genetically-engineered mice 
 
 The development of genetically-engineered mice with either a specific deletion or 
over-expression of a particular gene has been an invaluable tool in assessing the contribution 
of individual effectors to disease pathogenesis. Throughout this research I have been 
fortunate to have the use of IL-17
-/-
 mice generated by Professor Iwakura (Nakae et al., 
2002) to assess the contribution of IL-17 to the pathogenesis of glomerulonephritis, and to 
examine the relative contributions of bone-marrow derived and intrinsic cells to 
pathogenesis. It is also convenient for interpreting work by other groups on IL-17 deficiency 
and autoimmunity that, to my knowledge, all published work using IL-17
-/-
 mice has been 
carried out using mice generated in this way by Professor Iwakura.  
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However, there are broad limitations in the use of these models that should always be 
borne in mind. Not all gene products can be studied by the use of knock-out mice since a 
significant minority of mutations are fatal. In those that are not fatal, the deletion of a 
particular gene may affect the development of the embryo, which may then influence the 
adult phenotype and affect the interpretation of experimental results. If the gene of interest is 
important in embryonic development or has wide-ranging effects in multiple pathways then 
the use of inducible knock-outs is required. In this way, normal development can occur in 
the presence of the gene, and the adult phenotype is unaltered prior to the deletion of the 
gene of interest. IL-17
-/-
 mice are grossly functionally and phenotypically normal (Nakae et 
al., 2002). However, the deletion of a particular gene in a mouse will not necessarily result in 
a phenotype that mirrors or is relevant to that in humans, and therefore findings using these 
models cannot necessarily be extrapolated to human disease. Finally, in the absence of a 
particular gene, previously redundant mechanisms may be activated. For example, there is 
functional overlap between IL-17F and IL-17A, and once more this may affect the 
interpretation of experimental outcomes (Ishigame et al., 2009; Iwakura et al., 2011).  
 
In the generation of knock-out mice, the embryonic stem cells used to incorporate the 
altered DNA sequence may be derived from different strains, although they are usually 
derived from the sv129, as is the case for IL-17
-/-
 mice. These stem cells are then implanted 
into a C57BL/6 blastocyst to generate chimeric mice. Mice can then be bred onto the genetic 
background of choice. For IL-17
-/-
 mice, these were backcrossed for 10 generations onto 
C57BL/6 mice to generate mice with >99% C57BL/6 genotype. However small regions of 
DNA from the sv129 strain often persists, and this is inevitably so in the region immediately 
adjacent to the gene of interest and this may also influence the final phenotype (Botto et al., 
1998). The genetic background of the mouse may also have an effect on the outcome of 
disease. For example, glomerulonephritis in C57BL/6 mice is predominantly Th1 mediated, 
whilst in BALB/c mice it is predominantly Th2 mediated (Huang et al., 1997b). Therefore it 
is also important to ensure that control mice are of an appropriately selected background. IL-
17
-/- 
mice were backcrossed onto a C57BL/6 background and for the work in this thesis, 
C57BL/6 mice were used as WT controls. However, WT litter-mate controls, generated from 
IL-17
-/-
 heterozygote matings, would have been the most closely matched control mice, 
taking into account any minor background genetic contribution. 
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6.2.2 Limitations of the accelerated nephrotoxic nephritis model 
 
 The accelerated nephrotoxic nephritis model in the mouse has been used throughout 
this thesis as a well-established model of immune-mediated crescentic glomerulonephritis. 
The main limitations of this model are that disease often tends to be predominantly 
thrombotic rather than crescentic, and that there is considerable variability in disease 
outcome between individual animals. The acute onset of disease, its severity and its 
thrombotic nature differ from that in human disease, which is often more indolent in onset. 
The variability in disease between mice in the same experimental group persists despite 
using mice of an identical genetic background which are injected with the same batch of 
NTS by the same operator, and are housed in the same conditions. It is likely that a small 
part of the variability might originate from the technical difficulty of the intravenous 
injection of NTS. However, this still does not explain the very wide degree of variation 
sometimes seen and even those groups which use intra-peritoneal injection of NTS have 
pronounced variation between mice in the same group (Paust et al., 2009). Therefore 
differences relate to the active murine immune response and, when using this model, 
sufficient numbers of mice in each experimental group are required so that statistically 
significant differences in disease outcome can be detectable, despite the range of data from 
each group. In spite of these limitations, this model is widely used and remains a useful and 
robust mechanism for examining effectors of glomerulonephritis. 
 
6.3 Hypothesis of the role of IL-17 in nephrotoxic nephritis 
 
The pleiotropic pro-inflammatory effects of IL-17 are well recognised, and the 
effects of IL-17 in non-renal models of autoimmunity have been detailed throughout the 
course of this thesis. In nephrotoxic nephritis, it is clear that the role of IL-17 is complex. 
Work described here and that contributed by others (Paust et al., 2009) has demonstrated that 
IL-17 is pathogenic in NTN, with IL-17
-/-
 mice protected from disease in both accelerated 
and non-accelerated NTN. However, in late non-accelerated NTN, IL-17 appears to have a 
protective role (Odobasic et al., 2011), and data from bone marrow transplant experiments in 
this thesis has shown that IL-17 production by radio-resistant intrinsic cells is protective in 
accelerated NTN. 
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Th17 cells themselves are predominantly pro-inflammatory but can assume an 
immunosuppressive phenotype, with production of IL-10, under the influence of TGFβ and 
IL-6, despite the fact that TGFβ and IL-6 are required for initial lineage commitment of 
Th17 cells (McGeachy et al., 2007). It may be that IL-23 is additionally required for full 
pathogenic effector function of Th17 cells. IL-23 is largely produced by antigen-presenting 
cells and plays a role in the terminal differentiation of Th17 cells (McGeachy et al., 2009). 
However IL-23, together with IL-1β, is also required for the stimulation of cells of the innate 
immune system to produce IL-17. These may be activated early on in disease or infection to 
promote recruitment of neutrophils and the release of pro-inflammatory mediators. However, 
my data suggest that some IL-17 production by these innate cells (or by other radio-resistant 
immune cells or by intrinsic renal cells) may also lead to anti-inflammatory effects. In view 
of the levels of IL-10 found in the bone-marrow transplant experiments, it is possible that 
these cells co-produce IL-10, or that IL-17 production results in increased IL-10 from other 
immune cells. This would be a counter-regulatory mechanism to that recognised whereby 
IL-10 limits Th17 responses (Gu et al., 2008). IL-10 would serve to limit local inflammation 
by down-regulating production of pro-inflammatory cytokines such as IL-6, IL-1 and TNFα 
by activated macrophages (Fiorentino et al., 1991), and IL-10 may also influence 
macrophage phenotype to one that is more anti-inflammatory (Martinez et al., 2008), which 
further promotes resolution of tissue injury. 
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Figure 53. Suggested schema for the protective and pathogenic roles of IL-17 in nephrotoxic 
nephritis. 
Both Th17 cells and innate IL-17 producing cells are able to adopt a pathogenic or an 
immuno-regulatory phenotype depending on the signals received during the course of NTN. 
In both cases, protective effects may be mediated by an increase in IL-10 and a move 
towards alternatively activated macrophages which promote resolution of tissue injury. 
Other cell types such as radio-resistant follicular dendritic cells may also be responsible for 
IL-17 and/or IL-10 production. 
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6.4 Further questions arising from this Thesis 
 
From the experimental data generated during the course of this work, I have 
supported my original hypotheses of a role for IL-17 in experimental glomerulonephritis and 
AAV. However, the data presented in this thesis raise a number of important further 
questions. 
 
Is the most significant source of IL-17 in NTN from T cells or non-T cells? 
 
Data presented has shown both a pathogenic role for IL-17 production from bone-
marrow derived cells and a protective role for IL-17 from radio-resistant cells. It is pertinent 
that the total number of renal IL-17-producing CD3+ cells in NTN is small, between 3 and 
7% of the total number of CD3+ cells (Paust et al., 2009). This suggests either that 
amplification of IL-17 signalling is extremely potent and efficient; or that the major effects 
of IL-17 are modulated through production in local lymphoid tissue not in the kidney or that 
non-CD3+ cells are a more important source. Neutrophils (Velden et al., 2012) and γδ T 
cells (Turner et al., 2012) have already been identified as significant alternative sources of 
IL-17 in human renal biopsies and in early NTN respectively. How the complex relationship 
between protective and pathogenic effects of IL-17 is mediated is, as yet, unclear, as is 
whether production of IL-17 in these different scenarios is necessarily by the same or by 
different cell types.  Unravelling these mechanisms in vivo will be challenging. It is also 
hampered by the fact that immunohistochemistry for IL-17 in murine kidney is difficult and 
has not successfully been reported. In my own experience, using two of the commercially 
available antibodies (IL-17A rabbit polyclonal antibody, Protein Tech and IL-17 (H-132) 
rabbit polyclonal antibody, Santa Cruz Biotechnology inc.), levels of background staining 
are persistently high. This may be partially due to weak cross-reactivity with IL-17F, since 
there is 20% homology between IL-17A and IL-17F. Consequently, data on renal IL-17 has 
tended to rely on flow cytometry or quantitative PCR (Paust et al., 2009; Turner et al., 2012).  
Furthermore, since Th1 cells appear to also play a role in the pathogenesis of NTN, the 
nature of their interaction with Th17 cells or other IL-17 producers remains to be clarified, 
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along with the factors that determine the dominant Th effector phenotype, and the effect of 
this on disease outcomes.   
 
How is macrophage phenotype altered during the course of NTN in IL-17 deficiency, 
and how does this affect disease outcomes? 
 
Both NTN experiments in WT and IL-17
-/-
 mice, and those carried out in chimeras 
after bone marrow transplantation showed no difference in macrophage numbers. However, 
preliminary analysis of macrophage markers in the bone marrow transplant experiments 
showed significant differences between the groups in iNOS, arginase and mannose receptor 
expression. It would be helpful to corroborate these results by flow cytometry or 
immunohistochemistry, and to examine more macrophage markers, in order to construct a 
fuller picture of macrophage phenotype in NTN in IL-17
-/-
 compared to WT mice. In 
addition, given the protective role of IL-17 identified in the bone marrow transplant 
experiments, it would be useful to examine macrophage phenotype at different time points 
during the course of disease, or to deplete macrophages at different points during disease in 
IL-17 deficient mice and bone marrow chimeras with NTN, to see whether disease is 
attenuated or exacerbated. 
 
Are the protective effects of IL-17 most marked at a particular time point in disease? 
 
One group has suggested that IL-17 promotes disease in the early phase of NTN 
partially by promoting neutrophil recruitment (Gan et al., 2010), but attenuates disease in the 
established phase by suppressing Th1 responses (Odobasic et al., 2011). In my bone marrow 
transplant experiments, I looked at outcomes at day 8 or 9 only, so it would be useful to 
repeat the experiment and compare disease in the bone marrow chimeras at an earlier time-
point to see whether the protective effects of IL-17 from radio-resistant cells are also 
apparent early on in disease. Similarly, examination of macrophage phenotype or 
macrophage depletion as suggested above would help to clarify the role of IL-17 at different 
time-points in disease. 
Sally Hamour  PhD thesis 2012 
234 
 
 
Are the protective effects of IL-17 directly related to increased levels of IL-10 and, if so, 
are these co-secreted by the same cell? What is the nature of this cell? Is there an 
intrinsic defect of IL-10 production in the IL-17 deficient mice? 
 
IL-10 is an important immuno-regulatory cytokine which is well-recognised to 
modify Th17 responses (Gu et al., 2008). In the bone marrow transplant experiments, levels 
of IL-10 were lowest in the most severely affected WT to IL-17
-/-
 transplant group, which 
raises the possibility of a counter-regulatory mechanism whereby protective IL-17 results in 
increased production of IL-10. It is not clear if this is the only mechanism by which IL-17 is 
able to mediate protection, or whether other changes such as macrophage phenotype may 
also contribute.  
 
There may be an intrinsic defect of IL-10 production in IL-17
-/-
 mice. I have 
presented preliminary FACS and ELISA data from WT and IL-17
-/-
 splenocytes, which 
showed no significant difference for IL-10 production.  However, I feel that these data are 
still inconclusive and that, if modifications to the stimulation protocol resulted in a higher 
baseline of IL-10 production, any differences might be more apparent. In this way, FACS on 
splenocytes or renal cells could also be used to identify any IL-10 and IL-17 co-producing 
cells which could then be phenotyped. If these cells are identified, then their persistence 
following irradiation in IL-17
-/-
 to WT bone marrow transplant mice would be convincing in 
favour of my hypothesis for production by non-bone-marrow derived cells. To support this, 
whole kidney or leucocyte cell suspension and lymph node cells from pre-immunised, 
irradiated mice could be stimulated to demonstrate residual IL-17 production. I have 
suggested some radio-resistant cells such as spleen follicular dendritic cells that can produce 
cytokines and modulate immune responses. The addition of IL-17 to splenocyte cultures 
from IL-17
-/-
 mice might be predicted to restore levels of IL-10 production. Serum levels of 
IL-10 during the course of NTN could be measured, and levels of IL-10 and IL-17 in 
patients with AAV during active disease and in remission could be measured and correlated. 
 
Sally Hamour  PhD thesis 2012 
235 
 
6.5 The role of IL-17 in other models of autoimmunity 
 
 The roles of IL-17 in other models of auto-immunity, particularly those such as EAE, 
CIA and models of colitis, have previously been ahead of those in renal disease in terms of 
an understanding of pathogenicity. Models of uveitis (EAU) have also contributed to this 
understanding. However, in addition to the work in NTN in this thesis and by other groups, I 
have also described that carried out in other renal models such as EAG and AIMPOGN.  
What is clear is that the role of IL-17 varies significantly according to the model and, for 
example, in colitis the effects of IL-17 can be different even in different models of the same 
disease. This is important when considering IL-17 blockade or manipulation of the Th17 axis 
as a therapeutic tool and this is discussed in the next section. It remains to be seen whether 
murine bone marrow chimeras with EAG or AIMPOGN will demonstrate the same 
protective effect of IL-17 that has been demonstrated in NTN.  
 
6.6 Prospects and limitations of the use of IL-17 blockade in renal 
disease and AAV 
 
IL-17 blockade or manipulation of the Th17 axis remains a potentially useful 
therapeutic tool. I have discussed the clinical outcomes of those trials that have completed in 
a number of autoimmune diseases. I have considered those that have been ineffective or, in 
the case of Crohn’s disease, that have resulted in a worse outcome for patients. Evidence for 
a protective role of IL-17 is gradually emerging. Whether there is a protective role for IL-17 
in human immune-mediated glomerulonephritis or AAV, as has been demonstrated here in 
mice with NTN, is not known. Whether similar local protective mechanisms to those 
identified also operate in humans is also unknown. Furthermore, the relationship between 
Th1 and Th17 cells in renal disease, and the degree to which they operate synergistically or 
independently, must be carefully understood since, if Th17 cells do suppress Th1 responses, 
this is another way in which IL-17 blockade may exacerbate disease. The outcome of IL-17 
blockade in patients with these conditions is uncertain and we should acquire a more 
informed mechanistic understanding before reconsidering this as a therapeutic target. 
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6.7 Concluding remarks 
 
 This thesis has reviewed previous work relevant to an understanding of the role of 
IL-17 in autoimmunity and in immune-mediated renal disease.  
 
 The experimental work presented has addressed the question of a role for IL-17 in the 
pathogenesis of nephrotoxic nephritis and has identified the important immune mediators of 
disease. IL-17 has a pathogenic role in murine accelerated nephrotoxic nephritis, which is 
mediated by bone-marrow derived cells. However, IL-17 also plays a protective role in 
disease which is conversely mediated by local radio-resistant cells that may be intrinsic or 
immune in origin. In human disease, AAV, elevated serum levels of IL-17 and IL-23 are 
associated with disease, and production of IL-17 by memory T cells in response to 
stimulation with ANCA autoantigen may be relevant to pathogenesis.  
 
 I have discussed the limitations of using gene-targeted animals and the nephrotoxic 
nephritis model. I have suggested a hypothesis for the complex role of IL-17 in 
glomerulonephritis and discussed important questions arising from this work along with 
possible future experiments to address these. The work described in this thesis is all my own 
work. Where others have contributed, this has been acknowledged in the text. Ultimately I 
hope that these data will contribute to a better understanding of pathogenesis, and to the 
advantages and limitations of considering the use of IL-17 blockade in patients with renal 
disease and AAV. 
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